<SEC-DOCUMENT>0001062822-23-000024.txt : 20230504
<SEC-HEADER>0001062822-23-000024.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504071048
ACCESSION NUMBER:		0001062822-23-000024
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		40
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		23886429

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059,d:1a19930e9f764c8baa91ba0b6295c6fe--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:lxrx="http://www.lexpharma.com/20230331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF81LTQtMS0xLTQxODg5_3be4854c-fd0b-4537-a089-7e427dc2f18a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF85LTQtMS0xLTQxODg5_3986df09-e54d-4964-b05c-19731f1ef33c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xMC00LTEtMS00MTg4OQ_0952126b-2c94-4bf4-82d6-c4db30c9f183">2023</ix:nonNumeric><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xMS00LTEtMS00MTg4OQ_32dc04fd-d8db-4c0c-93b2-45cf24220d3d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xNC00LTEtMS00MTg4OQ_4d55197d-2e87-43e0-ac3f-a63f9e99f78b">0001062822</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20996cadc68f450b9cdae24983d13cb4_I20221107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib79166a07a8341019133d1767451366c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4486d192c3418a887c00fdae579410_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0d60f9ebe14ff6adf4c90cbaf04f93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b52788551bf4ba09d90c25c260474ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3780c853ca62493095fa01c99c96a50b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd9833fa7e645c68143dcfd76af2e58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908be8c8318f430fa0dcb565f616e66e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1928596f4b5435191e331ad33500d98_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5b75bdf9b3e45cfa77e885ac49788f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia219aede096c4cf0b514d5a736ae7245_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40101591a3a747d39081c3865fa29914_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida35814b016d4540b1321674b0722978_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e92df6f278d4c19a869b984471be038_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d08dad083a947c387d54202008989a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636d41fbcdb344b7be8e6238915276b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b540e964324fb0b61132eb59b41f73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69cc6c5cf6684519a5d00d853fa37565_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cfd6d4e8e2473aa197ec5caf0a0e38_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017100090664431eae4b4d902a7a2069_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122cc45b24a040dca3939cb8ebe170a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d09fe0d1af4d7db5d3ab1d00f6cb8e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if294b62ddc5941a89003bac80ce657a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b21eb47f1d44a0801b1c165ff6a310_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5c48a42a0b4346b4984be1e404c5e3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122a411cbee64663b669721e52d22969_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4590c26f966346da952432b88fccff44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52cb6e46f3004a31b017f45441c3a197_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1150bd512a24422facf2a358e5f34712_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e6cd144aee4e95b362bf083223bd6d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a9aa0068e404b4d801ff1de1e630584_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b7b245845b4744bdcafd4a64ae9457_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbff2c0bc8914b5083a706874111931f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f0211b426c48a7928c9fe72bdf5fce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c5cb7217034320b1cf86d2516d1891_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ee63580e7f4cee956584a4be4fc152_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ede3bf23094d30ab019f2c0cae03fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i375e3a3d13094b578b03f23910d47681_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85ac8033ec684725b9503d12d0b48ada_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901f7eff00b440ac8fd3b85aa8b94826_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb4426fae2448009d2f24b25517721b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied2630f42a2e4991858d1dab84290767_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf58b0d98384a0e865d446c3a2387f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV84Mg_762fae39-f7b3-42e1-888a-21876220e218">10-Q</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6NGJiNjhmMzU0NzVjNDg5N2EyYThjNTQxM2QxNDk3ZGEvdGFibGVyYW5nZTo0YmI2OGYzNTQ3NWM0ODk3YTJhOGM1NDEzZDE0OTdkYV8wLTAtMS0xLTQxODg5_4f1defff-b2b0-4271-b15b-8d462f1b8bd0">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8xMjk_e8eb9b95-cd03-483d-8ffc-e4eed012c38b">March 31, 2023</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6OWRhNWExYjVjYWQ0NDllNzhkMjRhOTFhNTY4MWJlNDQvdGFibGVyYW5nZTo5ZGE1YTFiNWNhZDQ0OWU3OGQyNGE5MWE1NjgxYmU0NF8wLTAtMS0xLTQxODg5_1049616a-9311-47bd-b1cc-e08e9202ff19">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from _____________ to _____________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMjU_cddb464c-e90e-47fd-a484-a8e85b004ad7">000-30111</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMjg_71201487-1aa0-4b6d-bb9b-ee44e077203c">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6ODFlZDY1YTFiNGY5NGMwMGE1OTlkMTIxM2U3MGEyNGYvdGFibGVyYW5nZTo4MWVkNjVhMWI0Zjk0YzAwYTU5OWQxMjEzZTcwYTI0Zl8wLTAtMS0xLTQxODg5_31a8fa80-8c12-4c2d-b041-0ad15a706b7c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6ODFlZDY1YTFiNGY5NGMwMGE1OTlkMTIxM2U3MGEyNGYvdGFibGVyYW5nZTo4MWVkNjVhMWI0Zjk0YzAwYTU5OWQxMjEzZTcwYTI0Zl8wLTEtMS0xLTQxODg5_bba6df93-d705-4079-ba3b-4ac0a47695d3">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yODc_98629628-a69b-4b4c-b49f-124d06c6013d">2445 Technology Forest Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTA_1d91a034-6e87-41b9-9b35-a9ef1b5b48c5">11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTM_d8017cb1-445f-4d1f-a280-e430daa792a7">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTc_c3f06f04-ed63-4b7b-937f-3884756bb7c9">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zMDA_6da9bb86-e815-48ca-bf34-09d12ee71cc3">77381</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zNTg_656d4378-4633-4896-b7b0-755733761422">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zNjI_03f2b7bc-ac44-4f52-8efb-095589d5116b">863-3000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTAtMS0xLTQxODg5_863e03ba-3388-4a09-80cc-de4a31c8a8a8">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTEtMS0xLTQxODg5_1c7472df-b291-4041-96e4-6e69ee2e7aa2">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTItMS0xLTQxODg5_28981613-6b7c-400a-8ccd-3c035c359670">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6NTc0MzUxMjc0ZTc0NGJhM2I0N2IzZGZkZWE4NzdiYTAvdGFibGVyYW5nZTo1NzQzNTEyNzRlNzQ0YmEzYjQ3YjNkZmRlYTg3N2JhMF8wLTAtMS0xLTQxODg5_f33a2389-9456-4da6-aa6b-ec617ffa79b4">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MjMyOTVlZTYzOGYxNGI3MWI5NDVkMzVjOGZhOTZlNTQvdGFibGVyYW5nZToyMzI5NWVlNjM4ZjE0YjcxYjk0NWQzNWM4ZmE5NmU1NF8wLTAtMS0xLTQxODg5_cd11204e-4bad-4ee0-97d3-4bb7f46de55a">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;     Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          <ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMzAx_1f9954c6-4591-4268-911e-0982c5c6f035">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMzAy_11a6a3d9-609c-4632-b795-ba164be1afdd">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6YWJlNTQyZjMzYzZhNDJlYzllZDcwMTViNTFlOTI3NTMvdGFibGVyYW5nZTphYmU1NDJmMzNjNmE0MmVjOWVkNzAxNWI1MWU5Mjc1M18wLTEtMS0xLTQxODg5_516d0bbc-39d5-424a-9484-4d46e980435c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;2, 2023, <ix:nonFraction unitRef="shares" contextRef="i20996cadc68f450b9cdae24983d13cb4_I20221107" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV81NDk3NTU4MTYyMzA_3dd09e19-b831-43c4-aa37-63a68033f187">189,561,819</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_10">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets - March 31, 2023 (unaudited) and December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) - Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_61">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_70">19</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_73">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_70">19</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_76">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_76">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_79">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_79">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_82">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_82">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_852">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_852">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_85">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_85">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_88">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a19930e9f764c8baa91ba0b6295c6fe_88">24</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2022, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I &#8211; Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_16"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNC0yLTEtMS00MTg4OQ_0b20ed5c-bdc7-46d9-969d-71f732150088">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNC00LTEtMS00MTg4OQ_04099760-4dd9-449f-aeec-903bd6beee26">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNS0yLTEtMS00MTg4OQ_a8018863-7d22-4bbc-82b3-0d93561ef426">79,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNS00LTEtMS00MTg4OQ_acb7f4bd-ddaf-4a6a-8919-91ac653f4bde">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNi0yLTEtMS00MTg4OQ_35ffce38-0262-41e7-98c3-8da04eedde5a">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNi00LTEtMS00MTg4OQ_bc75f933-ca0e-4134-a93c-74870666b68c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNy0yLTEtMS00MTg4OQ_913b82ed-7a4c-4d58-8f2e-b6568800cd62">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNy00LTEtMS00MTg4OQ_af1a398d-cbb8-4a00-bb59-ff0e429acc2b">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOC0yLTEtMS00MTg4OQ_2fe41355-faff-4d75-84a2-869417564390">109,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOC00LTEtMS00MTg4OQ_c159b7e6-983e-4c72-90c0-8aaeb0b20fce">140,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjE0ZmE1NzY1ZDlkODQ0YmQ5MmZlZmVmYjZhYzM4MmQ2Xzgw_2ef41df4-7783-42f1-83be-7b2bf9365525">4,096</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjE0ZmE1NzY1ZDlkODQ0YmQ5MmZlZmVmYjZhYzM4MmQ2Xzg3_30ce6064-0bbf-49ee-80f5-1b15d9b74e16">3,984</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0yLTEtMS00MTg4OQ_b948e41a-f024-449b-94e4-43e935d80d21">2,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS00LTEtMS00MTg4OQ_7e19d888-a332-45d6-8ede-70ce227335b5">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTAtMi0xLTEtNDE4ODk_1c20677f-5ed7-46a1-bcd1-8efc139f26e5">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTAtNC0xLTEtNDE4ODk_f67213fa-6f29-4617-850e-d7070544c97a">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTEtMi0xLTEtNDE4ODk_66ad4899-b006-4bbb-a29e-1ff04602098c">6,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTEtNC0xLTEtNDE4ODk_4faa9e39-d98a-4fe7-8b1c-6aacd969f681">6,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTItMi0xLTEtNDE4ODk_4e2d657c-423f-4f0e-b6a5-5588a62c1c76">162,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTItNC0xLTEtNDE4ODk_38edbf2e-f68d-4a8d-bb5c-519366db3aad">194,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTUtMi0xLTEtNDE4ODk_9fb9cc78-a9c4-48b0-ac98-806b48eb6993">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTUtNC0xLTEtNDE4ODk_68442efe-2eaa-434b-8508-83d5d61bd323">10,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTYtMi0xLTEtNDE4ODk_9d30927b-098b-4553-84d2-0ed9c2dfda2a">10,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTYtNC0xLTEtNDE4ODk_f8cf20b4-216d-498d-a74d-89cca6700cf3">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTctMi0xLTEtNDE4ODk_6410c48b-8880-402a-a7c2-3337498f0483">20,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTctNC0xLTEtNDE4ODk_e3794cbe-b2ff-43a0-a26a-3c8351df2a33">23,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTgtMi0xLTEtNDE4ODk_215772f1-de28-4c4a-b410-86058883a9dc">48,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTgtNC0xLTEtNDE4ODk_c378f3b4-2bd9-41d8-a412-62e87430a53d">48,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTktMi0xLTEtNDE4ODk_c22c9a14-0928-416e-bf2e-45124e7ff099">5,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTktNC0xLTEtNDE4ODk_3ff9b801-6e49-468a-8b04-b379da5019ac">5,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjAtMi0xLTEtNDE4ODk_98104564-2ded-4601-a122-edf414e2d0f6">74,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjAtNC0xLTEtNDE4ODk_a983e219-4c75-4f3f-bc1c-3eaf3c9f9459">77,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjEtMi0xLTEtNDE4ODk_ab469599-b910-46b5-a72b-19d2b2d69058"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjEtNC0xLTEtNDE4ODk_ea769f1c-4c8c-422d-9dae-d36518eb3ce2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8yMQ_5bbb3e57-b29c-4d57-b98a-0ddeb64e5bd9"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8yMQ_b5223806-e743-455b-af12-7baa4e52733d">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8zNQ_3f7421f3-5055-46bd-93d4-6e333307f8b7"><ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8zNQ_bf6d22d9-6e16-4d49-83d9-9432d0d54acd">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_343d3796-bcd9-42e8-90cf-0084ef70e690"><ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_973f5d69-e06d-42c8-92bf-d60fa8bf9362"><ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_a6cd203d-71fd-473a-b72f-445ce1eff6bb"><ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_b15f6b8f-dc66-4a66-bfbd-2ea913720d1a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMi0xLTEtNDE4ODk_94912028-a014-4795-a1ab-d30f55c4f2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtNC0xLTEtNDE4ODk_ee04d63d-2d3d-4a5c-9a9b-133b9d9ded60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8xOA_584c53d4-c75c-427c-a02c-3aed48330611"><ix:nonFraction unitRef="usdPerShare" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8xOA_5d0cca67-cb82-4004-b666-99fc0ffa2c6f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8zMg_7374f9b6-9342-4756-8b0e-508ef3d3b522"><ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8zMg_9d051b41-4106-4ad3-bd71-eb01ad631680">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV81NA_250be8ff-65d7-4661-83a2-5fba9a4b63c0">190,430</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV82MQ_6b60cff6-a856-4d75-b9a8-44947fc28d83">189,214</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMi0xLTEtNDE4ODk_8859b71a-26d4-4478-9850-489028bda7c2">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtNC0xLTEtNDE4ODk_3f600de3-0d1f-4ff9-b72c-4536b401416f">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjUtMi0xLTEtNDE4ODk_7cfc1f57-d845-4bc8-a8d8-42cfbce360cd">1,712,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjUtNC0xLTEtNDE4ODk_ef80c978-dc15-40a7-b25a-96c2b1bdea5c">1,709,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjYtMi0xLTEtNDE4ODk_542701a5-3790-422d-993c-f5b4b046fab4">1,621,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjYtNC0xLTEtNDE4ODk_e8a31893-4652-472f-a24c-fa7e70b053d0">1,589,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjctMi0xLTEtNDE4ODk_a8a9bf1f-cc5a-4ac5-b198-d91e184b80a3">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjctNC0xLTEtNDE4ODk_6ff32939-b329-45d7-97f7-91dbb8b2e05e">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo3ODBkN2JiY2E1Yzc0NjAzYWJmZGVjYjczNGExYjc2N18yOQ_1d642955-6827-4660-85be-3ae0ceade1e6">868</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo3ODBkN2JiY2E1Yzc0NjAzYWJmZGVjYjczNGExYjc2N181NDk3NTU4MTM5NTc_effaab24-641b-4d66-bdbc-88882d59b5f1">488</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMi0xLTEtNDE4ODk_599e5858-19a0-4fda-a648-424dd5bc6772">2,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtNC0xLTEtNDE4ODk_12b8dbed-098d-4da1-9e28-41aa41ca877a">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjktMi0xLTEtNDE4ODk_8d10bae4-fddb-4a62-a2e8-721a386aea71">88,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjktNC0xLTEtNDE4ODk_59505a19-62ff-4bd5-bccf-548d371d4bc3">117,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMzAtMi0xLTEtNDE4ODk_b0d44f04-ce1a-46f6-83b9-4f50bc539b38">162,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMzAtNC0xLTEtNDE4ODk_198b8660-dfff-4616-a322-8ad1b71d0294">194,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:78.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMy0xLTEtMS00MTg4OQ_5b68a0c5-09a8-4a93-bf6b-55dec47238d2">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMy0zLTEtMS00MTg4OQ_9ce50b0d-fd57-4d51-a9ff-7255861ab13d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOmM2MWVmNmU4ZDFhNTQ2NTRhM2E0ZWQ5YWNhNDQwOWMxXzY4_2b0f6dd1-2fe0-4a90-b484-e2d8c2c46565">1,203</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOmM2MWVmNmU4ZDFhNTQ2NTRhM2E0ZWQ5YWNhNDQwOWMxXzcy_acb7ffb9-fef1-46b9-80b3-e156a95893e9">1,032</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0xLTEtMS00MTg4OQ_eeb2f56a-0114-4d46-9cc4-c5388eee51c7">12,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0zLTEtMS00MTg4OQ_2a76a703-469c-478b-85db-f3bf55576701">14,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjAyOTM0YzZiYWY5NTQwMjJhMmI3MzM4ZmI1OWJjMzQ0Xzc5_edb5b250-3036-4ff1-b2fa-55768c739bf9">2,212</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjAyOTM0YzZiYWY5NTQwMjJhMmI3MzM4ZmI1OWJjMzQ0Xzgz_e38fba18-e66f-4f1a-bdd4-d979ada0a3ea">1,740</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0xLTEtMS00MTg4OQ_80e2a70d-0d66-456f-b632-3eff8f433aec">19,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0zLTEtMS00MTg4OQ_f5281726-8772-4fbf-acd6-65b283554c94">8,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOC0xLTEtMS00MTg4OQ_791a4bd4-d14a-407f-97ea-eb37e0f4ff2a">31,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOC0zLTEtMS00MTg4OQ_81230dab-bf90-4fe0-8ff0-e0e7d29031a1">23,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOS0xLTEtMS00MTg4OQ_a0947ed7-4c0a-40d9-a92a-f3357b3eed20">31,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOS0zLTEtMS00MTg4OQ_cd881e9a-6e1a-4a73-8655-478b11e07932">23,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTAtMS0xLTEtNDE4ODk_9ee55280-3637-421f-ac76-17b929b49d93">1,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTAtMy0xLTEtNDE4ODk_2a452f43-5cf9-4dc7-a13a-620cb56282ad">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTEtMS0xLTEtNDE4ODk_1600b54d-0d39-4861-aca1-35e58af1e803">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTEtMy0xLTEtNDE4ODk_9b177c8b-0ab8-4e90-bc74-8b162e0713b1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTItMS0xLTEtNDE4ODk_21cf9e3d-043b-4326-bc71-dcbe18627731">31,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTItMy0xLTEtNDE4ODk_59c67a79-e53c-4731-b607-c81c715b8e24">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTMtMS0xLTEtNDE4ODk_8ed32585-0f4d-4bf6-872e-a1b2fe9b0730">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTMtMy0xLTEtNDE4ODk_f5bab7d2-c581-479e-82b4-798c28abab55">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTUtMS0xLTEtNDE4ODk_56d14aef-0c0b-4b14-9ba0-b5ff42a5fe54">189,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTUtMy0xLTEtNDE4ODk_86e0520e-0dc9-43f8-ab0b-7b09c23d9b61">149,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTgtMS0xLTEtNDE4ODk_34c3e812-57a6-49de-b570-2b20fd9a9b59">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTgtMy0xLTEtNDE4ODk_ac28429b-e636-4148-8576-40457c850394">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTktMS0xLTEtNDE4ODk_bb75c558-42ae-4d90-abf1-a60c0243e509">31,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTktMy0xLTEtNDE4ODk_2924ede3-a6db-43b4-b2ad-ac12c8eb87c7">23,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.779%"><tr><td style="width:1.0%"></td><td style="width:36.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b4486d192c3418a887c00fdae579410_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0yLTEtMS00MTg4OQ_f19b3103-20fd-470b-a648-7a89be200eb7">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b4486d192c3418a887c00fdae579410_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi00LTEtMS00MTg4OQ_b6f9316b-4add-4ab3-88d1-5a89270aa06d">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0d60f9ebe14ff6adf4c90cbaf04f93_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi02LTEtMS00MTg4OQ_df4cf9e5-1901-4deb-b3ff-dad5f7179a70">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b52788551bf4ba09d90c25c260474ea_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi04LTEtMS00MTg4OQ_af42f778-5216-4f3f-a2b4-dc9d7ca2224f">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3780c853ca62493095fa01c99c96a50b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xMC0xLTEtNDE4ODk_0b84a04f-868c-4e4d-83ef-e5b22bfa411b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fd9833fa7e645c68143dcfd76af2e58_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xMi0xLTEtNDE4ODk_c75a9952-3e34-476d-b8c9-6a66b5d038ae">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908be8c8318f430fa0dcb565f616e66e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xNC0xLTEtNDE4ODk_63199d35-2e2c-4c5e-af04-5d8b5de882d4">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy00LTEtMS00MTg4OQ_79799c4a-6de5-4de3-9b6a-ab7ab075ec9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy02LTEtMS00MTg4OQ_f64cfabf-4b52-4ac8-820e-735e7c2316ce">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy04LTEtMS00MTg4OQ_ca309f95-5cbb-4e58-9328-4325c97c8f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xMC0xLTEtNDE4ODk_58ec37a9-224c-4cb2-920f-7a2d5213b5f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xMi0xLTEtNDE4ODk_505ed3b2-57aa-4782-b583-2fe7f9ff19eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xNC0xLTEtNDE4ODk_d92ece76-ebc0-43f3-ad8a-d61ab9834304">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0yLTEtMS00MTg4OQ_024664fc-6f4a-4644-a39a-2288724af2b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC00LTEtMS00MTg4OQ_a2d2ac9e-fd19-4c75-987d-1832495de9b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC02LTEtMS00MTg4OQ_97f96034-4e3b-49d9-9c46-de5dfc7c09dd">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC04LTEtMS00MTg4OQ_b1d77113-8de8-4b65-8310-e9e0392c71dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xMC0xLTEtNDE4ODk_77a13f81-9408-41b3-b102-91a774f83e4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xMi0xLTEtNDE4ODk_f5185b5b-b72d-4e3e-866d-7a05823dbbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xNC0xLTEtNDE4ODk_6c42204e-84d9-44c8-94eb-246c893f3fe8">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0yLTEtMS00MTg4OQ_f73c6251-5fbc-4085-a67d-033601e5f10f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS00LTEtMS00MTg4OQ_ff2ae27e-bf30-464a-aa07-2e635081d9c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS02LTEtMS00MTg4OQ_267855f2-2ad7-4569-b3b7-4083ffeb42c0">6,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS04LTEtMS00MTg4OQ_fc00962a-e574-43a7-a28b-ef4c31293d7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xMC0xLTEtNDE4ODk_8d4af8a6-f96f-43cf-8673-da129fa939a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xMi0xLTEtNDE4ODk_0b168486-040f-48f0-82b3-14c82ec88b97">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xNC0xLTEtNDE4ODk_33d48efd-fb95-45a6-a75b-f98a137804fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0yLTEtMS00MTg4OQ_bb9d3684-6c42-489e-94a6-210e21efd309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi00LTEtMS00MTg4OQ_d8f2940c-f6c1-4245-8ea6-ec5ec36ea63c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi02LTEtMS00MTg4OQ_a95c03b9-bbea-411d-b718-c3b44e27356c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi04LTEtMS00MTg4OQ_6e992a04-e89d-4493-8975-3496df171cd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xMC0xLTEtNDE4ODk_7cfb7898-17a3-47cf-b771-5160132d86f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xMi0xLTEtNDE4ODk_79cc4de0-cc17-4e9b-a05f-cb19ec1160a3">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xNC0xLTEtNDE4ODk_c8a736c2-98e8-4a63-bd60-21685dfa88ec">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy00LTEtMS00MTg4OQ_033e0275-a074-4b1a-b372-a364d9946ad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy02LTEtMS00MTg4OQ_4eb02e3c-f1d5-4b97-a0d9-b039d73e6a8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy04LTEtMS00MTg4OQ_e598c5af-c61e-4d45-9243-4b63efd21030">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xMC0xLTEtNDE4ODk_d30dc5bd-882a-4bcb-b7d3-75ba0bf533ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xMi0xLTEtNDE4ODk_f8f011b1-cfc7-4d2e-ac72-eca09ac141cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xNC0xLTEtNDE4ODk_f8330fd9-3c00-44ee-9be5-bc66e63b81e1">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC00LTEtMS00MTg4OQ_de8c36a4-85b9-4e2f-a8e3-8a34a41996ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC02LTEtMS00MTg4OQ_6c541894-7235-4e2b-a9e9-a2fe8444ab51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC04LTEtMS00MTg4OQ_ac9f3de3-af13-4279-b504-4174942aa246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xMC0xLTEtNDE4ODk_53bc57f0-55c9-4e37-ba48-bc73a80bad91">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xMi0xLTEtNDE4ODk_9b165700-8c63-4955-8ee3-1adc354faca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xNC0xLTEtNDE4ODk_80a40ad6-7207-4500-995e-dc41b62df4a0">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1928596f4b5435191e331ad33500d98_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0yLTEtMS00MTg4OQ_984a6be7-b0b9-40b6-9a3b-5694aa0b494f">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1928596f4b5435191e331ad33500d98_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS00LTEtMS00MTg4OQ_db12dfba-5fdc-4885-b0fe-65ea0ad16e71">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b75bdf9b3e45cfa77e885ac49788f5_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS02LTEtMS00MTg4OQ_9f03c9ed-b94d-41f0-8487-ea96c2a03184">1,605,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia219aede096c4cf0b514d5a736ae7245_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS04LTEtMS00MTg4OQ_a65b82e8-4604-455e-9a8e-ca776d9d4e88">1,511,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40101591a3a747d39081c3865fa29914_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xMC0xLTEtNDE4ODk_ffcec5ce-9f55-4325-ac08-0a3abbfc03c0">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida35814b016d4540b1321674b0722978_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xMi0xLTEtNDE4ODk_acd5a4cd-0194-4bb5-ae15-3ffe91dc709b">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xNC0xLTEtNDE4ODk_bd508427-212f-4470-9cfb-de26a84b0602">92,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.779%"><tr><td style="width:1.0%"></td><td style="width:36.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d08dad083a947c387d54202008989a3_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0yLTEtMS00MjM0Nw_60c415e2-2bee-4601-ae81-2a2b0c263306">189,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d08dad083a947c387d54202008989a3_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi00LTEtMS00MjM0Nw_c985b5a8-5722-4fe9-979b-5359b261ce91">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636d41fbcdb344b7be8e6238915276b9_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi02LTEtMS00MjM0Nw_beb8433c-e1fa-4456-a3e7-bed552638b94">1,709,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53b540e964324fb0b61132eb59b41f73_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi04LTEtMS00MjM0Nw_0b3b860f-4f8a-481c-878d-fbaca1463c3d">1,589,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69cc6c5cf6684519a5d00d853fa37565_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xMC0xLTEtNDIzNDc_7d605407-6f63-4c3e-af5f-7118764a0caf">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1cfd6d4e8e2473aa197ec5caf0a0e38_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xMi0xLTEtNDIzNDc_926ab7f5-32dd-42bf-99d1-da4fdeb33585">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xNC0xLTEtNDIzNDc_3c86f912-7ac4-4569-8575-68bcb2c26dcc">117,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy00LTEtMS00MjM0Nw_373259e4-22d3-478c-997a-52714369d47c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy02LTEtMS00MjM0Nw_77396c31-3c4f-4094-990b-fe349ac39722">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy04LTEtMS00MjM0Nw_43780746-4746-495c-a79b-55501954adaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xMC0xLTEtNDIzNDc_f1fae219-7ee8-4206-8342-87a8b0bf383c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xMi0xLTEtNDIzNDc_fe73f81a-4a46-42f6-8a63-5d6783bead11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xNC0xLTEtNDIzNDc_bb55445c-bda9-4819-ae6e-4e61936db54e">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0yLTEtMS00MjM0Nw_0e10ba5c-676f-4ee1-b3ab-6635ebe20741">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC00LTEtMS00MjM0Nw_33d25b5f-b024-4dc6-aa62-e2162f9a33e6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC02LTEtMS00MjM0Nw_014796e6-5f78-45f2-81b1-9af5176fb19c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC04LTEtMS00MjM0Nw_4777e006-a0d3-4f77-aca3-cc02393df57b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xMC0xLTEtNDIzNDc_a2383946-e977-4ce9-a94c-557acd147d09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xMi0xLTEtNDIzNDc_045ac294-0896-49e3-89e8-cd4436d74c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xNC0xLTEtNDIzNDc_b5aed8af-a05e-4543-89d7-e451c1faeb1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi00LTEtMS00MjM0Nw_c2021bb8-4b64-42c5-af96-b8004ef27178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi02LTEtMS00MjM0Nw_7eda0b7c-68c6-4df4-83ee-899f98a39be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi04LTEtMS00MjM0Nw_b669b027-f0c4-4ea3-8989-01f94dc854fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xMC0xLTEtNDIzNDc_3a920e9e-4bba-467e-95aa-10c38eeca971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xMi0xLTEtNDIzNDc_665aabaa-79f8-43a2-9b7a-5a6d1dca65a4">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xNC0xLTEtNDIzNDc_dd42297f-8e77-453e-90df-a0de579f9612">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy00LTEtMS00MjM0Nw_212a52c3-9e65-4065-8f49-467ab24c6bc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy02LTEtMS00MjM0Nw_bdf014ff-c099-4ae2-b458-ebb0b9625104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy04LTEtMS00MjM0Nw_307af532-015e-416f-bf0b-69c3f6ede097">31,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xMC0xLTEtNDIzNDc_866f592b-749e-4b38-8747-3e6284ab51d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xMi0xLTEtNDIzNDc_89060c00-bb4a-4341-a1da-7d3200ae51d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xNC0xLTEtNDIzNDc_88077a16-f034-4114-83a6-a4cfd8128d99">31,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC00LTEtMS00MjM0Nw_7f90962d-6de4-4d21-95e7-59fd0897ba86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC02LTEtMS00MjM0Nw_c515020f-e3d4-45f5-b582-ed72ee910041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC04LTEtMS00MjM0Nw_30ce0980-66be-453c-be5b-48738d2eb45b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xMC0xLTEtNDIzNDc_44691da7-daf3-420d-8743-d0954cb73f9d">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xMi0xLTEtNDIzNDc_ffcf24d9-3d4d-4b9a-adc2-fe52680688ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xNC0xLTEtNDIzNDc_d66c3a45-e815-4351-8ef1-25198fb84f16">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i122cc45b24a040dca3939cb8ebe170a1_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0yLTEtMS00MjM0Nw_b5d76e73-468c-4a97-8945-2e37131ff0b2">190,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122cc45b24a040dca3939cb8ebe170a1_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS00LTEtMS00MjM0Nw_da81694f-46ee-4946-ab6c-b622dea9a6a5">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d09fe0d1af4d7db5d3ab1d00f6cb8e_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS02LTEtMS00MjM0Nw_88661f10-2a16-4f87-84e2-e5a01bb5b00a">1,712,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if294b62ddc5941a89003bac80ce657a0_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS04LTEtMS00MjM0Nw_d711cb7a-295b-460f-b2ea-f447ec3807c7">1,621,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30b21eb47f1d44a0801b1c165ff6a310_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xMC0xLTEtNDIzNDc_97dd3344-1780-4293-9326-a67cda668aad">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f5c48a42a0b4346b4984be1e404c5e3_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xMi0xLTEtNDIzNDc_62bdb59d-a4ab-464a-8363-24db4e488a3a">2,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xNC0xLTEtNDIzNDc_0281ffb5-d700-471d-b4db-b7121c2c306a">88,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMy0yLTEtMS00MTg4OQ_ba402028-95f8-4fdb-8bda-c0280630eea2">31,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMy00LTEtMS00MTg4OQ_25246456-0da4-4f45-9184-7fd4a9af978b">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNS0yLTEtMS00MTg4OQ_015a0045-4ff4-4c21-912e-f1f3abe99500">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNS00LTEtMS00MTg4OQ_c9324415-1a11-4ff0-9ab5-7242026fb442">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNi0yLTEtMS00MTg4OQ_1527aef2-d8f9-4303-b533-94dfbdce6b51">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNi00LTEtMS00MTg4OQ_5a73dd79-075a-4352-997e-1bfed48c100a">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNy0yLTEtMS00MTg4OQ_b8c24df5-d576-4657-9eb3-da5547693bad">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNy00LTEtMS00MTg4OQ_03d08a4d-ed5a-49c7-8362-0e032c24a55f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfOS0yLTEtMS00MTg4OQ_0b32bfc3-d531-430f-9b20-23340cebb4f6">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfOS00LTEtMS00MTg4OQ_243adf42-0546-4070-a389-5e8332a2fd50">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTAtMi0xLTEtNDE4ODk_928f96a5-e01d-4fb9-9b24-e6e60efd8b6d">867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTAtNC0xLTEtNDE4ODk_edcdff53-6ed8-4e2f-97ca-b6a0d928373f">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in operating lease right-of-use-assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTEtMi0xLTEtNDE4ODk_e745d945-11dc-4ba3-87d5-ceb6423a620c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTEtNC0xLTEtNDE4ODk_fc027070-2379-4562-8f47-4f7a82fac142">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTItMi0xLTEtNDE4ODk_165ed8c0-064a-454a-af48-876c8ea9aba0">2,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTItNC0xLTEtNDE4ODk_12991a8e-ed3e-4287-9ea0-f3801cdc9e21">3,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTMtMi0xLTEtNDE4ODk_839c1bd2-77c8-4520-87d6-87710a1d2250">31,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTMtNC0xLTEtNDE4ODk_165f3a0c-210d-4fc4-9ce1-aa62484da36e">23,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTUtMi0xLTEtNDE4ODk_00f6377e-87e1-4d2e-b700-06e2fdd252de">248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTUtNC0xLTEtNDE4ODk_4455d7d3-a5e8-4eb7-91fc-95221b1f08c5">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTYtMi0xLTEtNDE4ODk_709855f6-f8a2-47b0-8ee6-84ea1c5b85c9">28,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTYtNC0xLTEtNDE4ODk_23731229-d10c-4ccb-a872-b0c527cffc21">17,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTctMi0xLTEtNDE4ODk_7ee2dceb-dd8d-4311-bd72-44c7f5a31209">41,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTctNC0xLTEtNDE4ODk_fb8da4f3-9253-4170-aeb3-5562f859e109">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTgtMi0xLTEtNDE4ODk_66b7b9ce-36f4-4d26-b2b2-e3ad480d2801">12,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTgtNC0xLTEtNDE4ODk_b525e0fd-f51e-439a-b1ab-8ec0bf55c29a">4,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjEtMi0xLTEtNDE4ODk_c0c73e4b-d939-4dff-82b0-cf5fa0185202">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjEtNC0xLTEtNDE4ODk_15959900-7431-4da8-aae5-77bd341a52b2">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt borrowings, net of fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjItMi0xLTEtNDE4ODk_44eca5fd-89bd-4fce-acb3-4661ae6f9873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjItNC0xLTEtNDE4ODk_a4879332-d9ee-48c1-9705-b374012dcc16">24,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjMtMi0xLTEtNDE4ODk_d6979586-3c34-4154-813d-ececc340ba07">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjMtNC0xLTEtNDE4ODk_ed0eb821-a356-4722-896b-da0a9b1a770f">23,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjQtMi0xLTEtNDE4ODk_eed96b7a-2814-4b7c-9828-9cc0c2052991">20,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjQtNC0xLTEtNDE4ODk_ee6a1fcc-959b-4553-8109-eb2accd2ec51">4,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjUtMi0xLTEtNDE4ODk_3620bedc-af55-453f-8bbf-eba67702fd22">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908be8c8318f430fa0dcb565f616e66e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjUtNC0xLTEtNDE4ODk_c731970a-1061-4fd8-8b85-3f9bc1355686">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjYtMi0xLTEtNDE4ODk_4d1cb0b2-56f9-4629-b123-855f58a6cf6b">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjYtNC0xLTEtNDE4ODk_3e6d14be-91e5-44d8-b2f7-c7452311f4b8">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjktMi0xLTEtNDE4ODk_34900e40-c46f-4d34-9a22-a175d7ac615d">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjktNC0xLTEtNDE4ODk_a0f872c4-3133-400f-a2fe-55ce40ebea44">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzMtMi0xLTEtNDE4ODk_8e4a33c9-7753-424a-b273-12b6ec45ee56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzMtNC0xLTEtNDE4ODk_690dfcf2-590a-424e-aaa7-6ebd75790c70">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzQtMi0xLTEtNDE4ODk_e4817ebe-c053-4ad2-b6e7-a8db92361e19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="3" name="us-gaap:TreasuryStockCarryingBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzQtNC0xLTEtNDE4ODk_834106f1-5073-422d-aa3f-3c21238c6b50">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Recognition of exit fee liability related to debt borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzUtMi0xLTEtNDE4ODk_77a4aff9-65b1-47b6-aefa-e51b3f02c3cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="3" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzUtNC0xLTEtNDE4ODk_28d8f282-e959-4b3b-8938-c903536286b8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzY_a81472f2-25f1-40a2-8054-c471ea193e58" continuedAt="i9a6fb2966ce64709968414dce4f561d8" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i9a6fb2966ce64709968414dce4f561d8" continuedAt="if84503242b8b4ff48870a39921f9560b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjQ_7d5bee75-8594-48e4-aa6e-94ca0d53f22c" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzNDA_95d5ca06-8a47-4373-9114-f66c0e95839b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjE_d442ec7a-64b4-4644-ad75-c1a0ae70b7d2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2023 and December&#160;31, 2022, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzA_38aa1a95-ffc6-4acc-bc05-a4cc9d429881" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfMy0yLTEtMS00MTg4OQ_55655b4d-daa4-4c09-be15-f2c1887edfd6">3,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfMy00LTEtMS00MTg4OQ_4b46bce8-586e-409b-897c-81fdaac518ff">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNC0yLTEtMS00MTg4OQ_3952b122-a1e9-4632-a4e1-f489c2ad1841">4,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNC00LTEtMS00MTg4OQ_2c50feb3-da68-40ef-81d2-538c939c09a4">7,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNS0yLTEtMS00MTg4OQ_89e4f1af-10cb-44c1-b43e-6f743ffe2020">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNS00LTEtMS00MTg4OQ_78d1f1d6-2f8f-4a44-b74e-92028fd2fb1e">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNi0yLTEtMS00MTg4OQ_8c53ff66-3aee-4623-94c2-34b0fd6d8ed4">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNi00LTEtMS00MTg4OQ_ff9e54da-fe24-4ec8-b2fd-b0dcdb2bbabc">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNy0yLTEtMS00MTg4OQ_3af02587-2ce7-4d44-9e0a-8f6e3700724a">10,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNy00LTEtMS00MTg4OQ_5d5b0aa9-c265-4e88-b8a8-6201424ed510">12,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="if84503242b8b4ff48870a39921f9560b" continuedAt="i8f0cf19d53ef4cba9ace65570158db4a"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzNTM_ccb58324-3484-45f9-a9c1-144a9baa928f" continuedAt="idca73596831740838f36e806f418e13d" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements that include development milestones, the Company evaluates at contract inception whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idca73596831740838f36e806f418e13d">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMDU_c09b6f43-bff1-42dd-8c0d-398b2d2915d5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjU_d90f34fd-b974-4fe9-9bbc-b8a70fb3eb77" continuedAt="i3b9af880952c4f8094d1d7d394aeabaf" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i8f0cf19d53ef4cba9ace65570158db4a" continuedAt="ia7472686c4d841df98dd12be39a97077"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3b9af880952c4f8094d1d7d394aeabaf" continuedAt="i7cec89fa278c428797bf4f676f8accc3">&#160;</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cec89fa278c428797bf4f676f8accc3">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2023 and 2022:</span><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTk_07c9be1d-2e52-41c2-9de5-121b05bf1d68" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi0yLTEtMS00MTg4OQ_7795da0a-4844-4922-a58a-dd79c42b4036">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi00LTEtMS00MTg4OQ_fc41e433-ec43-4799-ac6c-facfbd3bd125">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi02LTEtMS00MTg4OQ_b703a052-27c5-44ca-8b43-d030147ed090">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi04LTEtMS00MTg4OQ_427a965c-c713-4203-a56e-1d654661bb41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy0yLTEtMS00MTg4OQ_eccc5c3f-2348-4a2d-9daf-14d9ada66882">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy00LTEtMS00MTg4OQ_11bc90df-c578-4d2c-9257-b065dd6d5dfa">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy02LTEtMS00MTg4OQ_e36ccee2-2121-499e-b5d2-af8c6119765a">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy04LTEtMS00MTg4OQ_daa4414a-a486-482b-8f40-e0f607b87c15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS0yLTEtMS00MTg4OQ_63b138ae-c90c-421e-8115-69da967cd25c">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS00LTEtMS00MTg4OQ_8c1c3f0e-b169-4f28-a2a0-fbf2f701124b">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS02LTEtMS00MTg4OQ_c4d1c573-c788-4186-ae0f-cfc53459a39c">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS04LTEtMS00MTg4OQ_5049b544-b104-4142-b5f1-ff8444d40432">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi0yLTEtMS00MTg4OQ_60f0b696-9f02-46bf-b22f-431f5de2f150">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi00LTEtMS00MTg4OQ_fc88fad7-dc97-4599-928b-5f64727a7bf6">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi02LTEtMS00MTg4OQ_ad848b54-ad39-4358-b525-0ba867022a5d">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi04LTEtMS00MTg4OQ_de323b6f-c7ef-4b47-b4cb-69f358386487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTg_9b789b96-41f0-498d-8194-3f9a3e491fb5" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i122a411cbee64663b669721e52d22969_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMi0yLTEtMS00MTg4OQ_4332d37d-5970-4338-ace9-4e9849a50247">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i122a411cbee64663b669721e52d22969_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMi00LTEtMS00MTg4OQ_d8049034-48d7-45d4-9f1f-d2de6aedeb05">5.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMy0yLTEtMS00MTg4OQ_9b7d604c-15f5-49f3-bd49-bceef1f48488">5,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMy00LTEtMS00MTg4OQ_4e605f82-5e5b-48c4-8f39-9bcc324e46e5">2.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNS0yLTEtMS00MTg4OQ_d729145a-6a75-40f0-aa7c-d880a818f8e3">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNS00LTEtMS00MTg4OQ_a14f3a06-8835-4238-ae2e-a9c4747db9ce">14.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNi0yLTEtMS00MTg4OQ_a8ca2ebb-3821-464b-990d-fe9915097470">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNi00LTEtMS00MTg4OQ_446929c1-9528-4f79-b1b8-c8368a953941">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNy0yLTEtMS00MTg4OQ_a1c3c279-f0b1-4eff-866f-b022a366ffad">17,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNy00LTEtMS00MTg4OQ_93227fd2-f9a7-4d11-8ece-a2cd8b514f68">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfOC0yLTEtMS00MTg4OQ_dbb2597a-7e1c-4b07-834d-5bb235b8c524">6,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfOC00LTEtMS00MTg4OQ_a65afe16-eb2e-4ea9-ac1f-0b752fee14e1">6.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2023:</span><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTQ_1b392d1e-1c37-4d3e-af5e-e518c297570a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4590c26f966346da952432b88fccff44_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMi0yLTEtMS00MTg4OQ_02e7d754-d299-4e57-a70a-5f01aada71cf">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4590c26f966346da952432b88fccff44_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMi00LTEtMS00MTg4OQ_082e99f4-d88d-4fa6-9b44-573dec2e95cb">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMy0yLTEtMS00MTg4OQ_9ac02d4d-7276-44b5-a861-20b52ee85895">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMy00LTEtMS00MTg4OQ_27ee3bc4-333e-45ea-8156-c2cb6d384359">2.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNC0yLTEtMS00MTg4OQ_4da5630b-6aa3-4c22-9707-1acbf3f9964c">1,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNC00LTEtMS00MTg4OQ_e2e25980-076c-464d-8f0a-7a247a762c8b">3.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNS0yLTEtMS00MTg4OQ_999f10cc-9897-447a-a079-a85c4d0bb599">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNS00LTEtMS00MTg4OQ_7e8c40f9-4cf5-497f-9582-89de45c643f1">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52cb6e46f3004a31b017f45441c3a197_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNi0yLTEtMS00MTg4OQ_b7ae3695-894f-4079-a87d-e73e34d691de">5,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52cb6e46f3004a31b017f45441c3a197_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNi00LTEtMS00MTg4OQ_28ed3f37-114c-4488-83c1-6171158cf8b2">2.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ia7472686c4d841df98dd12be39a97077" continuedAt="i6119f887843640f886a2c76bcc599ed1"><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzQ_dc2cf51f-b530-4f69-9e74-850d38ff4c27" continuedAt="ia8121fe792654c4d98bb040fa94a68d8" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6119f887843640f886a2c76bcc599ed1"><ix:continuation id="ia8121fe792654c4d98bb040fa94a68d8"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with stock warrants, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_37"></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNy9mcmFnOjk1NDVjNDBiYmUxYzQ4ZTE4ODQ2ZDgwZGY4YjNmOTRkL3RleHRyZWdpb246OTU0NWM0MGJiZTFjNDhlMTg4NDZkODBkZjhiM2Y5NGRfNzc4_be18714b-c956-41d6-b15c-45dedc3cc0f5" continuedAt="ia8030bde42624bf096408ca41fe48007" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8030bde42624bf096408ca41fe48007">We do not expect that any recently issued accounting pronouncements will have a material impact on our financial statements.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMzM1_66ca9705-4038-416b-a5ec-ff322d583419" continuedAt="ic18cdd4ed3da44559d5db693c7fb929f" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><ix:continuation id="ic18cdd4ed3da44559d5db693c7fb929f"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2023 and December&#160;31, 2022 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMzI4_47d9be94-ab84-449c-a504-734c4a1d256f" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1150bd512a24422facf2a358e5f34712_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy0yLTEtMS00MTg4OQ_c811dae8-5313-45f2-8089-76cf1809cb2e">26,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1150bd512a24422facf2a358e5f34712_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy00LTEtMS00MTg4OQ_75f69d33-9f9b-4dc8-9c61-af66b1f159f3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1150bd512a24422facf2a358e5f34712_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy02LTEtMS00MTg4OQ_760079f0-8072-4503-b4ab-e0378d4a1197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1150bd512a24422facf2a358e5f34712_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy04LTEtMS00MTg4OQ_fdf0e77b-5fd8-49ab-ae8b-3a0388d3d92b">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS0yLTEtMS00MTg4OQ_baf208f3-4a73-4c00-9256-1191b3717fcf">70,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS00LTEtMS00MTg4OQ_c710d613-7ddd-41d9-8d8f-854a54fb7b46">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS02LTEtMS00MTg4OQ_f97b9b8c-325f-42ff-9f22-8613a1795ad8">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS04LTEtMS00MTg4OQ_f926047f-e9ae-4f8d-a635-ddca5e3fff0b">70,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi0yLTEtMS00MTg4OQ_e0042884-38aa-4f7e-8dff-0d679f3fac89">9,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi00LTEtMS00MTg4OQ_a7884611-dcd3-4f09-aab2-950f08efa3ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi02LTEtMS00MTg4OQ_f2d7aa76-4094-417d-b825-8534d40cb111">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi04LTEtMS00MTg4OQ_bd965f60-e0b4-4712-9844-a87a564363c4">9,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy0yLTEtMS00MTg4OQ_63243cc5-1529-44ef-92b2-a1d6c7d14a2d">80,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy00LTEtMS00MTg4OQ_3ab6cc5e-21f7-42fa-a96b-4dd3a6103fa3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy02LTEtMS00MTg4OQ_c17ed57a-9322-4930-8e10-c4bd9599706e">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy04LTEtMS00MTg4OQ_80b2c72f-baf7-452b-ad7b-e3c6148fe5b2">79,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC0yLTEtMS00MTg4OQ_8c879d61-cdba-464f-b594-953d84e12347">106,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC00LTEtMS00MTg4OQ_b455b878-fdeb-4ced-aaf9-618d1bf6a57b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC02LTEtMS00MTg4OQ_4f47aa57-4d69-499d-91c5-ae5d4a3af3d4">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC04LTEtMS00MTg4OQ_f84478c2-8267-4a08-b3cc-88d6efc2081c">105,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtMi0xLTEtNDE4ODk_d67f8786-8eff-4b12-91ab-02df92880280">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtNC0xLTEtNDE4ODk_f3497334-3702-45bf-b618-0924b76c5a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtNi0xLTEtNDE4ODk_db835035-155b-4459-be2a-31406e2c64bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtOC0xLTEtNDE4ODk_d0021d2c-7f50-4cb7-9986-613276d2da15">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtMi0xLTEtNDE4ODk_b2a5dd20-840a-4a87-887e-bfe8409f7b0a">74,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtNC0xLTEtNDE4ODk_ed8826f6-9db4-4eae-9d4c-3d5ef91511c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtNi0xLTEtNDE4ODk_9b074d4c-ec34-4cb3-a640-33fefd4edabc">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtOC0xLTEtNDE4ODk_76a72644-66dc-480d-812e-e8cc9032915d">73,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtMi0xLTEtNDE4ODk_f6ed8930-167a-40ea-a8f3-691c83875f6b">18,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtNC0xLTEtNDE4ODk_9b747f95-8105-4218-a07f-25173dfce298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtNi0xLTEtNDE4ODk_58561502-019d-4916-9cef-44082ec96855">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtOC0xLTEtNDE4ODk_0181d16f-a5be-4065-aa23-ba8876805600">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctMi0xLTEtNDE4ODk_34b9ca79-57e1-4c62-a386-f28d1db4da66">92,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctNC0xLTEtNDE4ODk_23c048f8-9e72-4727-8e88-bfe1bbf93b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctNi0xLTEtNDE4ODk_7c111834-d4c5-4ac5-abf7-5cb509cfcc5e">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctOC0xLTEtNDE4ODk_cabf26fd-1b1a-488c-b0a3-7af8a427fb81">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e3a3d13094b578b03f23910d47681_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtMi0xLTEtNDE4ODk_c476988e-8f2e-4082-91f9-acd9b4d319f5">138,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e3a3d13094b578b03f23910d47681_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtNC0xLTEtNDE4ODk_aa735043-39ff-4f65-b2bc-f0a54de201ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375e3a3d13094b578b03f23910d47681_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtNi0xLTEtNDE4ODk_51169c85-01cf-43bf-bbf6-6a1863299f8e">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e3a3d13094b578b03f23910d47681_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtOC0xLTEtNDE4ODk_68b149eb-ae3c-4780-b935-3019a484cffa">138,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMTcw_4ef6aafe-0391-4552-b6fc-aad887b7c9b1"><ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="0" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMTcw_b950e8e4-549c-474c-90e6-e4b100fbfee9">no</ix:nonFraction></ix:nonFraction> realized losses during either of the three month periods ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_43"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RleHRyZWdpb246MDExOWIzMmU2YTRlNDNkODk1MTNhMzllMDRhNzNhNDVfMTU3Mg_be616c5b-6224-411d-bd54-aeeef6cd4c44" continuedAt="i153c5e67449349a1a449be88b5a26c10" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i153c5e67449349a1a449be88b5a26c10" continuedAt="i22843cbe0a494693bdba52f4f7309d49"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i22843cbe0a494693bdba52f4f7309d49"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RleHRyZWdpb246MDExOWIzMmU2YTRlNDNkODk1MTNhMzllMDRhNzNhNDVfMTU3OQ_ff697cee-0f12-41be-a8c4-d2ebd31d67ac" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC0yLTEtMS00MTg4OQ_ad07a0ac-2597-4389-961c-5b916a121c06">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC00LTEtMS00MTg4OQ_b5cd6cee-8ec2-4e2e-b5cb-34bb778b186f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC02LTEtMS00MTg4OQ_ee0128bb-d994-41e1-b684-79963852e3fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC04LTEtMS00MTg4OQ_6f14d4fb-d754-4e19-a06e-509a6289a770">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS0yLTEtMS00MTg4OQ_1a3f62a6-2b7f-493a-824e-3e7f05d407e4">70,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS00LTEtMS00MTg4OQ_14410e9a-f79f-4bd7-9e08-9865e4054e75">9,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS02LTEtMS00MTg4OQ_e5a7c05a-2427-4c79-a3fd-fca2dd56555f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS04LTEtMS00MTg4OQ_4bf7ee4d-d4ad-49d1-9a01-c7e02f411d42">79,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi0yLTEtMS00MTg4OQ_89caf90b-9e90-449c-abf9-f05e9cd5021a">96,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi00LTEtMS00MTg4OQ_ef201d34-fece-4698-8b22-acac821844a2">9,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi02LTEtMS00MTg4OQ_b1a59420-a50d-4238-b015-d9241c97c354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi04LTEtMS00MTg4OQ_fc8574ae-4414-413d-ac08-ae531c63777b">105,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb4426fae2448009d2f24b25517721b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC0yLTEtMS00MTg4OQ_90679471-69fe-419c-a67b-618ea35dbbc1">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2630f42a2e4991858d1dab84290767_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC00LTEtMS00MTg4OQ_69d6cab6-133c-4a2d-8d47-f8d8103ec8e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC02LTEtMS00MTg4OQ_96d93e7b-9bbe-4e74-a082-932d93e59862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC04LTEtMS00MTg4OQ_c5e88551-5b58-427a-a2e0-d1a38ff9c9d5">46,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb4426fae2448009d2f24b25517721b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS0yLTEtMS00MTg4OQ_90bce22a-5905-4d0a-bb30-d9a6d4768eda">73,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2630f42a2e4991858d1dab84290767_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS00LTEtMS00MTg4OQ_1f071da4-e759-4125-a843-dc82290062c9">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS02LTEtMS00MTg4OQ_e6e1b09d-2c2c-4e17-9175-4ba76df34234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS04LTEtMS00MTg4OQ_c6af218b-d426-45ef-8885-f697f5622199">92,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb4426fae2448009d2f24b25517721b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi0yLTEtMS00MTg4OQ_d08235ed-310f-4814-9d69-5ad854eec048">120,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2630f42a2e4991858d1dab84290767_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi00LTEtMS00MTg4OQ_ee636bb3-9d8d-49a8-923e-a7c8e6204371">18,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi02LTEtMS00MTg4OQ_619ef301-3baa-465b-8ad4-e580f45a0c02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi04LTEtMS00MTg4OQ_37ee94e4-1e5a-4118-b677-4023d67cd3cd">138,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2023 or December&#160;31, 2022. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNjE2Mw_77f92618-239a-4dde-be13-7580a1d07cdb" continuedAt="i396eccf2cca240c8b127991fd67b49b6" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="i396eccf2cca240c8b127991fd67b49b6"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $<ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="-3" name="lxrx:OxfordLoanFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTg4_4520ebdc-567d-478c-a5f5-2ed308a05b85">150</ix:nonFraction>&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with financial covenants relating to net sales of sotagliflozin following regulatory approval and minimum cash balance requirements following funding of the third tranche. The interest-only period will be followed by an amortization period extending through the maturity date.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $<ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="-3" name="lxrx:TermLoanA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIyMTA5_d3b712bf-1e84-4b09-ae22-c999a8ba848e">25</ix:nonFraction>&#160;million tranche was funded at closing. The second $<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="lxrx:TermLoanB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIyMTU1_e5b58373-0b92-4182-895a-e7bb383ee89b">25</ix:nonFraction>&#160;million tranche was funded on December 30, 2022. The loan and security agreement was amended on May 1, 2023, to increase the amount available for draw under the third tranche from $50 million to $75 million and decrease the amount available for draw under the fourth tranche from $50 million to $25 million.  The third tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. An unused fee will be due in the event Lexicon does not draw the full amount available under the third tranche. The fourth tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTg5MA_e0fd7378-1481-4719-8394-3c5f1a3e3198">420,673</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTk1MA_98b21f0b-4c16-4716-9d88-f5f8d9f6efe9">2.08</ix:nonFraction> per share. Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIzMTk0_169896a5-bf22-4221-bba5-86e316045026">224,128</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIzMjAw_78b2f383-0eaf-4a4d-a95b-d77b7fd41455">1.95</ix:nonFraction> per share. The loan and security agreement provides that, upon funding of the third tranche, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 0.875% of such tranche, as determined by reference to a 10-day average closing price of the shares, and having an exercise price equal to such average closing price. All warrants are exercisable for five years from their respective grant dates and feature a net cashless exercise provision.  The warrants that have been issued in connection with the funding of the first and second tranches are classified as equity instruments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus <ix:nonFraction unitRef="number" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjQ0OA_b48685c7-80fb-40be-99b1-5d7cb4d9f0af">7.90</ix:nonFraction>%, but not less than <ix:nonFraction unitRef="number" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjQ3MA_9a780f29-161f-4c54-8aee-00c282fa9ed9">8.01</ix:nonFraction>%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2023, the interest rate was <ix:nonFraction unitRef="number" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="INF" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjU4Nw_64f5963a-734a-4a04-83fb-9cb304c61711">12.57</ix:nonFraction>%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to <ix:nonFraction unitRef="rate" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="lxrx:FinalPaymentWithNoExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzAwOA_9941466c-dc05-483f-ab7e-5e3ecf968f4b">6</ix:nonFraction>% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to <ix:nonFraction unitRef="rate" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="lxrx:FinalPaymentWithExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzEzNg_d6e001b9-5c63-462f-95a7-1a7bd4f43d2c">7</ix:nonFraction>% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i5e92df6f278d4c19a869b984471be038_I20220331" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzI0Mw_225497c8-79ab-4104-aadd-b1aa31ebb7fc">1.5</ix:nonFraction>&#160;million was recorded once for each tranche as a debt discount on the funding date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the balance of the debt discount was $<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="lxrx:TermLoanADebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODI0NDg5_9936ac2e-7f8d-4d41-aa57-f6148bacfe15">4.2</ix:nonFraction>&#160;million which offsets long-term debt on the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023, the Company recognized interest expense of $<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="0" name="lxrx:TermLoanAInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNDI3Mg_6db69083-1c3c-4d29-b676-9880e8e07e50">1.8</ix:nonFraction>&#160;million.  As of  March&#160;31, 2023, the carrying value of the Oxford Term Loans was $<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNDMzNg_14b5dcfd-9719-4dcd-bcae-d6ba7d27bc10">48.8</ix:nonFraction>&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics.  The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenants, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2023.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Bridgewater, New Jersey and will expire in August 2025 and January 2034, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTQ4_c9048f55-792b-4c7a-9d1e-ad81b159df7e">6.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE2ODU2_2ac6d2a7-e971-4573-aef2-b13d25916c86">6.8</ix:nonFraction>&#160;million, respectively, which is included in operating lease right-of-use-assets in the condensed consolidated balance sheet. Current and long-term liabilities as of March&#160;31, 2023, relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTY0_ecf2003a-e697-43b4-8181-00a58d500b3b">1.3</ix:nonFraction>&#160;million and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTU2_9f793bc6-211c-4523-a062-afed343133d9">5.5</ix:nonFraction>&#160;million, respectively, which are included in accrued liabilities and long-term operating lease liabilities in the condensed consolidated balance sheet, respectively.   Current and long-term liabilities as of December&#160;31, 2022, relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTcx_d72456c3-b4d2-49ed-93f0-e74f6463a5ef">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTgy_94d87a89-9974-4458-b824-1387dd500b77">5.4</ix:nonFraction>&#160;million, respectively, which are included in accrued liabilities and long-term operating lease liabilities in the condensed consolidated balance sheet, respectively.  During each of the three months ended March&#160;31, 2023 and 2022, the Company incurred lease expense of $<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQy_f14312df-1398-4ddd-b46e-188181f911f1">0.4</ix:nonFraction> million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company made cash payments for lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331" decimals="5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQz_3f87d2e1-2620-4d62-a280-8adb98b748aa">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331" decimals="5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQ4_9c21080c-6970-4573-9144-6bbb4bdaa792">0.3</ix:nonFraction> million, respectively. As of March&#160;31, 2023 and December&#160;31, 2022, the weighted-average remaining lease terms were <ix:nonNumeric contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQ5_be219bff-b7b3-46f8-b107-88c4bb22c1c4">9.4</ix:nonNumeric> years and <ix:nonNumeric contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUw_1d289d73-93ad-4d9b-b6f9-eff24149113d">9.5</ix:nonNumeric> years, respectively, with weighted-average discount rates of <ix:nonFraction unitRef="rate" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="1" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUx_14df1f81-7ce0-46af-a962-f4a54b23d3af">9.6</ix:nonFraction>% and <ix:nonFraction unitRef="rate" contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231" decimals="1" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUy_1943b5b3-cfb0-412d-a9f5-8a34d08955d8">9.6</ix:nonFraction>%, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2023:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:80.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMi0xLTEtMS00MTg4OQ_9dcd34c1-4f0d-49a0-b9fb-857dac07903e">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMy0xLTEtMS00MTg4OQ_8f99de18-ca74-4918-81a7-e58ca95981af">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNC0xLTEtMS00MTg4OQ_4027a258-862c-4c03-b784-db23822c95f7">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNS0xLTEtMS00MTg4OQ_6a644e8e-69db-4789-91f5-96d2d528deca">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNi0xLTEtMS00MTg4OQ_c49f2192-0091-4a63-b153-e9ad202f9ae9">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNy0xLTEtMS00MTg4OQ_4c1eca02-fec5-4c61-b498-d582dd07f40e">5,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfOC0xLTEtMS00MTg4OQ_11fc30f8-f381-413f-8f99-14777f753126">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfOS0xLTEtMS00MTg4OQ_7b700c5d-b7f8-4706-bd6a-feb9e67a0674">3,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTAtMS0xLTEtNDE4ODk_0207894d-9755-48a7-b709-bd2df028bc10">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTEtMS0xLTEtNDE4ODk_c18d4b04-f7da-4aac-898a-2eb378fbe0b6">1,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331" decimals="INF" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTItMS0xLTEtNDE4ODk_d9c4172c-c795-45d8-8342-23517b958a85">5,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.  We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a pending NDA for sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure. The NDA is currently under review by the FDA and has been assigned a PDUFA target action date of May 27, 2023. The NDA is supported by positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively. Under the NDA, we are seeking regulatory approval to market sotagliflozin to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and in adults with type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. We are now preparing for the anticipated commercial launch of sotagliflozin in the United States following approval.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA. That NDA was supported by positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively. The FDA issued a complete response letter regarding our NDA for sotagliflozin in type 1 diabetes. At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our NDA and the hearing process is ongoing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have reported positive results from a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain. We have reported top-line results from a separate Phase 2 clinical trial of LX9211 in post-herpetic neuralgia which demonstrated clear evidence of effect. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts, and LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb. Our efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs. We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians. We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020. To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our planned commercial launch of sotagliflozin in the United States for heart failure, if approved; the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receipt of milestones, royalties and other payments under such arrangements; and general and industry-specific economic conditions which may affect research, development and commercialization expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.  We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.  Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of March&#160;31, 2023, we had an accumulated deficit of $1.6&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants.  Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.  We expect to continue to incur significant research and development costs in connection with the continuing research and development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:69.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.304%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services for the three months ended March&#160;31, 2023 decreased 42% to $5.5 million as compared to the corresponding period in 2022 primarily due to decreases in external research development costs and professional and consulting fees relating to preparations for the submission of our application for regulatory approval to market sotagliflozin in the United States for heart failure. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs for the three months ended March&#160;31, 2023 increased 24% to $4.0 million as compared to the corresponding period in 2022, primarily due to higher employee salaries and benefit costs as a result of increasing headcount.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended March&#160;31, 2023 increased 17% to $1.2 million as compared to the corresponding period in 2022, primarily due to increased headcount.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and equipment costs for the three months ended March&#160;31, 2023 and 2022 were $0.4 million and $0.3 million, respectively.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for each of the three months ended March&#160;31, 2023 and 2022 were $1.0 million.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:69.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.304%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees for the three months ended March&#160;31, 2023 increased 213% to $7.1 million as compared to the corresponding period in 2022, primarily due to higher marketing and professional fees. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs for the three months ended March&#160;31, 2023 increased 131% to $7.7 million as compared to the corresponding period in 2022, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2023 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended March&#160;31, 2023 increased 27% to $2.2 million as compared to the corresponding period in 2022 due to increasing headcount in the current period.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs for the three months ended March&#160;31, 2023 and 2022 were $0.4 million and $0.3 million, respectively. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended March&#160;31, 2023 increased to $1.7 million from $0.9 million in the corresponding period in 2022, primarily due to travel, training and software licenses in preparation for commercialization of sotagliflozin.  </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Interest and Other Income, Net</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was $1.8 million during the three months ended March 31, 2023, due to the Oxford debt financings during March and December of 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Interest and other income, net increased to $1.0 million during the three months ended March 31, 2023 from the corresponding period in 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss per Common Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss and Net loss per Common Share.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $31.9 million, or $0.17 per share, in the three months ended March&#160;31, 2023 as compared to a net loss of $23.5 million, or $0.16 per share, in the corresponding period in 2022.    </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our collaborations and strategic licenses, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.  In March 2022, we entered into a loan and security agreement with Oxford Finance LLC that provides up to $150 million in borrowing capacity, available in four tranches, under which $50 million has been funded.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $105.9&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2022, we had $138.4&#160;million in cash, cash equivalents and short-term investments.  We used cash of $31.6&#160;million from operations in the three months ended March&#160;31, 2023.  This consisted primarily of the net loss for the period of $31.9&#160;million and a net decrease in operating liabilities net of assets of $3.5 million, partially offset by non-cash charges of $3.4&#160;million related to stock-based compensation expense. Investing activities provided cash of $12.1&#160;million in the three&#160;months ended March&#160;31, 2023, primarily due to net maturities of investments.  Financing activities used cash of $0.8&#160;million to repurchase common stock in satisfaction of tax withholding obligations of recipients of vested restricted stock units granted under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, sotagliflozin was approved in the United Kingdom for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. Upon the achievement of certain European regulatory approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our drug discovery alliance with Bristol-Myers Squibb, we will be required to make a milestone payment of $5 million upon dosing of the first patient in a Phase 3 clinical trial of LX9211.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas. The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, our subsidiary, Lexicon Pharmaceuticals (New Jersey), Inc., leased a 22,000 square-foot office space in Bridgewater, New Jersey. The term of the lease extends from February 2023 through January 2034 and provides for escalating yearly base rent payments starting at $820,000 and increasing to $986,000 in the final year of the lease.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our planned commercial launch of sotagliflozin in heart failure, if approved; the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.  Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.  We expect to continue to devote substantial capital resources to prepare for the commercialization of sotagliflozin, if approved; to successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.  We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our currently planned operations for at least the next 12 months from the date of this report.  During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.  If we are unable to obtain adequate financing when needed, we may have to delay or reduce the scope of one or more of our clinical trials, or research and development programs. Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $105.9&#160;million in cash and cash equivalents and short-term investments as of March&#160;31, 2023.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are subject to interest rate sensitivity on our outstanding Oxford Term Loans as they contain a floating rate tied to the 30-day LIBOR rate.  The Oxford Term Loans interest is payable in cash monthly and matures in March 2027, unless earlier repaid in accordance with their terms.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_70"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_73"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II -- Other Information&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_79"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_82"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical communit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">y.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to establish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;The outbreak of the novel coronavirus, or COVID-19, has had an adverse impact on our business operations and clinical trials and it could continue to adversely affect our business in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not have sufficient capital to support a full Phase 3 development program for LX9211 in neuropathic pain.  If we are unable to establish a strategic collaboration or other arrangement for that purpose, our capital needs will be substantially higher and we may be unable to obtain financing sufficient to fund Phase 3 development of LX9211 in neuropathic pain on acceptable terms, or at all, and may be required to reduce the scope of any such Phase 3 development program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We lack the capability to manufacture materials for nonclinical studies and clinical trials and commercial supplies for any products which gain regulatory approval. Our reliance on third parties to manufacture our drug candidates may harm or delay our research, development and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Our stock price may be extremely volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_852"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information about our purchases of shares of our common stock during the three months ended March 31, 2023:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:26.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1-31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1-28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379,768</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1-31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) &#160;&#160;&#160;&#160;Represents shares retained by us in satisfaction of the tax withholding obligations of recipients of restricted stock units granted in February 2020, February 2021 and February 2022 under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;In the future, we may grant additional equity securities under our 2017 Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities.  Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions.  Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/exh101-2017equityincentive.htm">2017 Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as amended (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8&#8209;K dated April 27, 2023 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/exh102-2017nonxemployeedir.htm">2017 Non-Employee Directors&#8217; Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8&#8209;K dated April 27, 2023 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 37pt 2px 1pt;text-align:right;text-indent:-36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282223000019/exh101secondamendmenttooxf.htm">Second Amendment to Loan and Security Agreement, dated May 1, 2023, with Oxford Finance, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8&#8209;K dated May 1, 2023 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by &#8220;[**]&#8221;) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i1a19930e9f764c8baa91ba0b6295c6fe_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i700532e6d03a44c1bf4a5f32353b127a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:46.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9dd7deba7a0c4e93ae88da6842da0160_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.023%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i104bd142bd604227b0ced069c9a7fe17_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Lexicon's Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 4th day of May, 2023.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:8.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lxrx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>0000005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>0000009 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>0000010 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>0000012 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000014 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>0000015 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>0000018 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>0000019 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>0000020 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>0000021 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>0000022 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>0000023 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>0000027 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>0000028 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>0000029 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>0000030 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000031 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>0000032 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>0000033 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails_1" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1">
        <link:definition>0000034 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_OxfordAmendmentFee" abstract="false" name="OxfordAmendmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchange" abstract="false" name="FutureConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LexiconIncrementalBorrowingRate" abstract="false" name="LexiconIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeRemainingNotes" abstract="false" name="ConvertibleDebtExchangeRemainingNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2026OxfordPrincipalPayments" abstract="false" name="A2026OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_InitialRecognitionOfRightOfUseAsset" abstract="false" name="InitialRecognitionOfRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_TermLoanA" abstract="false" name="TermLoanA" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJuly2022Offering" abstract="false" name="SharePriceInJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInSeptember2021ATMOfferring" abstract="false" name="SharesSoldInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_A2025OxfordPrincipalPayments" abstract="false" name="A2025OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithNoExtention" abstract="false" name="FinalPaymentWithNoExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_TermLoanANetCashReceipt" abstract="false" name="TermLoanANetCashReceipt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberCashPortion" abstract="false" name="ConvertibleDebtExchangeSeptemberCashPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanB" abstract="false" name="TermLoanB" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromJuly2022Offering" abstract="false" name="ProceedsFromJuly2022Offering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordFacilityFee" abstract="false" name="OxfordFacilityFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LiabilitiesAssumedByTerSera" abstract="false" name="LiabilitiesAssumedByTerSera" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_SanofiDisputedCosts" abstract="false" name="SanofiDisputedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordLoanFacility" abstract="false" name="OxfordLoanFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAInterestExpense" abstract="false" name="TermLoanAInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPayments" abstract="false" name="A2027OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedInterestOnConvertible" abstract="false" name="AccruedInterestOnConvertible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithExtention" abstract="false" name="FinalPaymentWithExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesAxis" abstract="true" name="AccruedLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TermLoanDWarrant" abstract="false" name="TermLoanDWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_TermLoanADebtIssuanceCosts" abstract="false" name="TermLoanADebtIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_TermLoanAFinalPayment" abstract="false" name="TermLoanAFinalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesDomain" abstract="true" name="AccruedLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lxrx_TermLoanC" abstract="false" name="TermLoanC" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanD" abstract="false" name="TermLoanD" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantExercisePrice" abstract="false" name="TermLoanAWarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberSharePayment" abstract="false" name="ConvertibleDebtExchangeSeptemberSharePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TermLoanABWarrant" abstract="false" name="TermLoanABWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchangeShares" abstract="false" name="FutureConvertibleDebtExchangeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeTotalPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtDiscount" abstract="false" name="TermLoanADebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJuly2022Offering" abstract="false" name="SharesSoldInJuly2022Offering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_TermLoanCWarrant" abstract="false" name="TermLoanCWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ProceedsFromSeptember2021ATMOffering" abstract="false" name="ProceedsFromSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantsNumber" abstract="false" name="TermLoanAWarrantsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharePriceInSeptember2021ATMOfferring" abstract="false" name="SharePriceInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lxrx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_457be432-58a4-461c-84d7-6f77a6989ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00d5f150-6eb9-432a-8da9-1f14dd9ffdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_457be432-58a4-461c-84d7-6f77a6989ac6" xlink:to="loc_us-gaap_AccountsPayableCurrent_00d5f150-6eb9-432a-8da9-1f14dd9ffdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ae3e605-0a83-4e7a-bc21-d37f6ddfaefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_457be432-58a4-461c-84d7-6f77a6989ac6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ae3e605-0a83-4e7a-bc21-d37f6ddfaefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8a25e957-e89d-47e9-ac01-0e337d076276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_457be432-58a4-461c-84d7-6f77a6989ac6" xlink:to="loc_us-gaap_LongTermDebtCurrent_8a25e957-e89d-47e9-ac01-0e337d076276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_94b82f71-49b2-479a-be9f-4e929c4c8a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b10b75fc-1dd9-43f9-a6d3-38ab09ee35be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94b82f71-49b2-479a-be9f-4e929c4c8a24" xlink:to="loc_us-gaap_AssetsCurrent_b10b75fc-1dd9-43f9-a6d3-38ab09ee35be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2e07f7e-60cf-40dc-9000-94c2257c07f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94b82f71-49b2-479a-be9f-4e929c4c8a24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2e07f7e-60cf-40dc-9000-94c2257c07f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2adeeacc-5ac3-4af8-94ea-1cd8bca53e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94b82f71-49b2-479a-be9f-4e929c4c8a24" xlink:to="loc_us-gaap_Goodwill_2adeeacc-5ac3-4af8-94ea-1cd8bca53e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d825f967-faaf-4c8a-ad2a-f25454ad35bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94b82f71-49b2-479a-be9f-4e929c4c8a24" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d825f967-faaf-4c8a-ad2a-f25454ad35bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_088bec56-bf7e-4025-b9eb-abcb6a97cdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_PreferredStockValue_088bec56-bf7e-4025-b9eb-abcb6a97cdd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_17d4c953-ad01-4763-aafd-3141145002fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_CommonStockValue_17d4c953-ad01-4763-aafd-3141145002fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f76c5860-5101-40f1-a603-c2d8078613fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f76c5860-5101-40f1-a603-c2d8078613fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5edfb158-0389-476d-8791-c37b70c14965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5edfb158-0389-476d-8791-c37b70c14965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d28ed28f-f53a-4235-b5bb-2c089597d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d28ed28f-f53a-4235-b5bb-2c089597d1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f43a4483-5084-4f72-88e1-720235508d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b760480-0e0a-494c-b4f8-4d29c5b243e6" xlink:to="loc_us-gaap_TreasuryStockValue_f43a4483-5084-4f72-88e1-720235508d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f0924b9e-a5a9-49d1-ba8a-a0d8e27d5836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ec867f76-2861-40de-aafe-85163695a6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f0924b9e-a5a9-49d1-ba8a-a0d8e27d5836" xlink:to="loc_us-gaap_LiabilitiesCurrent_ec867f76-2861-40de-aafe-85163695a6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_94b669fa-3640-4813-8a19-7b8311b7dc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f0924b9e-a5a9-49d1-ba8a-a0d8e27d5836" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_94b669fa-3640-4813-8a19-7b8311b7dc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4aa7f42b-a907-4d66-9101-271cbb630eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f0924b9e-a5a9-49d1-ba8a-a0d8e27d5836" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4aa7f42b-a907-4d66-9101-271cbb630eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e233d426-ac68-4a72-8dd6-9f53ed360225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38c4181-9192-43b3-a610-eefe23d237b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e233d426-ac68-4a72-8dd6-9f53ed360225" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38c4181-9192-43b3-a610-eefe23d237b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_79d83a28-633e-44cb-a78e-cc373c408e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e233d426-ac68-4a72-8dd6-9f53ed360225" xlink:to="loc_us-gaap_ShortTermInvestments_79d83a28-633e-44cb-a78e-cc373c408e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5c977a75-debd-4a9c-b403-01c5fe15bddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e233d426-ac68-4a72-8dd6-9f53ed360225" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5c977a75-debd-4a9c-b403-01c5fe15bddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2cecb3e9-9af0-489d-b493-691e8c647838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e233d426-ac68-4a72-8dd6-9f53ed360225" xlink:to="loc_us-gaap_OtherAssetsCurrent_2cecb3e9-9af0-489d-b493-691e8c647838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98c7d25a-e9e7-4570-9b4a-895972ee27f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a1c8b80d-7d68-4c37-93fd-475e16c610fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98c7d25a-e9e7-4570-9b4a-895972ee27f3" xlink:to="loc_us-gaap_Liabilities_a1c8b80d-7d68-4c37-93fd-475e16c610fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ecb08fb-11c8-4644-a6eb-1524ebcffcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98c7d25a-e9e7-4570-9b4a-895972ee27f3" xlink:to="loc_us-gaap_StockholdersEquity_5ecb08fb-11c8-4644-a6eb-1524ebcffcb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fe2353b2-bc0e-4450-ad62-e414031d616f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_580481ba-884f-40c5-b216-118273cd4588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fe2353b2-bc0e-4450-ad62-e414031d616f" xlink:to="loc_us-gaap_Revenues_580481ba-884f-40c5-b216-118273cd4588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b014992-03dc-48c5-a9b4-503c300243a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fe2353b2-bc0e-4450-ad62-e414031d616f" xlink:to="loc_us-gaap_OperatingExpenses_6b014992-03dc-48c5-a9b4-503c300243a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c36e5bb6-f598-4c82-8fa2-091b16c88a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_2eabb3a1-027c-4ecb-a30e-fcc700cfb2ed" xlink:href="lxrx-20230331.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c36e5bb6-f598-4c82-8fa2-091b16c88a4e" xlink:to="loc_lxrx_Netproductrevenue_2eabb3a1-027c-4ecb-a30e-fcc700cfb2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6dd4ed34-b416-4473-b579-f6fa207e1925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c36e5bb6-f598-4c82-8fa2-091b16c88a4e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6dd4ed34-b416-4473-b579-f6fa207e1925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_608c7d5e-de9c-4116-8165-c003afb0924e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c36e5bb6-f598-4c82-8fa2-091b16c88a4e" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_608c7d5e-de9c-4116-8165-c003afb0924e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_69d458e6-f706-4d1a-bb91-33b61284672b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4f48196-23f3-41b3-b076-33e3237f4fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_69d458e6-f706-4d1a-bb91-33b61284672b" xlink:to="loc_us-gaap_NetIncomeLoss_f4f48196-23f3-41b3-b076-33e3237f4fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2c931ba7-5f9d-4290-9e5f-be35ba8e888a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_69d458e6-f706-4d1a-bb91-33b61284672b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2c931ba7-5f9d-4290-9e5f-be35ba8e888a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b54eea68-4d4e-4926-afb8-55c07e7bbd39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dd853868-cd96-48a0-a9a0-9e315bdbe3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b54eea68-4d4e-4926-afb8-55c07e7bbd39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dd853868-cd96-48a0-a9a0-9e315bdbe3b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_6134a990-27ab-4576-a5ee-0eb98fba95b9" xlink:href="lxrx-20230331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b54eea68-4d4e-4926-afb8-55c07e7bbd39" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_6134a990-27ab-4576-a5ee-0eb98fba95b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adb242e-5f59-4f97-a693-a222c7fbb3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e8f2bae-9dfc-450f-9f8d-40b676134f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adb242e-5f59-4f97-a693-a222c7fbb3b9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e8f2bae-9dfc-450f-9f8d-40b676134f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8367d85f-8b9d-4575-ad64-0da4fc394820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adb242e-5f59-4f97-a693-a222c7fbb3b9" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_8367d85f-8b9d-4575-ad64-0da4fc394820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d062acd2-966e-45b7-ae45-61df513266cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adb242e-5f59-4f97-a693-a222c7fbb3b9" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d062acd2-966e-45b7-ae45-61df513266cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_565c5623-06fa-4434-9833-11051688534e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adb242e-5f59-4f97-a693-a222c7fbb3b9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_565c5623-06fa-4434-9833-11051688534e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d9cd0808-703a-48da-8652-6df8d431715a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_ShareBasedCompensation_d9cd0808-703a-48da-8652-6df8d431715a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75360705-af3a-4573-9591-4cd2c9485ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75360705-af3a-4573-9591-4cd2c9485ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_94554848-c79e-4a09-b612-1b53acd0f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_94554848-c79e-4a09-b612-1b53acd0f55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c556e23c-719c-4ee3-b79c-5775cf4722d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_AssetImpairmentCharges_c556e23c-719c-4ee3-b79c-5775cf4722d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3f8224e1-f0a2-4c49-bf08-3f7662c5df75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3f8224e1-f0a2-4c49-bf08-3f7662c5df75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d0675dd-11db-4e36-a5c7-241902de007e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_NetIncomeLoss_0d0675dd-11db-4e36-a5c7-241902de007e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_48c67806-045e-4b3f-8cfe-637b87f68601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_48c67806-045e-4b3f-8cfe-637b87f68601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_485df474-fe78-4c03-a1d3-b668d7ba78ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_485df474-fe78-4c03-a1d3-b668d7ba78ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_16a74cc0-0d0b-4448-899e-7856b2296edd" xlink:href="lxrx-20230331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_16a74cc0-0d0b-4448-899e-7856b2296edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2da7608-6ecd-48de-8bda-3eabd161a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2da7608-6ecd-48de-8bda-3eabd161a3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_94308d76-fd6b-4a4b-b88d-78d2295824cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_94308d76-fd6b-4a4b-b88d-78d2295824cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2e08a5a3-cb63-42e5-8d77-dbbebdc40fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de6c3ea4-f170-4829-aed4-e00e7459621f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2e08a5a3-cb63-42e5-8d77-dbbebdc40fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_553a8c35-5095-4aba-8d63-48a277fcde62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b9c078-13b3-4a8f-834d-3936534809cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_553a8c35-5095-4aba-8d63-48a277fcde62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05b9c078-13b3-4a8f-834d-3936534809cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3be4b198-452c-441a-8bfd-9de14346b14a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_553a8c35-5095-4aba-8d63-48a277fcde62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3be4b198-452c-441a-8bfd-9de14346b14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e9f9f07-a762-4e1a-9de7-86363aadee90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_553a8c35-5095-4aba-8d63-48a277fcde62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e9f9f07-a762-4e1a-9de7-86363aadee90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3049897-cd39-4aa4-abe8-e1f36cdb648b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ee2856bb-3dcb-4dab-b334-f12719c5fd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3049897-cd39-4aa4-abe8-e1f36cdb648b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ee2856bb-3dcb-4dab-b334-f12719c5fd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6da20025-075e-44fa-b347-fd1855416eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3049897-cd39-4aa4-abe8-e1f36cdb648b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6da20025-075e-44fa-b347-fd1855416eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96a05b56-ab6a-4690-b2b7-9cb8a3332b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3049897-cd39-4aa4-abe8-e1f36cdb648b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96a05b56-ab6a-4690-b2b7-9cb8a3332b35" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lxrx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="ic2ed5ec52f7c482ca1c3bdb70d78a570_ConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f07e3f-b20b-4612-b334-890382a2d217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f07e3f-b20b-4612-b334-890382a2d217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ebab7e23-8ac1-47de-838c-5ac1bda1f78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_ShortTermInvestments_ebab7e23-8ac1-47de-838c-5ac1bda1f78d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_feac00bb-672b-407e-8bc8-b2b1b318814b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_feac00bb-672b-407e-8bc8-b2b1b318814b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_293e12c8-cdbd-47f8-ae71-66074a9cb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_OtherAssetsCurrent_293e12c8-cdbd-47f8-ae71-66074a9cb0aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f1625785-e1d0-40b5-a9d1-16a4e25cac48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_AssetsCurrent_f1625785-e1d0-40b5-a9d1-16a4e25cac48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dd1f424a-4672-4350-9572-61c0cd332742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dd1f424a-4672-4350-9572-61c0cd332742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_88cb1388-a601-4a90-9de2-5b4556ce24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Goodwill_88cb1388-a601-4a90-9de2-5b4556ce24c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_be3df8e3-147b-4dee-a7f0-3da5e3d1688a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_be3df8e3-147b-4dee-a7f0-3da5e3d1688a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_703d1899-f722-426b-bcea-25895938dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Assets_703d1899-f722-426b-bcea-25895938dc06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5d269505-ebdf-4a9f-8a86-f57276f9bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_AccountsPayableCurrent_5d269505-ebdf-4a9f-8a86-f57276f9bb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_712b087d-d439-48e6-a942-eaa30dcc4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_712b087d-d439-48e6-a942-eaa30dcc4d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9f2372dd-70d3-47aa-a152-2aace1c9c901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_LongTermDebtCurrent_9f2372dd-70d3-47aa-a152-2aace1c9c901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbe1b747-c788-496d-892a-030fbe82645b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_LiabilitiesCurrent_fbe1b747-c788-496d-892a-030fbe82645b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_e5501e2f-6682-46a2-95a2-a656b5451355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_SecuredLongTermDebt_e5501e2f-6682-46a2-95a2-a656b5451355" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b14731fc-6eeb-49fd-88d0-adbdc792b983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b14731fc-6eeb-49fd-88d0-adbdc792b983" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d477ce2e-2772-4ad0-b51b-dad1894a6857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Liabilities_d477ce2e-2772-4ad0-b51b-dad1894a6857" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b4b02ab0-c1cc-491d-90fc-8d933cf2e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b4b02ab0-c1cc-491d-90fc-8d933cf2e78d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ffe2084c-4b23-4b06-b675-68179736a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_PreferredStockValue_ffe2084c-4b23-4b06-b675-68179736a52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c8c68155-bb4a-422f-883d-dd94ed16d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_CommonStockValue_c8c68155-bb4a-422f-883d-dd94ed16d71f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9422e4e0-cbb3-4216-baa3-682cd698dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9422e4e0-cbb3-4216-baa3-682cd698dfd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e073c7fa-3bc4-4cd3-8a36-8b2d87730f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e073c7fa-3bc4-4cd3-8a36-8b2d87730f6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c34ed0d-dcfb-4947-8938-72f7dcf0f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c34ed0d-dcfb-4947-8938-72f7dcf0f8bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e7f51d71-63da-4b27-8700-e9173ba9eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_TreasuryStockValue_e7f51d71-63da-4b27-8700-e9173ba9eb5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53b817f9-6e2c-48d0-ba2f-99dab16d73e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_StockholdersEquity_53b817f9-6e2c-48d0-ba2f-99dab16d73e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_764bca5e-27d7-417f-b51b-e201cfd1ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_764bca5e-27d7-417f-b51b-e201cfd1ff0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_da35daa3-7d9a-4d26-b9e7-aa2b7b4e82c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_da35daa3-7d9a-4d26-b9e7-aa2b7b4e82c4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:to="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e001ad84-14ca-4dc6-8740-df33167017f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e001ad84-14ca-4dc6-8740-df33167017f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_47557898-6664-4914-8778-515c6bd42f27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_47557898-6664-4914-8778-515c6bd42f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41d26d8a-77ba-4883-a58e-dc5894b3d0cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:to="loc_us-gaap_ClassOfStockDomain_41d26d8a-77ba-4883-a58e-dc5894b3d0cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1e51fd1-0994-4586-8f7d-b6cc656d6c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:to="loc_us-gaap_ClassOfStockDomain_d1e51fd1-0994-4586-8f7d-b6cc656d6c71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="id99399413317471e80e8c04aaf1022b5_ConsolidatedStatementsofComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_c621f91e-3e9f-4a4d-a195-8392a71ba7ee" xlink:href="lxrx-20230331.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_lxrx_Netproductrevenue_c621f91e-3e9f-4a4d-a195-8392a71ba7ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9615e2eb-17ca-4d4c-9c33-ffe8456813e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9615e2eb-17ca-4d4c-9c33-ffe8456813e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_e2925644-6efa-4c69-9546-ac50af2f0216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_e2925644-6efa-4c69-9546-ac50af2f0216" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_78c3ffb1-927c-4afe-a9b0-c56c727e8f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_Revenues_78c3ffb1-927c-4afe-a9b0-c56c727e8f8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_21519e19-4202-4a34-a60e-5bd02fcd1279" xlink:href="lxrx-20230331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_21519e19-4202-4a34-a60e-5bd02fcd1279" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f927b0d8-4842-402a-b93b-36c242661ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f927b0d8-4842-402a-b93b-36c242661ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8641749b-5ee5-4963-945f-68a22f99241f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8641749b-5ee5-4963-945f-68a22f99241f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_371400ab-c4e1-4fc5-82e2-d0ddd3a2d110" xlink:href="lxrx-20230331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_371400ab-c4e1-4fc5-82e2-d0ddd3a2d110" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cda3d18a-9b58-4796-a78f-bd91578c2d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_AssetImpairmentCharges_cda3d18a-9b58-4796-a78f-bd91578c2d32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_356d96c7-6d38-4037-9d53-caba79f39553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_OperatingExpenses_356d96c7-6d38-4037-9d53-caba79f39553" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5d884296-1b08-4cc6-86a8-f4edae5e9b8a" xlink:href="lxrx-20230331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5d884296-1b08-4cc6-86a8-f4edae5e9b8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d220c440-997d-4cac-8630-81db3fad77a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OperatingIncomeLoss_d220c440-997d-4cac-8630-81db3fad77a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_490e03d3-cd1d-4c00-a6e0-3c7010689db1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_490e03d3-cd1d-4c00-a6e0-3c7010689db1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_25105437-202d-4cf7-9312-f47e8cf8807d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_InterestExpense_25105437-202d-4cf7-9312-f47e8cf8807d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a9aa0f0c-4f21-451f-b99b-3c3fd15fe64b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a9aa0f0c-4f21-451f-b99b-3c3fd15fe64b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6fc14d7-1588-4330-a9d8-6f4e016ebead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_NetIncomeLoss_e6fc14d7-1588-4330-a9d8-6f4e016ebead" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab379954-7c23-4cf9-80a1-e3c5b6c93c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab379954-7c23-4cf9-80a1-e3c5b6c93c5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6cdceb5-7645-460b-b36c-c4f80183e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f6cdceb5-7645-460b-b36c-c4f80183e34c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a9475fa-5d0f-4a69-8759-616d5ac17956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a9475fa-5d0f-4a69-8759-616d5ac17956" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_397d22d7-de78-4421-95fd-a7e72ad1e1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_397d22d7-de78-4421-95fd-a7e72ad1e1bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52388c5c-7659-4b2b-9fc6-73df49698e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52388c5c-7659-4b2b-9fc6-73df49698e04" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0834bbc-dbd3-4682-8981-11121e458314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0834bbc-dbd3-4682-8981-11121e458314" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0694e1c4-1899-45bd-987d-0e3a4b65bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0694e1c4-1899-45bd-987d-0e3a4b65bc70" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:to="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8a52e2b6-1457-4fe9-ba59-22d6da48e648_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8a52e2b6-1457-4fe9-ba59-22d6da48e648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2e4d85bd-4ae5-43fa-9cd0-1a4ec2dcde53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2e4d85bd-4ae5-43fa-9cd0-1a4ec2dcde53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="ia40b6e5c4f924d1ea2c3cd6cbf7f1945_ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d18e333f-ece4-4d97-a71c-b4c4df4ca05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_CommonStockSharesIssued_d18e333f-ece4-4d97-a71c-b4c4df4ca05b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff0349df-aaba-4dca-b2b8-aa17dd9d91a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff0349df-aaba-4dca-b2b8-aa17dd9d91a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b52c311d-c3af-4901-95d1-c40a62bcb8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b52c311d-c3af-4901-95d1-c40a62bcb8e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e4bc8cc-879d-4b9f-b41f-6a03068e8d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e4bc8cc-879d-4b9f-b41f-6a03068e8d3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23329a74-bab3-4e6e-9717-5fd6e195a031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23329a74-bab3-4e6e-9717-5fd6e195a031" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7fa2392c-2035-48f9-82d0-5cca87efb268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7fa2392c-2035-48f9-82d0-5cca87efb268" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_90b7cd30-7886-43ff-a73e-e13ca0417a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_90b7cd30-7886-43ff-a73e-e13ca0417a69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3e67cd9-e169-4ca8-9abe-3d7ba4394d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_NetIncomeLoss_d3e67cd9-e169-4ca8-9abe-3d7ba4394d9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_60968fab-61cc-43ad-bce0-c8adfd8f2018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_60968fab-61cc-43ad-bce0-c8adfd8f2018" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2e9d9d63-3c1b-4765-bb31-c937876ad548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2e9d9d63-3c1b-4765-bb31-c937876ad548" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1228a0ea-b3e9-41f7-8916-497901bfbc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b75ead-c792-42be-af94-ebb877a3ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e877bbe3-16b0-413c-ab9a-83375feea222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e877bbe3-16b0-413c-ab9a-83375feea222" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a9922394-b4c1-4777-a90f-24745081cf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a9922394-b4c1-4777-a90f-24745081cf3b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d796cb08-82e2-4c9f-883c-5f12c1e3bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d796cb08-82e2-4c9f-883c-5f12c1e3bc29" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_acc551c2-8543-4f49-b1b4-672af57667eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_acc551c2-8543-4f49-b1b4-672af57667eb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8947457c-88d5-47c9-900c-556342f36297_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8947457c-88d5-47c9-900c-556342f36297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b7b82dc7-b943-4d9e-bbb5-bf2192850e52" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b7b82dc7-b943-4d9e-bbb5-bf2192850e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_88ed6c7d-e2b6-4da5-b9cf-410afb509a47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:to="loc_us-gaap_EquityComponentDomain_88ed6c7d-e2b6-4da5-b9cf-410afb509a47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:to="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_397733e6-ad9f-433a-8d02-4555a1b191d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_CommonStockMember_397733e6-ad9f-433a-8d02-4555a1b191d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7c8a10dc-b46a-4165-ac45-4858d762c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7c8a10dc-b46a-4165-ac45-4858d762c49d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_259b5729-c10e-4476-b5d0-732d40df82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_RetainedEarningsMember_259b5729-c10e-4476-b5d0-732d40df82b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d45372a8-2644-45b8-8d0d-790fd95e127a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d45372a8-2644-45b8-8d0d-790fd95e127a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_52038c8b-66f0-4818-8688-a30f43d5b287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_TreasuryStockMember_52038c8b-66f0-4818-8688-a30f43d5b287" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00af0793-3e80-42a2-8212-cdafe1200d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:to="loc_us-gaap_ClassOfStockDomain_00af0793-3e80-42a2-8212-cdafe1200d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88b705d3-67fe-49f4-ba8f-0bb96ee04ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:to="loc_us-gaap_ClassOfStockDomain_88b705d3-67fe-49f4-ba8f-0bb96ee04ced" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="i5f087c0108bd4110a24322c19bc9a0f2_SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_652afc36-f340-4647-9400-b8fc651e337c" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_652afc36-f340-4647-9400-b8fc651e337c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_9d387ecb-b456-465f-b5c0-b43a6156d9fc" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_9d387ecb-b456-465f-b5c0-b43a6156d9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_aff90806-600a-497a-9ada-553e442f9b30" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_aff90806-600a-497a-9ada-553e442f9b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_6d7cd903-de0b-4822-841f-86a60d988874" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_6d7cd903-de0b-4822-841f-86a60d988874" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0d412270-d583-4ebd-b99d-10e463ed74b6" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0d412270-d583-4ebd-b99d-10e463ed74b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_a6cca34e-f9f6-4cc7-9468-8f20f7e77e7b" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_a6cca34e-f9f6-4cc7-9468-8f20f7e77e7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_1b67aa32-2d66-4ba4-9d4d-a9ea77278038" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_1b67aa32-2d66-4ba4-9d4d-a9ea77278038" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c83339e1-df9d-40a4-b19e-f56b78640dac" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c83339e1-df9d-40a4-b19e-f56b78640dac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_e065fb71-9e9a-429b-904d-3bf2b3200f6f" xlink:href="lxrx-20230331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_e065fb71-9e9a-429b-904d-3bf2b3200f6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:to="loc_us-gaap_PlanNameDomain_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2f144f6-37da-4784-bc22-3c400c3feadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:to="loc_us-gaap_PlanNameDomain_d2f144f6-37da-4784-bc22-3c400c3feadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c4fbbc20-02d5-4c73-9316-397233089af5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:to="loc_us-gaap_AwardDateDomain_c4fbbc20-02d5-4c73-9316-397233089af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c23289a7-15b5-4111-84d3-cd40fc5bb101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:to="loc_us-gaap_AwardDateDomain_c23289a7-15b5-4111-84d3-cd40fc5bb101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e9ebc63-8214-4cc2-9d57-25520fbf51ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e9ebc63-8214-4cc2-9d57-25520fbf51ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_8daa9cb7-0a7a-4fa3-be64-77aa5a96551d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:to="loc_us-gaap_StockOptionMember_8daa9cb7-0a7a-4fa3-be64-77aa5a96551d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6c7919b-c2f8-43f8-a6f1-767a5b86a430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:to="loc_us-gaap_ClassOfStockDomain_c6c7919b-c2f8-43f8-a6f1-767a5b86a430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_39c8fb0b-aad8-44bd-8f86-aefbcb52cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:to="loc_us-gaap_ClassOfStockDomain_39c8fb0b-aad8-44bd-8f86-aefbcb52cfbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:to="loc_srt_RangeMember_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf13cfcd-28c5-437e-b35a-2a138b5a2d7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:to="loc_srt_RangeMember_bf13cfcd-28c5-437e-b35a-2a138b5a2d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_bda75552-0c90-473b-b70b-544f8eb9c70d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:to="loc_us-gaap_VestingDomain_bda75552-0c90-473b-b70b-544f8eb9c70d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_504c1078-ac65-4e9e-bc63-db728c8bd964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:to="loc_us-gaap_VestingDomain_504c1078-ac65-4e9e-bc63-db728c8bd964" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="if0ff3e67f8574ffcb566dfc2ec7ec711_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3665c3b5-df2e-460e-85d6-24693c5ab9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3665c3b5-df2e-460e-85d6-24693c5ab9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4a17b5d-70c8-45ee-8a82-8c241eeafe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4a17b5d-70c8-45ee-8a82-8c241eeafe7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7775ceb0-bc88-4797-aa56-77be133bae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7775ceb0-bc88-4797-aa56-77be133bae4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49a149b2-8149-4953-8c03-29a308e912b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49a149b2-8149-4953-8c03-29a308e912b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_297f1141-7afd-4677-94c8-6d96d9360a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_297f1141-7afd-4677-94c8-6d96d9360a05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d158baaf-10a0-40d5-a36f-dcdbd4d05d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d158baaf-10a0-40d5-a36f-dcdbd4d05d1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3053f00d-2e47-4671-9429-8d429f088e31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3053f00d-2e47-4671-9429-8d429f088e31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e1e14cee-ef11-464e-978c-772317a76240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e1e14cee-ef11-464e-978c-772317a76240" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f01fc11-d0d1-411e-b171-118f1f5bdfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f01fc11-d0d1-411e-b171-118f1f5bdfb7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7941bdfc-0f29-40b1-a71f-dbf67308d709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7941bdfc-0f29-40b1-a71f-dbf67308d709" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5fdd391-72f6-4858-b84d-ba8be28eb325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5fdd391-72f6-4858-b84d-ba8be28eb325" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_78f0ada1-1557-4cdb-8841-558e70461496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_78f0ada1-1557-4cdb-8841-558e70461496" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c731c6eb-46ad-4848-91ac-60fec1c55ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c731c6eb-46ad-4848-91ac-60fec1c55ea8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f342570a-35b7-4895-990c-2efedfe1e776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f342570a-35b7-4895-990c-2efedfe1e776" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34e4bfd0-5933-44a7-af4e-ab7b6891628b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34e4bfd0-5933-44a7-af4e-ab7b6891628b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84494122-01ae-4f1f-9f42-2f23786fa620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84494122-01ae-4f1f-9f42-2f23786fa620" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb21bb1b-04c4-4728-8a61-9bc2744c9646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb21bb1b-04c4-4728-8a61-9bc2744c9646" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6fab34bc-0d91-4738-a7f1-d665395255b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6fab34bc-0d91-4738-a7f1-d665395255b2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_11263f9c-e397-49a2-975d-05246f9da0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_11263f9c-e397-49a2-975d-05246f9da0ce" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_199a638a-2bf1-44ac-ac47-b7e190925240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_199a638a-2bf1-44ac-ac47-b7e190925240" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_03de0fe5-3369-4e59-9946-4767fb5968bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:to="loc_us-gaap_PlanNameDomain_03de0fe5-3369-4e59-9946-4767fb5968bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c1420c4-9c29-43f8-ab50-73b00a7ce433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:to="loc_us-gaap_PlanNameDomain_6c1420c4-9c29-43f8-ab50-73b00a7ce433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_7444f608-6e68-4eb0-9fac-3cdda7209d04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:to="loc_us-gaap_AwardDateDomain_7444f608-6e68-4eb0-9fac-3cdda7209d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f21932f3-3232-44ec-8233-866ef65b6572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:to="loc_us-gaap_AwardDateDomain_f21932f3-3232-44ec-8233-866ef65b6572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d859537a-e03f-4353-b0e6-38d03fad09ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d859537a-e03f-4353-b0e6-38d03fad09ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25a77ced-05e5-481f-806b-3d1c2799c8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25a77ced-05e5-481f-806b-3d1c2799c8c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e07e9dfa-07d6-4eb8-942e-3832a36e1e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e07e9dfa-07d6-4eb8-942e-3832a36e1e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eae295b8-8848-4cda-972f-bfedbab55ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:to="loc_us-gaap_ClassOfStockDomain_eae295b8-8848-4cda-972f-bfedbab55ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4142e5e-04f2-4221-a873-c4a8b71db1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:to="loc_us-gaap_ClassOfStockDomain_f4142e5e-04f2-4221-a873-c4a8b71db1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:to="loc_srt_RangeMember_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37341491-22a0-4d74-9473-d0f744b35747" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:to="loc_srt_RangeMember_37341491-22a0-4d74-9473-d0f744b35747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2015fb7b-2920-4845-a556-ce30f15a3ff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:to="loc_us-gaap_VestingDomain_2015fb7b-2920-4845-a556-ce30f15a3ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_51a90c1d-1b6f-49e3-a8bc-306cf563bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:to="loc_us-gaap_VestingDomain_51a90c1d-1b6f-49e3-a8bc-306cf563bcba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="i394d727656ae4123b46512b523032f5e_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51845c1-13ec-4811-b519-d6d84e9c7d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51845c1-13ec-4811-b519-d6d84e9c7d64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_41f72724-a9ac-4c62-890d-be3c1035ef55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:to="loc_us-gaap_PlanNameDomain_41f72724-a9ac-4c62-890d-be3c1035ef55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_53099a32-c056-45db-917b-a4f88f5ec2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:to="loc_us-gaap_PlanNameDomain_53099a32-c056-45db-917b-a4f88f5ec2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eae469a9-2d65-4391-89ce-de6731e5187c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eae469a9-2d65-4391-89ce-de6731e5187c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fff5216c-6d25-4271-93b2-cfa371080c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fff5216c-6d25-4271-93b2-cfa371080c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_17a44ac0-840c-4a65-998b-d36b7a4aa8b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:to="loc_us-gaap_ClassOfStockDomain_17a44ac0-840c-4a65-998b-d36b7a4aa8b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58a7b193-bdc9-430a-b73b-a3fad20327d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:to="loc_us-gaap_ClassOfStockDomain_58a7b193-bdc9-430a-b73b-a3fad20327d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:to="loc_srt_RangeMember_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_123149aa-8ae6-4569-820b-1ed23acdf886" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:to="loc_srt_RangeMember_123149aa-8ae6-4569-820b-1ed23acdf886" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended" id="i3e0b081a652e4f138329b9c6c23476d6_SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_61623f9c-6f3e-4d34-8e19-3897d98426fa" xlink:href="lxrx-20230331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_61623f9c-6f3e-4d34-8e19-3897d98426fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1aedc083-5b4b-4e03-8234-215acc3ffb55" xlink:href="lxrx-20230331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1aedc083-5b4b-4e03-8234-215acc3ffb55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15ea49c8-a723-4fbd-a55b-5d8de7d9368a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15ea49c8-a723-4fbd-a55b-5d8de7d9368a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d0f64a75-5d5f-4bac-883b-59f5e31f6470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d0f64a75-5d5f-4bac-883b-59f5e31f6470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_d276c842-7642-46c7-be32-987b94d55dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_d276c842-7642-46c7-be32-987b94d55dec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_49eb4f96-8c17-41c0-a75d-8c63dbc5a368" xlink:href="lxrx-20230331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_49eb4f96-8c17-41c0-a75d-8c63dbc5a368" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_917cb3f5-ea59-4439-9f0a-b88c6296c498_default" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_917cb3f5-ea59-4439-9f0a-b88c6296c498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_fa22f331-4da5-4882-a47c-7e891007118d" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_fa22f331-4da5-4882-a47c-7e891007118d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="i2f47d76a0c8f4b2e81d24e75ac6612b7_CashandCashEquivalentsandInvestmentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00ebc91c-53ce-4d3b-a2b7-759c7e2663b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00ebc91c-53ce-4d3b-a2b7-759c7e2663b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3b7d65e0-20f9-443c-a807-6f79d030a347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3b7d65e0-20f9-443c-a807-6f79d030a347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_bac785a6-55a5-4de2-8c4c-129071408a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_bac785a6-55a5-4de2-8c4c-129071408a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e94afebd-b505-4055-b7b6-cdc926747ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e94afebd-b505-4055-b7b6-cdc926747ece" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_489d2cc3-fd91-4c07-a734-9bdf3b2abe05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_489d2cc3-fd91-4c07-a734-9bdf3b2abe05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_076f347a-6851-4032-ad62-f909bdfd6c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_076f347a-6851-4032-ad62-f909bdfd6c8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_72999efb-47ab-4897-bd6f-deeae09030ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_72999efb-47ab-4897-bd6f-deeae09030ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:to="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6357a823-9721-4c0a-ba46-d07ceba8cffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6357a823-9721-4c0a-ba46-d07ceba8cffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_84e72fd7-6aba-45ce-95bc-aff6c6f166aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_CashMember_84e72fd7-6aba-45ce-95bc-aff6c6f166aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b32ce546-361e-4b22-b17c-cc57dcda38d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b32ce546-361e-4b22-b17c-cc57dcda38d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_001f2ac5-f59e-4379-a837-23f1f43afda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_001f2ac5-f59e-4379-a837-23f1f43afda3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_0369c1dd-ad08-46db-8c34-0aa577a90bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_InvestmentsMember_0369c1dd-ad08-46db-8c34-0aa577a90bda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9921fc26-17aa-454d-96ab-8a29dbca3fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9921fc26-17aa-454d-96ab-8a29dbca3fbb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i2fd006e9993b4212800e5fdcdcd64973_CashandCashEquivalentsandInvestmentsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_67e9b599-f1eb-40cb-9aa8-831b12912f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_67e9b599-f1eb-40cb-9aa8-831b12912f4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_bd43c77f-9e1d-4264-8108-67dc9aa12f24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_bd43c77f-9e1d-4264-8108-67dc9aa12f24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_ba8a424d-e6b1-4ee4-82d9-3fb0a2e1e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_ba8a424d-e6b1-4ee4-82d9-3fb0a2e1e7ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i3cec228ca692467b8ff10321765a9d50_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d22057d6-d98c-472c-bbfb-55e511c96608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d22057d6-d98c-472c-bbfb-55e511c96608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d99981ea-3d8c-44ad-b4f2-36c390323f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d99981ea-3d8c-44ad-b4f2-36c390323f3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_05423a36-38d0-4d06-a4ad-c063ef4ee6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_AvailableForSaleSecurities_05423a36-38d0-4d06-a4ad-c063ef4ee6f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4ac52e40-af70-4c5a-880e-835c14b6378a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4ac52e40-af70-4c5a-880e-835c14b6378a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b43de10-1865-4b88-87cb-1374e4380ee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b43de10-1865-4b88-87cb-1374e4380ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef6b1372-e805-410a-bdb4-eb15687e0bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef6b1372-e805-410a-bdb4-eb15687e0bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4599f1b4-59e1-4001-a1c6-f59227e5b542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4599f1b4-59e1-4001-a1c6-f59227e5b542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1d7cd85e-b0b8-4d8d-b819-2a4c4fc73bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1d7cd85e-b0b8-4d8d-b819-2a4c4fc73bb3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="i433b0d935c7e434bb20e3ba7b355e253_DebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_439b4cb2-7932-4971-8c0a-827d2baade78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_439b4cb2-7932-4971-8c0a-827d2baade78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0a7c5392-aa82-465d-b05b-bc05e65d4aed" xlink:href="lxrx-20230331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0a7c5392-aa82-465d-b05b-bc05e65d4aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_60182d26-00a0-48ba-946f-59589d4e4a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_60182d26-00a0-48ba-946f-59589d4e4a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8756c5f6-a2b4-4136-bc56-98ff4aef7e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8756c5f6-a2b4-4136-bc56-98ff4aef7e43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_62d8aad3-3c24-4f41-bd35-27c818d91454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentFairValue_62d8aad3-3c24-4f41-bd35-27c818d91454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8fc59ee0-12e9-42fe-9146-afb651e5b351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_CommonStockSharesIssued_8fc59ee0-12e9-42fe-9146-afb651e5b351" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_8817e0e1-00c5-4908-822e-34dac50cb6d4" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchange_8817e0e1-00c5-4908-822e-34dac50cb6d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_de6e533c-b15c-4aaf-b562-8439fcdac253" xlink:href="lxrx-20230331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_AccruedInterestOnConvertible_de6e533c-b15c-4aaf-b562-8439fcdac253" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_36002dc2-5ce2-48b7-9d54-120c1a70985c" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_36002dc2-5ce2-48b7-9d54-120c1a70985c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_8acb3fe5-2afd-472a-8ed3-eaff5fd1d380" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_8acb3fe5-2afd-472a-8ed3-eaff5fd1d380" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_42a28d95-0abc-47ae-9a9d-c1192fb11f6d" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_42a28d95-0abc-47ae-9a9d-c1192fb11f6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_99c4f9bd-7df9-4357-86a8-17e76acc76a2" xlink:href="lxrx-20230331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_99c4f9bd-7df9-4357-86a8-17e76acc76a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_0f41108b-2611-4e81-aca2-0ab355ac273d" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_0f41108b-2611-4e81-aca2-0ab355ac273d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_c43ba348-1abf-4d35-89b3-8c08740a2f7c" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_c43ba348-1abf-4d35-89b3-8c08740a2f7c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_eb04707f-7b27-4b3f-a860-3e5186309e11" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_eb04707f-7b27-4b3f-a860-3e5186309e11" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_db319cc8-e904-4aea-9e30-b31282be89ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_db319cc8-e904-4aea-9e30-b31282be89ed" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d07de78-772e-4688-9bfd-ef8d54284fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebt_4d07de78-772e-4688-9bfd-ef8d54284fe1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_b2020bd4-ade8-45a1-9fbf-914264bec7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtTerm_b2020bd4-ade8-45a1-9fbf-914264bec7cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f3ca30bf-3529-4686-81ec-27efc6c750fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f3ca30bf-3529-4686-81ec-27efc6c750fb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_cf86942d-3fcf-431a-9b0f-fa27ae7b7a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_cf86942d-3fcf-431a-9b0f-fa27ae7b7a34" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_fef3df6c-68dd-42d0-967c-0bbbedb36ae2" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanB_fef3df6c-68dd-42d0-967c-0bbbedb36ae2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_5fe01599-37e1-4e37-bbf7-0232d0ae7040" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanC_5fe01599-37e1-4e37-bbf7-0232d0ae7040" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_07f841c3-776d-45ee-9a79-b2ff73f9cdd4" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanD_07f841c3-776d-45ee-9a79-b2ff73f9cdd4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_fb1ad4e6-082f-49de-929e-e00f04c468b9" xlink:href="lxrx-20230331.xsd#lxrx_OxfordLoanFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordLoanFacility_fb1ad4e6-082f-49de-929e-e00f04c468b9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_2db1ef96-9999-4d44-8eb3-91731b225b13" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanA_2db1ef96-9999-4d44-8eb3-91731b225b13" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_a3f82fcd-8dbd-4fdc-b020-2757c85e8023" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanABWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanABWarrant_a3f82fcd-8dbd-4fdc-b020-2757c85e8023" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_568bbbec-63f6-48d7-9a11-ef7513bafe94" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanCWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanCWarrant_568bbbec-63f6-48d7-9a11-ef7513bafe94" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_b1621345-9b50-454c-9d01-bd613af43f4d" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanDWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanDWarrant_b1621345-9b50-454c-9d01-bd613af43f4d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_52002852-f24d-4fd7-93ce-fc613b8aae15" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_52002852-f24d-4fd7-93ce-fc613b8aae15" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_a2ca14aa-bce4-4a59-9ec1-02137614c256" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_a2ca14aa-bce4-4a59-9ec1-02137614c256" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_78ca1575-d14f-4524-adf5-29c64b4efd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_78ca1575-d14f-4524-adf5-29c64b4efd36" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64edb283-5761-4249-b094-3a5191681981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64edb283-5761-4249-b094-3a5191681981" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36184e8a-0034-4bbf-95cb-2839ba38d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36184e8a-0034-4bbf-95cb-2839ba38d0f5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_d4366314-8d3a-4685-9b64-6e3811fbe884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_d4366314-8d3a-4685-9b64-6e3811fbe884" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_d5ff093e-a4e3-4e66-a949-a88b6ec5bb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_d5ff093e-a4e3-4e66-a949-a88b6ec5bb0c" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_28b5cd67-b0ed-4765-b41a-07097cbeba19" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_28b5cd67-b0ed-4765-b41a-07097cbeba19" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_d1b513ee-8899-480e-ac4f-2e5ac15cec8c" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FinalPaymentWithExtention_d1b513ee-8899-480e-ac4f-2e5ac15cec8c" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_8a4e7b2c-24e9-4282-93e3-7d32ddb3c3cb" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAFinalPayment_8a4e7b2c-24e9-4282-93e3-7d32ddb3c3cb" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_56260197-3cd4-4664-a2d6-e44fd08a1c94" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanANetCashReceipt_56260197-3cd4-4664-a2d6-e44fd08a1c94" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_11cecc97-cf9a-4e91-a995-6a98c87f3de7" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_11cecc97-cf9a-4e91-a995-6a98c87f3de7" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_a53f360a-d83a-4296-a98b-7dcd7c9bf599" xlink:href="lxrx-20230331.xsd#lxrx_OxfordFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordFacilityFee_a53f360a-d83a-4296-a98b-7dcd7c9bf599" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_a7b7b3cf-42c7-4f4a-ad61-d7720b288b3e" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanADebtDiscount_a7b7b3cf-42c7-4f4a-ad61-d7720b288b3e" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_4a04d684-a122-427d-ac95-0231ca8bedf2" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAInterestExpense_4a04d684-a122-427d-ac95-0231ca8bedf2" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_18aec9d5-fef2-4abe-8aa4-10e30f2032c3" xlink:href="lxrx-20230331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_18aec9d5-fef2-4abe-8aa4-10e30f2032c3" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_4d1e2ee3-0860-4a51-b3f9-b1e498fd5e86" xlink:href="lxrx-20230331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_4d1e2ee3-0860-4a51-b3f9-b1e498fd5e86" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_49c4dddd-41d5-49b0-9089-40e951a90e64" xlink:href="lxrx-20230331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_49c4dddd-41d5-49b0-9089-40e951a90e64" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee_5d656d76-0cea-4db8-b8b5-fd36cdc7307f" xlink:href="lxrx-20230331.xsd#lxrx_OxfordAmendmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordAmendmentFee_5d656d76-0cea-4db8-b8b5-fd36cdc7307f" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9a81e8b3-c038-46c3-8217-d6ab8eaf2c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentTable_9a81e8b3-c038-46c3-8217-d6ab8eaf2c1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ib0072a41ac74489b8187bb1132083c9e_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f465ad81-87c7-4fef-9301-286685ae2caa" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f465ad81-87c7-4fef-9301-286685ae2caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c01f16ca-c51b-4e7b-8666-fc3e0c5f7033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c01f16ca-c51b-4e7b-8666-fc3e0c5f7033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4fdfe5d9-11d2-488b-8ca3-5c6a0576b6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4fdfe5d9-11d2-488b-8ca3-5c6a0576b6c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b47bbe9a-b6ae-4da9-89d5-e001b02ecbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b47bbe9a-b6ae-4da9-89d5-e001b02ecbb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8523fbb8-c57b-47da-b9ee-ceb6587850ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8523fbb8-c57b-47da-b9ee-ceb6587850ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d2ee35c-fa19-4448-bd30-346f91dcfeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d2ee35c-fa19-4448-bd30-346f91dcfeaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18976f2f-4e98-4a08-a80c-42b17b131669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18976f2f-4e98-4a08-a80c-42b17b131669" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b0a7493-3052-4a54-87d0-b7045c5a073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b0a7493-3052-4a54-87d0-b7045c5a073d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86770d33-3307-4bd0-a93c-56e8807ba05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86770d33-3307-4bd0-a93c-56e8807ba05b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7fc1293c-71cb-4129-a086-99b8b1d523ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7fc1293c-71cb-4129-a086-99b8b1d523ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a209cbf-0517-4184-a57d-ef094e15800b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseLiability_4a209cbf-0517-4184-a57d-ef094e15800b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_38a90037-d9fb-4a3b-9cb9-85547c0f9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_38a90037-d9fb-4a3b-9cb9-85547c0f9e49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_990d38b8-0736-4ea1-b37b-04b27dca28d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_990d38b8-0736-4ea1-b37b-04b27dca28d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_44ff38e7-87e9-4d24-9734-7708fec636a0" xlink:href="lxrx-20230331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_lxrx_SanofiDisputedCosts_44ff38e7-87e9-4d24-9734-7708fec636a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c4bff4cf-bdc9-412a-ae0f-97a8831a6ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseExpense_c4bff4cf-bdc9-412a-ae0f-97a8831a6ca6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_5113e0ac-1d2c-4046-b63e-c13ce8935537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_PaymentsForRent_5113e0ac-1d2c-4046-b63e-c13ce8935537" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_38d481a4-a63b-45f4-922e-592e3ad088b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_38d481a4-a63b-45f4-922e-592e3ad088b3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a7d20f65-b4c6-4288-8888-cb53db14f002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a7d20f65-b4c6-4288-8888-cb53db14f002" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_71312960-9914-456c-976e-1d4b6526dddd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:to="loc_us-gaap_ReceivableTypeDomain_71312960-9914-456c-976e-1d4b6526dddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:to="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dd275ff0-2c74-41db-bdf8-16672b24aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:to="loc_us-gaap_AccountsReceivableMember_dd275ff0-2c74-41db-bdf8-16672b24aac4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lxrx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lxrx_ConvertibleDebtExchange_f86cf59b-ae83-403d-93d0-c6eb576f839e_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0b785eaf-980e-40b8-832e-5fec1405a945_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_707e3b1e-d84a-4b43-acdb-4362692ed6f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_89f44206-da38-4182-b1be-db551d228533_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ec66bf5b-d2c2-4968-bfbd-94de19b83ddb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cd065d77-e602-428e-8050-de0c44ec83e1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d1fbfde6-647e-4637-bf3c-c3d04094c0bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $1,203 and $1,032, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_81b58507-53da-4967-b25e-feaaf7432c29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0e1d5130-719e-4d54-98d0-ac2c56dc1bf6_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_20cebddd-39d3-46ce-9bb2-21f0fa77cd7a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_361303f8-1a32-42b4-9ad7-29dd8092bc19_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:to="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_2e4cdb0d-e7b1-4975-95da-cf70a84f050a_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_e6d5cd94-db35-4e6b-a553-dcdfd1d6007d_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20230331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_75267a9d-f6cd-41bf-a98c-fc3d871e5090_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_818ab305-0829-4682-8d0c-697ae18bce27_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57754cd1-e8dd-42dd-9192-c1101c4c1ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_08b5d9e4-4b2f-433b-a3c0-fb1cc07d78be_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_587fec63-18d0-4420-9299-c5dfd6bbfa07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_345c639a-a353-4c84-9a6a-893465229e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d0514b13-0b7f-4224-a7f0-d286f63febdd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3618c5d1-0513-4132-a222-4f22152a1654_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d89d8782-5a45-4035-9796-ba569b246bde_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_94f1380b-ded5-4a40-8cd1-0a92fb73e516_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_48cbffb3-12fc-4391-b43d-4f53f7786c4b_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_11d9ec4d-448d-4e59-bba0-f0758ab5e3c2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_cf53ecb1-013f-44e3-8db4-2869a3c86732_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_72b59f2f-c168-4c6c-9ea4-85d60081dc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_fc80d39d-90b4-4eee-a575-53783f6ada4a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_453606b2-4c7d-4926-a215-4d75fa17742e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_6606c3f4-2dfb-4b6b-8135-d40b4dd50bfc_terseLabel_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_label_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_documentation_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:href="lxrx-20230331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:to="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_3fbb4b53-8de2-4901-b996-0de9aa609061_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_5d92b4c1-3469-41c2-b625-1171d7d54f77_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e837546d-18a7-4737-ac56-12482d9f0857_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_26e3f1a0-61f0-42f3-9c51-da019b44acf3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_749a711f-4dcd-4534-b8f7-0d68757d40f3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_69c1b883-e3df-4e81-8dba-5c670881334a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Current (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a72657b9-170c-47a9-9568-1b7b10bebc12_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_54fcc899-c4db-47d7-a74a-f23d84adf8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb73a93f-4b33-42a5-b253-b4579866795d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7b29e7a7-d805-4d93-992b-e427eab1e23d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_a59f980a-63d5-4d17-95a1-5bb685b2757d_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithNoExtention" xlink:to="lab_lxrx_FinalPaymentWithNoExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8fb6681b-000c-4e38-b680-2872a070281c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_adc7c121-6f69-485d-849f-c3e8d25a8b3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_1ebf9474-24fb-4b4f-be05-4f2eb851560d_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_9b85f63a-6547-4196-adad-92d6e967d54b_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_43105ad8-292b-4b60-832f-7f99e1506dfe_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a81ecdd4-eff9-4dc0-b4a4-5f8616bcfdcc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1dda6fbd-1c76-4898-9e5b-83efe10e365a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_844cd3a2-c8e2-46cf-b21c-d02590987d83_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $2,212 and $1,740, respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20230331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_ac98f9d2-13b8-4754-b54f-c8fa4ada495d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33302bc7-e3e1-46e0-a88c-10a1b5b5cba9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_9917ffc4-d4ba-47e4-b6d2-a7b77d639b69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_5814d065-fd6b-4a92-bdbd-77bda431afd5_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20230331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_a5a92efb-1b0b-4779-95c2-5bba86cad13c_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_403b9f93-e15c-46d4-babc-5bc2c4ce32c4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanDWarrant_c324c0b6-7e1b-4416-a314-1f66b352d876_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanDWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanDWarrant" xlink:to="lab_lxrx_TermLoanDWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_f4c587de-f272-493f-9085-1780359ef8da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f87d08d9-8656-4c89-8747-cc512ee076b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7e2af49a-afce-49bf-acfc-2dd6315464f0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_766fd661-c00f-4843-9c7c-abd4433f6725_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d0ecc41e-bbba-4ee5-8032-7cd081e54bd0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_86460c95-48f3-4d86-bfc8-953c618ff9da_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bef85d28-c25a-4664-8546-d4895c2c7f43_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_47c601c5-4bcb-4c4f-a26b-9ba82e943680_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchange" xlink:to="lab_lxrx_FutureConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_34fb8cf7-6b0d-4f7d-89e4-4ac35312962d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_9579f28d-c764-4270-b04c-2b23b534edba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_b7855b7a-88ca-472a-b670-e25ab7259e41_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_b5f9e882-1577-4181-8e16-c50158ab03fc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_e02c7b50-78ca-40e3-811a-d5042d447afc_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesAxis" xlink:to="lab_lxrx_AccruedLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3c2cf80-49a1-4a8d-8704-42aa25528f91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_a8127804-0abb-4ff7-9a15-1199f1783623_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_0c908d9d-a7ba-410b-881b-69d15abd6d05_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 868 and 488 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b57d968c-ee24-47fe-803f-248e20a25815_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_59fbeaf0-a931-4e89-9538-90300173fb6f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_a18ad7fb-db7b-4eea-a7db-d96007853397_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments2</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments" xlink:href="lxrx-20230331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPayments" xlink:to="lab_lxrx_A2027OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4f4e3c7e-f750-4475-8f21-2fb3d54c7475_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_14ac9622-0e10-4ba8-b5bd-32a2053430d1_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c0165e18-cd76-4670-b337-73283038d30f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb517c1a-2035-4c1a-a412-722ad2d6bcd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a3bb277a-e998-48a4-b6f1-fe955b2dad9e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_97a06951-3bec-4348-92ac-9e76537a1ea4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_e2cfd160-e5ad-4f7e-98cf-8bbed3119252_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44e374cf-6c86-4b85-beda-848944a48916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_de0316f3-d1e7-4c3b-b7ad-cacf0f041144_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1024dcf7-7b33-4f7e-af8e-d1cf32fa646e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_311ab61c-c913-4407-867d-e967349c5b7d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_89cb41f7-e768-4190-8d41-7877014f212c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_159875b1-2aaf-4da3-9b69-91cd49b4b0fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_765c9c0b-5527-4aec-a31e-aed8aa25259f_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_2d674b25-c676-4126-9d44-1e952a1dd508_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5a4b0354-a561-4bab-a967-fe9b9ab0ed3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d3c57925-cca7-4218-8ac5-e2aca6454d16_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_ad57c11b-5ae3-44ce-a0cf-dfb6b176f6ac_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesDomain" xlink:to="lab_lxrx_AccruedLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_f6468d98-ef60-4b85-b28d-7b7cca40c264_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20230331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_53bb18ac-b27d-42da-ba6a-8c6ae8349472_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a67023d9-3797-426a-92ab-557b72578413_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_a2d0742f-a061-4a0a-9192-8e95d72d60d4_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJuly2022Offering" xlink:to="lab_lxrx_ProceedsFromJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c1833ef8-88e8-46c8-b746-944f90f34762_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_bdbf877c-c3ae-4daf-879a-e73149c8ec49_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55c8d4bc-fe85-4760-905e-1d6c44b0b3bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4990d804-b3af-4d0b-85a2-6b35b0b06ddd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_524fc50c-3ff2-4fcc-a35c-07dd2e4fc660_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_9c33ac0f-73ac-45a6-8c20-b5bb5a97bc2f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a08e083-9c84-4bb4-8e52-3e61ae860c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_17fccde2-90e2-4c10-baae-6b2532b4dcee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6e567b81-6f23-4120-8ba8-6ab3e273debe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_1e09d7da-c6ea-43c6-94de-c69716a5004c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_e19c3bc0-2537-4c0e-8813-ed14bc4af396_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree</link:label>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:to="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_22cdbcf3-3f35-46d3-bf79-bbf1b81badd6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_43acbdca-4896-4aed-9954-e22a00037d4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c8619182-dacb-4f4b-8e4c-b97d5ce662fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_40009663-c8f3-4106-854b-974d50583a64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3a02fb7e-6f7a-44aa-b364-c7344484ffab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b67f1950-fe64-44a2-b044-e4dce97b564f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5ff41f43-2a0c-4e59-acaa-ced5d476692b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a5ef69d7-5fa8-44e1-bac5-5eac11650394_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_62a8934a-1ed1-4714-abbc-1cc6aabc521e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8a8270f9-ce02-4f17-b51d-f244384d9d04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_c0a162ec-e98b-4a5c-a8b8-7b50d9bd0499_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20230331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_0b3d342f-d403-42e9-b82e-7ca618c08d6a_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_8bd1aedf-09c8-46a7-aa79-80f725d58d70_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6ffc66cf-b0af-422f-a3ee-88a64f1aa84a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5c2295d-3e3d-4e8d-a592-6bb6d476c581_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4ee426e-cf0d-417e-9f76-31060e609f81_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_1dcb6faa-5f1b-440d-9591-bce686011c47_terseLabel_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments" xlink:href="lxrx-20230331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2025OxfordPrincipalPayments" xlink:to="lab_lxrx_A2025OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cbc4eaed-eda6-4ec4-ad6b-3f57923e041b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_8541be89-be1e-484a-af53-9f2e238fdf9d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6c489292-873f-4745-8c45-0ac2b0bb815e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a9e8a3f0-b65a-4619-96d5-769da1766711_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_70fe06a1-7531-446f-82b2-7c1e92fc4f05_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $4,096 and $3,984, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_c62d9b39-6b7e-40b0-b238-6d34ea85d638_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_label_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_documentation_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAFinalPayment" xlink:to="lab_lxrx_TermLoanAFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_3ee170a9-a18b-4017-94e7-ad9efd6321d9_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e7771948-c1db-48fc-8c83-f417d24f2bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_55ff698a-e4b8-4b59-9eb3-3a32a3e20b64_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e9adde7f-6587-4369-a6f6-f94dcc50654f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fd2c5d2e-959e-4a6a-b37d-127d81cefe07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_613b2720-c5fe-49a2-9446-75c084cce466_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJuly2022Offering" xlink:to="lab_lxrx_SharePriceInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0b8cc854-37c4-4783-9f2f-4631210ec904_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_08eb761c-23b2-4e49-a73e-b352fc96ef80_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_29f340bf-c76a-4cd4-bfce-6b239d1202de_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_59cb0689-43cf-4594-8e33-1020dd96deaa_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_84124e14-3896-4b84-9194-92be0269be49_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a42ddfcc-7835-4757-abcf-d3fb2bfce2f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5bdb96fd-f197-4b7c-9d8d-947c684a92ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordAmendmentFee_93416b75-bd39-4da1-8a83-938fad870b70_terseLabel_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:label id="lab_lxrx_OxfordAmendmentFee_label_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:label id="lab_lxrx_OxfordAmendmentFee_documentation_en-US" xlink:label="lab_lxrx_OxfordAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Amendment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee" xlink:href="lxrx-20230331.xsd#lxrx_OxfordAmendmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordAmendmentFee" xlink:to="lab_lxrx_OxfordAmendmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_51f54eb0-478d-4446-afbe-d82b867dd933_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_065d2767-d774-4836-97b8-035b1f2b6343_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b750fd96-f6df-4012-85ce-8e8c9e3f3696_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ac3db6de-7758-495b-a3d1-ae3cb08779d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_2e7f71f5-bc1a-473a-b2da-e50dc8cd9c39_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20230331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8576e459-d986-4a14-9df9-e0c5873e1993_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_59964967-1b5e-44cd-a3dd-39800691a1fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d22bacbc-5c75-4708-9d63-90f6a99aac04_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanABWarrant_97f23a78-4659-431c-9897-cc4fdedea49e_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanABWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanABWarrant" xlink:to="lab_lxrx_TermLoanABWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_21fbd591-6417-49a0-bab1-0f1f477ef35b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_42eb2aa2-0423-4431-9ebc-2b53e588be8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b43a7fd3-ea7c-4050-9185-bd89cd9b0f1d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5e41c4e6-63a9-46d9-8f86-f02e09fd2bd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_eee23e90-6791-4575-aa46-29cf495b6b87_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_label_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_documentation_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanANetCashReceipt" xlink:to="lab_lxrx_TermLoanANetCashReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_70169743-24ab-498e-8c70-dea5cb88fe04_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_02490b4d-c6e8-4bce-97ae-e5187e068ea0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_1889d8ae-b4df-4e96-99fe-1e3bd5c0dfe4_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0181d33d-202c-4c20-a499-4dc6f4794995_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e5dabc2b-cbbc-46e9-b9f8-6228d0831833_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e7d21bea-5893-4f2f-b64f-fa9491d4ccdc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_5373408d-c75b-4b05-9bd8-3426513e488d_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20230331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_10059ab2-c050-4044-818c-2fda96712c66_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_b31d4ebe-406a-450f-862f-703704207fea_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f9f7daea-bdc7-46c7-845c-f9948aac2056_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4fc6b437-2e50-4fcd-8d92-9a6582769ae8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a15aaa3-4bfe-43cb-908e-b1a63ce97480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6dc33228-9eec-4702-910f-db5c4c94d4ad_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_15c745b5-81ba-40e6-abad-fa01c12b83ce_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_61ff79cc-98bd-4dfe-8055-33052cee448d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_755603bc-92e8-4c27-bd9a-63698c90996e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fec407ee-9f64-40bb-bd4f-6451dca140fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e498aba5-dac9-466f-8b00-63d34490a950_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae739211-4e28-4b03-98d0-1751b5da4056_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7e974966-a5a1-4d15-a85a-7f5a527a9ffe_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6eda913c-b49e-4b56-8d0b-7f0be2791b40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_bc6b6176-3efa-4357-be6b-8dfb5c4eadf1_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c8a33f04-2463-406a-b152-d1f20379af20_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b2b5c728-241d-436b-992e-c1af1a3dab71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fec36603-0c08-41df-890f-fec2ceec27a3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_0f904387-c8ef-429e-b083-ff48f4d4563d_terseLabel_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:href="lxrx-20230331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:to="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_eb201774-11c6-4a0a-a7f1-12b3152706ae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d0d9a15a-90d5-4dc1-ac0e-1a36b18dcb4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a25e4bef-9ccd-4573-bf96-f28ca5f88183_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_6f8ee350-5c57-48c3-8d6f-98c40c197b89_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_a7b552d5-dda4-4b90-9587-6d2ea92f16cb_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:to="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_05dbaf06-cfff-4d0b-9be2-330b79313499_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_cf99ca16-b5c2-4104-bd36-150647cc7d04_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20230331.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d82f7de3-232d-4a32-a76b-061b7e2505aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_293430ca-e01b-40cb-944a-06e477353293_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_e0195b07-f92a-4dab-93b0-706e3d977a6e_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06e6a64c-4460-4e82-a833-e90ee91d9d64_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_e5017154-df17-41f7-bbda-5a5602be9edf_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_29dafb47-f922-4ed6-b6f9-174f8af789a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a457eb8b-400c-4e04-bcda-20adcf87f257_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_e7b727b9-334b-419e-bc40-20f4213d8f52_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantsNumber" xlink:to="lab_lxrx_TermLoanAWarrantsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ae85cb09-7c48-4768-974c-d04f9b369a5c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d89af44f-d76f-40fd-9ddf-8f8a2fbc9b1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e1e61f3a-33fe-4615-9e40-231fe59bb654_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a5ae6065-1247-44fe-9a8f-29a963b0a9bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9c67f7f0-83ad-44d7-8ac3-c131ac089b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c285fa3f-c00b-4abc-b06b-1b2d28680ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8442f861-8034-4471-bcd5-61a8525205ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5fa63453-d714-4e9d-85c4-f99f962b43a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c3a2f78b-0b78-42a9-b0f0-9efd55a5d857_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_504a98ef-84ea-48ec-9cf1-0ce733741278_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_592abd8e-4cab-4656-a6f1-1ec4cfffa651_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_09c7447e-a58a-4069-842e-4dc72ed2d06d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanD_0f4aa912-bd77-46ea-b572-6662062c864b_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_label_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_documentation_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanD" xlink:to="lab_lxrx_TermLoanD" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanC_52f5ecea-1de3-43ce-9235-56a72e1295fe_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_label_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_documentation_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanC" xlink:to="lab_lxrx_TermLoanC" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_6cf320aa-dcfd-4dce-8358-384f1b0f34ff_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20230331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_77ba44bc-626b-42f8-bff3-64389e4b593f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5fb19137-08c2-4186-b9ad-7d19ebe97a25_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_75184a05-e787-48ea-86fe-91c20c7bd465_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanB_ff166440-08bf-4fc6-8966-64dc915baf83_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_label_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_documentation_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanB" xlink:to="lab_lxrx_TermLoanB" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanA_d895518b-85bc-48f4-8239-89357e60069d_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_label_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_documentation_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanA" xlink:to="lab_lxrx_TermLoanA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ea1d3f59-61e2-4f20-94be-7c16f0c3e140_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2c3eb6b8-2372-4c4b-89e9-0cc2b811f15b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a2b9790d-72e6-42e2-868a-3c6924e2d1cb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1506e6a7-e642-4b2e-b0f0-9842f63d9034_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_d9c5d069-dc0c-4285-a993-10b57408be35_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5783b7d1-9da7-4915-bd15-7dc1ca9ec50c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6e159b0b-5ea0-4c9c-a9af-4813e5408ea8_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_351b5a94-0dee-4e96-bcbb-7f4f32584eaa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b08ac3e3-36bc-41f9-aa0f-4236bf01995d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6d0c0d33-0d3e-46b4-9d59-9e4e28583b46_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_18145ea0-ede3-4668-b953-b418cee6a6b6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c56c5ad5-818a-4131-89ce-2f858f3aadc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_616824d5-3194-436b-ad50-2e03b41bda5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_47429fc5-106a-4515-a246-e494e18496c0_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cc7ec3ab-2030-4b89-9b31-c89268350713_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b0c0931-0545-4f84-9cc5-465cc6c6dfcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_73f57666-aa0d-4218-8e84-c90bdc75f615_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b6c81f58-73ff-433a-a08c-4db1f295078b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ff56126d-931b-479d-9148-d7708bb71b65_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_e022961b-3d3c-4ead-be37-c6c4a6734384_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e3c920f3-d512-486a-8a06-50f633d927d6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1061e5cf-03e6-47c6-89e4-f2a432580cbb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c2a4b78d-a2f1-4836-a3f8-f9cf86f9db26_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_9a1f5b13-28d3-4294-b8b0-10df3f2e7e33_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_e41d07c2-f011-4794-8148-36f39442ff27_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f7ac8117-4c7c-4911-a650-617c98a97640_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_d599f36f-d339-4826-8eb9-3702fc5bfb6c_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_f5cd165d-08bc-4cb9-84a9-f494759cf579_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc17e3b6-6cf8-4271-9786-61a5f47f96e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_da72ea56-827d-4347-81e2-35489bc75f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a7bbb9ea-066f-40db-aeda-50decd2913b7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_38fc0591-7b62-4f4c-8ec7-1f0b8d05b455_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_327a243f-b127-4781-a923-44ccd5adc1d7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_85753c85-fdad-4399-8e2e-f14afbf03a8b_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20230331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33eeebaa-267d-487e-8934-0f327c2bd6b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_8fd0bd4a-76cd-48fa-bbe1-180a9038947b_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20230331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_9d8ab3a7-214b-4204-bbf2-bc48a968bea7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_b5cac252-0d71-489d-8f7a-d60ff3e0e35a_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_07dde618-1056-4c96-ac6a-85fc3e02256b_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20230331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e53d354f-b4a0-4eaa-accb-d58014806733_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_757c35df-1627-4a83-b997-380aeff959e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1bf02b2c-aa35-4b0f-922c-878912c87f5f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_0f077113-8c0a-495d-9314-eab68aa1a5af_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_143105f6-ee07-470f-b028-734cf2ab409a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_87f8808c-d53f-4ea0-a8ad-d66f5b41398a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6b1b8718-6dff-411f-9fbd-7a79265aaf4e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_7d293a21-b82c-4118-9562-06a29444568e_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesTable" xlink:to="lab_lxrx_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bf67cc4-0bb3-424a-9a56-581b2ab16a96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5f1e5266-5b6e-4b65-942d-6ca4b58e417f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_bd40d281-9663-4f84-b212-b5bdfda8d477_terseLabel_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments" xlink:href="lxrx-20230331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2026OxfordPrincipalPayments" xlink:to="lab_lxrx_A2026OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanCWarrant_e14ce97f-05a9-448c-a37e-e7c4cf91f891_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanCWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanCWarrant" xlink:to="lab_lxrx_TermLoanCWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b28be9ef-7ea4-486d-b9b1-bc6aeda7e219_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_d4ebc27b-4eef-493b-a4f5-84e7316019e0_terseLabel_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_label_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:to="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_75d0c95d-37a7-4226-b009-fa7d15039e41_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6690e0cc-64ee-400e-9b81-372226f26707_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_52cb3340-3698-460a-bc4e-76b8014973ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_f4743e76-bc3e-4df2-8e96-2b56b727a651_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_label_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:to="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_63d0bb4f-59d5-4c65-8707-d30a6f7b6638_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_302af640-4025-4c5e-a2d4-e96fbc22204b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_a6ea5c4a-3d70-4115-b425-a751c5777c0a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_8cd1e283-d19c-4b29-aaaf-5554654670d4_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_c3a42195-1960-46fb-92ff-d92dba648c7d_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ec34e954-6cf5-47fe-8b0d-1300427f4c9b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_3d8beb8f-ed33-4d78-a21d-b9c288bf8907_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTerm_3431dd68-ddb8-4547-9125-9c9c8669e211_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTerm_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_85a39be4-a542-4f55-958f-b54872b93598_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_520bd9e6-5310-4c35-b401-c3c5f47fc121_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d17526ed-b80e-4491-a1c4-02803cadc867_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d769d7e5-d535-4806-b30d-c4096d440c87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_41464778-d5e4-4ffc-8d4d-53d4945222ff_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordLoanFacility_d1440365-04b7-4bd7-87f8-4a3273af1cc2_terseLabel_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_label_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_documentation_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility" xlink:href="lxrx-20230331.xsd#lxrx_OxfordLoanFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordLoanFacility" xlink:to="lab_lxrx_OxfordLoanFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2296a307-4c23-4144-9e85-c3cf28a29525_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3edc26d-d1eb-4eeb-94da-8ba84a95c799_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_c9d796fd-e488-4fe4-9f6f-c60230c09430_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_label_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtDiscount" xlink:to="lab_lxrx_TermLoanADebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_69c93a74-6236-49eb-95bb-2dde19ab61ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_c745bcbd-69a1-4d5b-ad50-01647f145406_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44ff3f54-6204-4fe7-99d6-339e384a3272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_e73325f4-64be-4ed1-a33e-88e3f8b1159b_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20230331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_35025495-0266-4b39-a201-4ad560fcce75_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b6ccb8f-e387-4e0f-8b3d-0d15f3cb7de7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_763d302d-e122-4111-a888-dd001b71e3a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordFacilityFee_40b9e3e8-b527-4b49-b3cd-8f32d62e30cd_terseLabel_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_label_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_documentation_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee" xlink:href="lxrx-20230331.xsd#lxrx_OxfordFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordFacilityFee" xlink:to="lab_lxrx_OxfordFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_962508ce-61b4-4062-8f9b-e3243203c122_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1a857030-503e-425e-844b-bfffb349af21_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dacae6e7-3286-4460-886c-4cedb4c9a3c0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ff9bf528-619c-42db-b406-e64223b38858_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_6fdde9cc-d869-46c7-877c-cdcb2748e2d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_bbbc6e47-34b5-4ad0-952e-d2bdc6ccf6fc_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_fd311514-48b2-4221-96db-ed60c0c397d9_terseLabel_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_label_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_documentation_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:href="lxrx-20230331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:to="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0879ecf0-8830-4701-b389-73d5b9f4a35e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_77a44c2c-afcf-49d9-9b89-482450b14457_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_d1189411-00cf-4250-9bc8-9132d61439b7_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20230331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5b2de572-5992-45e0-b5ad-4026308a4584_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDisputedCosts_9645ebad-4cdc-487f-8ce1-fbadc2a51b45_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_label_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_documentation_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts" xlink:href="lxrx-20230331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDisputedCosts" xlink:to="lab_lxrx_SanofiDisputedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_188b35b6-f7df-46af-9056-6d87d384b53b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_5b7c077f-9ceb-4f24-86cc-877cd7245f03_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ec787f6e-ffb1-48da-8b16-54fc5b63bc9c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_b5c89f31-bac9-4121-9c7c-6781e2a0ce15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_45baeb4f-817a-4e2a-a2ec-8b3d1a36a0e3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d25eed98-3e47-4f22-bdf6-a330dce8e34e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_97ae8c74-4f73-4b4f-9d5b-7a5bd1bbf8a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f03a8f01-5016-4b14-9e11-43556be62edd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_3c72c781-34c1-4e86-abcd-624655373b1c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_c3a86868-b5e4-4aa6-a6d9-61299dc92fe7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_e1ff12a9-b163-4e99-a692-faa306b47cb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_90ddac34-ef82-4646-a28f-5b816cc7d8dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_123c0ea0-dc93-4ea7-9ddb-815a0028d4f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_076fcdf0-005a-4300-9d58-15b1ae4ac23f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_1a8af273-6222-48cd-89d4-86704fd7ac79_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_013015e5-1f47-42d9-93b1-e08b72a52782_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_b1bdbc8f-c1fb-4612-900a-5e4786db1419_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJuly2022Offering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJuly2022Offering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in July 2022 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJuly2022Offering" xlink:to="lab_lxrx_SharesSoldInJuly2022Offering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_fd502428-cf70-48b6-9820-1831f249bdb0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_b20cc0ae-548b-4548-8cee-f356d86382ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd64cfb4-e19a-4586-b12b-29e4c0ec52d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_959c4df9-3b27-4a65-9216-b5e5ccc1591e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_18366af5-bc32-4a8e-9627-420d512828a1_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_2398e071-5b54-4785-a6f1-eb518e2ea6ea_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20230331.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e38b8d80-0abd-4387-bf89-c746f12b789d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_948c77f7-df47-46f8-aa33-66feaf22a188_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_b5c68027-33a4-4cae-a846-11fda2ea6988_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20230331.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5585b359-55d7-4b69-be65-c6da83436483_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c2ffecd9-ae95-4887-a0f1-65dbb01455a2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_48a888ea-d550-4138-b314-7aac6ca507dc_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_label_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_documentation_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAInterestExpense" xlink:to="lab_lxrx_TermLoanAInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_a58e14ca-ef8b-4b57-9003-a330fb6672f5_terseLabel_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_label_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_documentation_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible" xlink:href="lxrx-20230331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedInterestOnConvertible" xlink:to="lab_lxrx_AccruedInterestOnConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b90744e6-db85-4f26-a312-59fc9e881163_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8882a2a0-d5e5-4fb5-9247-ba295560dc9c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_7e7844a5-f23b-4bda-9cbc-dfc30e7850d5_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_f0599199-21f8-4cd4-ab32-12db363dafb2_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20230331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ac06d07f-88f2-4e29-8440-7789ff515d7e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6fb8429b-4aaa-4c0f-b1b4-4c5a5b7b6cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_70438a8a-016a-4b12-8876-7fa32182609f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_f7dd5a61-19cf-46e9-986e-59dd157d92fb_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_2998bd22-b91c-4151-a089-651bbbed071c_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0115e72d-a44f-40ef-b439-ca92b6a3465d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_457c708c-9ab9-4c8e-844a-781f05a6cb43_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems" xlink:to="lab_lxrx_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e7684086-0a34-4cd5-8e2d-a3c8ac0fa072_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1028daab-c82c-4932-9ff3-a5e6b0266acb_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5c1a23fe-2ee5-4bb6-becd-5d261d49e292_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2cf53f62-bfc3-489b-a340-c8e06b99b0cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_e870bdd0-9c59-4600-8ac0-d17fde821fd2_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_0acfb1d7-407e-438b-be95-6e701cf36535_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithExtention" xlink:to="lab_lxrx_FinalPaymentWithExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_df35ab7d-ae0e-4f48-be30-9a10ee586c18_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_4d38e61d-7c2e-4fe1-8056-5b3328752a17_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_959aee40-3f87-4dc3-9725-839ee45a94da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4ed4eaff-5026-45da-91c6-a3b54101af30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9e926083-b0aa-4a46-a78c-70de628ba671_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_f815bb9c-ec2d-4ae4-a145-c1e4ac9a139d_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_2245105a-7d98-47d5-b0a9-d31239c31eba_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member] (Deprecated 2023)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0038da35-2578-495a-957a-421138a48172_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCarryingBasis_9a9bed8d-27df-458a-b36b-376fee5dc774_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCarryingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Carrying Basis</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCarryingBasis_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCarryingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Carrying Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCarryingBasis" xlink:to="lab_us-gaap_TreasuryStockCarryingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_81bb408b-0779-448b-a707-74c3adfce08d_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:to="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bf6b8ac0-025a-4fee-9a62-f35a25f4cfdd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 300,000 shares authorized; 190,430 and 189,214 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lxrx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:04255599-9cd1-4a59-9827-89360938c3e0,g:d0579bd5-6b67-42b3-b871-98ff459cd059-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20230331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6f02f124-9fde-45b5-abba-8d6fb519bba9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentType_6f02f124-9fde-45b5-abba-8d6fb519bba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b202ff82-f9cb-4cbe-9b6c-eeea8f021aa3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b202ff82-f9cb-4cbe-9b6c-eeea8f021aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b3d5308f-286d-4d30-af68-01738c284410" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentQuarterlyReport_b3d5308f-286d-4d30-af68-01738c284410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70c7c9e0-9527-4fff-8817-a1ed64ac3f81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentPeriodEndDate_70c7c9e0-9527-4fff-8817-a1ed64ac3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c5a58489-4cbf-48ce-8741-023a4925cbe7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentTransitionReport_c5a58489-4cbf-48ce-8741-023a4925cbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_100204bc-5e71-4ea4-a663-e722f0897823" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_AmendmentFlag_100204bc-5e71-4ea4-a663-e722f0897823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30603f02-ae8b-495c-9def-daa68a38a5ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_DocumentFiscalYearFocus_30603f02-ae8b-495c-9def-daa68a38a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b7424e90-22e9-40e5-bd0e-91377eb06fd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_CurrentFiscalYearEndDate_b7424e90-22e9-40e5-bd0e-91377eb06fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eecf4343-c479-4966-8932-46523ee423b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityFileNumber_eecf4343-c479-4966-8932-46523ee423b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e6980c7c-ba25-4e94-9164-cb2487f1a4f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityRegistrantName_e6980c7c-ba25-4e94-9164-cb2487f1a4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5cf2966c-6b1f-4672-b008-58bed4c01654" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityCentralIndexKey_5cf2966c-6b1f-4672-b008-58bed4c01654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e2b44a46-e328-41b4-b193-945e8f56ef53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e2b44a46-e328-41b4-b193-945e8f56ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6ab5acaa-4200-4fc3-bc0c-a72ae83d3ed1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityTaxIdentificationNumber_6ab5acaa-4200-4fc3-bc0c-a72ae83d3ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_39c5b852-853b-4d8b-8244-1d3e7e2e51af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityAddressAddressLine1_39c5b852-853b-4d8b-8244-1d3e7e2e51af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_5e8f30e2-3bd8-44aa-97d3-253aec2563ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityAddressAddressLine2_5e8f30e2-3bd8-44aa-97d3-253aec2563ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_95164727-794b-4930-a540-bd69074bf2a9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityAddressCityOrTown_95164727-794b-4930-a540-bd69074bf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_01fe4dc7-44d0-4f68-9b49-bf2baa426514" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityAddressStateOrProvince_01fe4dc7-44d0-4f68-9b49-bf2baa426514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0652aa3d-0da2-4e74-9a30-aa119ce647c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityAddressPostalZipCode_0652aa3d-0da2-4e74-9a30-aa119ce647c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bb6c1ab4-77a3-4f92-9e7b-93e4a859756b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_CityAreaCode_bb6c1ab4-77a3-4f92-9e7b-93e4a859756b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8d245042-6bb4-42d0-843e-e37b7895e11e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_LocalPhoneNumber_8d245042-6bb4-42d0-843e-e37b7895e11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1c903d9e-296c-4fc5-9b45-d2bea8eed7a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_Security12bTitle_1c903d9e-296c-4fc5-9b45-d2bea8eed7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c8d25a66-e54c-4f27-b3f5-091953a9e908" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_TradingSymbol_c8d25a66-e54c-4f27-b3f5-091953a9e908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f56e68e9-d8e1-4405-825c-4ad5f74dc821" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_SecurityExchangeName_f56e68e9-d8e1-4405-825c-4ad5f74dc821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_03a4260d-84bc-4230-8681-fbd627878a3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityCurrentReportingStatus_03a4260d-84bc-4230-8681-fbd627878a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_38f7be53-e0f7-41f0-99dc-917af57aee84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityInteractiveDataCurrent_38f7be53-e0f7-41f0-99dc-917af57aee84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4823aaca-5ea9-4c28-abbb-60f45cda3bb8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityFilerCategory_4823aaca-5ea9-4c28-abbb-60f45cda3bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_90f447de-c8c0-4391-865a-ab8ce2b8a417" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntitySmallBusiness_90f447de-c8c0-4391-865a-ab8ce2b8a417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d7fe37ff-218d-4f76-b864-a99d5dff3ed3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityEmergingGrowthCompany_d7fe37ff-218d-4f76-b864-a99d5dff3ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f22495b3-4a57-49e6-90d3-e68851991923" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityShellCompany_f22495b3-4a57-49e6-90d3-e68851991923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_efb7c091-0047-4650-8e27-a95f06b40a0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_174cc736-b4bb-4e55-b595-bab3cbf577a7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_efb7c091-0047-4650-8e27-a95f06b40a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_faccbef7-5a39-45c3-9af0-53dc75e3e92d" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_faccbef7-5a39-45c3-9af0-53dc75e3e92d" xlink:to="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:to="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_47557898-6664-4914-8778-515c6bd42f27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e001ad84-14ca-4dc6-8740-df33167017f1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_47557898-6664-4914-8778-515c6bd42f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1e51fd1-0994-4586-8f7d-b6cc656d6c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41d26d8a-77ba-4883-a58e-dc5894b3d0cc" xlink:to="loc_us-gaap_ClassOfStockDomain_d1e51fd1-0994-4586-8f7d-b6cc656d6c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9fc12650-8dfd-4131-aebd-3d06e271c41e" xlink:to="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f07e3f-b20b-4612-b334-890382a2d217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f07e3f-b20b-4612-b334-890382a2d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ebab7e23-8ac1-47de-838c-5ac1bda1f78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_ShortTermInvestments_ebab7e23-8ac1-47de-838c-5ac1bda1f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_feac00bb-672b-407e-8bc8-b2b1b318814b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_feac00bb-672b-407e-8bc8-b2b1b318814b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_293e12c8-cdbd-47f8-ae71-66074a9cb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_OtherAssetsCurrent_293e12c8-cdbd-47f8-ae71-66074a9cb0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f1625785-e1d0-40b5-a9d1-16a4e25cac48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d4d8aa1b-7f12-499f-8cb8-ed2c8e79bf14" xlink:to="loc_us-gaap_AssetsCurrent_f1625785-e1d0-40b5-a9d1-16a4e25cac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dd1f424a-4672-4350-9572-61c0cd332742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dd1f424a-4672-4350-9572-61c0cd332742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_88cb1388-a601-4a90-9de2-5b4556ce24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Goodwill_88cb1388-a601-4a90-9de2-5b4556ce24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_be3df8e3-147b-4dee-a7f0-3da5e3d1688a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_be3df8e3-147b-4dee-a7f0-3da5e3d1688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_703d1899-f722-426b-bcea-25895938dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Assets_703d1899-f722-426b-bcea-25895938dc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5d269505-ebdf-4a9f-8a86-f57276f9bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_AccountsPayableCurrent_5d269505-ebdf-4a9f-8a86-f57276f9bb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_712b087d-d439-48e6-a942-eaa30dcc4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_712b087d-d439-48e6-a942-eaa30dcc4d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9f2372dd-70d3-47aa-a152-2aace1c9c901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_LongTermDebtCurrent_9f2372dd-70d3-47aa-a152-2aace1c9c901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbe1b747-c788-496d-892a-030fbe82645b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_LiabilitiesCurrent_fbe1b747-c788-496d-892a-030fbe82645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_e5501e2f-6682-46a2-95a2-a656b5451355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c40d65e6-83b3-4617-bec7-1597ae6699af" xlink:to="loc_us-gaap_SecuredLongTermDebt_e5501e2f-6682-46a2-95a2-a656b5451355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b14731fc-6eeb-49fd-88d0-adbdc792b983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b14731fc-6eeb-49fd-88d0-adbdc792b983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d477ce2e-2772-4ad0-b51b-dad1894a6857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_Liabilities_d477ce2e-2772-4ad0-b51b-dad1894a6857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b4b02ab0-c1cc-491d-90fc-8d933cf2e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b4b02ab0-c1cc-491d-90fc-8d933cf2e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ffe2084c-4b23-4b06-b675-68179736a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_PreferredStockValue_ffe2084c-4b23-4b06-b675-68179736a52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c8c68155-bb4a-422f-883d-dd94ed16d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_CommonStockValue_c8c68155-bb4a-422f-883d-dd94ed16d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9422e4e0-cbb3-4216-baa3-682cd698dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9422e4e0-cbb3-4216-baa3-682cd698dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e073c7fa-3bc4-4cd3-8a36-8b2d87730f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e073c7fa-3bc4-4cd3-8a36-8b2d87730f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c34ed0d-dcfb-4947-8938-72f7dcf0f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c34ed0d-dcfb-4947-8938-72f7dcf0f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e7f51d71-63da-4b27-8700-e9173ba9eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_TreasuryStockValue_e7f51d71-63da-4b27-8700-e9173ba9eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53b817f9-6e2c-48d0-ba2f-99dab16d73e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40f68a82-ebdc-43ec-9646-59664bdfae2d" xlink:to="loc_us-gaap_StockholdersEquity_53b817f9-6e2c-48d0-ba2f-99dab16d73e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_764bca5e-27d7-417f-b51b-e201cfd1ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_764bca5e-27d7-417f-b51b-e201cfd1ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_da35daa3-7d9a-4d26-b9e7-aa2b7b4e82c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_899e9468-b611-4cd7-8b22-f169a1a006c4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_da35daa3-7d9a-4d26-b9e7-aa2b7b4e82c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a607834e-9d79-4d7d-bb70-55e1903df412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a607834e-9d79-4d7d-bb70-55e1903df412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4266aa-7b52-4edf-8b0e-71f33d7110f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4266aa-7b52-4edf-8b0e-71f33d7110f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_364fb2e3-8f67-4073-a06e-8f914e17982c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_364fb2e3-8f67-4073-a06e-8f914e17982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ab4255d3-e748-4cd3-8883-5b803ea4ad95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ab4255d3-e748-4cd3-8883-5b803ea4ad95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_40ce8190-8c71-4320-b0c6-a579fc216b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_40ce8190-8c71-4320-b0c6-a579fc216b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1845aa49-ac84-4425-ac0d-442bc7744deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1845aa49-ac84-4425-ac0d-442bc7744deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fcccdb02-611c-4a13-9526-39c1a89572ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fcccdb02-611c-4a13-9526-39c1a89572ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c2ef8d38-283f-445d-acf8-8cc96ebe5ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_CommonStockSharesIssued_c2ef8d38-283f-445d-acf8-8cc96ebe5ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_256e0469-3f46-4ae0-9e76-48702db210c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_49d5bdda-65cf-48a0-9052-57483bf390a6" xlink:to="loc_us-gaap_TreasuryStockShares_256e0469-3f46-4ae0-9e76-48702db210c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_73c5c85d-01db-4afc-84ca-a77e610a3a90" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_73c5c85d-01db-4afc-84ca-a77e610a3a90" xlink:to="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:to="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2e4d85bd-4ae5-43fa-9cd0-1a4ec2dcde53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8a52e2b6-1457-4fe9-ba59-22d6da48e648" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2e4d85bd-4ae5-43fa-9cd0-1a4ec2dcde53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8b147d0-14e7-499c-9f3e-c914d9d9cc47" xlink:to="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_c621f91e-3e9f-4a4d-a195-8392a71ba7ee" xlink:href="lxrx-20230331.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_lxrx_Netproductrevenue_c621f91e-3e9f-4a4d-a195-8392a71ba7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9615e2eb-17ca-4d4c-9c33-ffe8456813e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9615e2eb-17ca-4d4c-9c33-ffe8456813e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_e2925644-6efa-4c69-9546-ac50af2f0216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_e2925644-6efa-4c69-9546-ac50af2f0216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_78c3ffb1-927c-4afe-a9b0-c56c727e8f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_us-gaap_Revenues_78c3ffb1-927c-4afe-a9b0-c56c727e8f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_21519e19-4202-4a34-a60e-5bd02fcd1279" xlink:href="lxrx-20230331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_adc86ef3-09c5-4a46-994c-c94750a6711d" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_21519e19-4202-4a34-a60e-5bd02fcd1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f927b0d8-4842-402a-b93b-36c242661ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f927b0d8-4842-402a-b93b-36c242661ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8641749b-5ee5-4963-945f-68a22f99241f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8641749b-5ee5-4963-945f-68a22f99241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_371400ab-c4e1-4fc5-82e2-d0ddd3a2d110" xlink:href="lxrx-20230331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_371400ab-c4e1-4fc5-82e2-d0ddd3a2d110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cda3d18a-9b58-4796-a78f-bd91578c2d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_AssetImpairmentCharges_cda3d18a-9b58-4796-a78f-bd91578c2d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_356d96c7-6d38-4037-9d53-caba79f39553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbd4c030-1ab5-4265-851c-268b860e48e5" xlink:to="loc_us-gaap_OperatingExpenses_356d96c7-6d38-4037-9d53-caba79f39553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5d884296-1b08-4cc6-86a8-f4edae5e9b8a" xlink:href="lxrx-20230331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5d884296-1b08-4cc6-86a8-f4edae5e9b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d220c440-997d-4cac-8630-81db3fad77a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OperatingIncomeLoss_d220c440-997d-4cac-8630-81db3fad77a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_490e03d3-cd1d-4c00-a6e0-3c7010689db1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_490e03d3-cd1d-4c00-a6e0-3c7010689db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_25105437-202d-4cf7-9312-f47e8cf8807d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_InterestExpense_25105437-202d-4cf7-9312-f47e8cf8807d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a9aa0f0c-4f21-451f-b99b-3c3fd15fe64b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a9aa0f0c-4f21-451f-b99b-3c3fd15fe64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6fc14d7-1588-4330-a9d8-6f4e016ebead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_NetIncomeLoss_e6fc14d7-1588-4330-a9d8-6f4e016ebead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab379954-7c23-4cf9-80a1-e3c5b6c93c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab379954-7c23-4cf9-80a1-e3c5b6c93c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6cdceb5-7645-460b-b36c-c4f80183e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f6cdceb5-7645-460b-b36c-c4f80183e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a9475fa-5d0f-4a69-8759-616d5ac17956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a9475fa-5d0f-4a69-8759-616d5ac17956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_397d22d7-de78-4421-95fd-a7e72ad1e1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_397d22d7-de78-4421-95fd-a7e72ad1e1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52388c5c-7659-4b2b-9fc6-73df49698e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52388c5c-7659-4b2b-9fc6-73df49698e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0834bbc-dbd3-4682-8981-11121e458314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0834bbc-dbd3-4682-8981-11121e458314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0694e1c4-1899-45bd-987d-0e3a4b65bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0a83af2-2ea9-4532-b6f6-42defd879929" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0694e1c4-1899-45bd-987d-0e3a4b65bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_ccfe1437-0e38-4287-ad5d-d0e5be857fcc" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_298fbe17-601a-4e39-a794-ccc07c38e70b" xlink:href="lxrx-20230331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_ccfe1437-0e38-4287-ad5d-d0e5be857fcc" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_298fbe17-601a-4e39-a794-ccc07c38e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_2dd5287a-00ba-4eee-9b86-1e1a49a48b08" xlink:href="lxrx-20230331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_ccfe1437-0e38-4287-ad5d-d0e5be857fcc" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_2dd5287a-00ba-4eee-9b86-1e1a49a48b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f016649-7fa6-4235-9ce4-88245d35da95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_NetIncomeLoss_7f016649-7fa6-4235-9ce4-88245d35da95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f484c03c-cb17-4ed3-b086-d07e108ed775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f484c03c-cb17-4ed3-b086-d07e108ed775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_378f369a-b445-4570-9a0f-ff3ddf39cad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_ShareBasedCompensation_378f369a-b445-4570-9a0f-ff3ddf39cad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0ef0b6e-9865-47a8-ba07-df15e9c4a4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0ef0b6e-9865-47a8-ba07-df15e9c4a4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_598fa828-2b4d-4a93-a30d-e31712270493" xlink:href="lxrx-20230331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_598fa828-2b4d-4a93-a30d-e31712270493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e3b02fa4-d7ad-4e52-b7ed-39bb95729ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_AssetImpairmentCharges_e3b02fa4-d7ad-4e52-b7ed-39bb95729ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6296ddb-6958-4b2f-99fc-4eed5283a493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6296ddb-6958-4b2f-99fc-4eed5283a493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a14f17e0-a4d5-4f30-bb2c-13be6a4a7e15" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28851df9-ba56-4029-9f04-62a9e8c393ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28851df9-ba56-4029-9f04-62a9e8c393ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1aedb564-4895-4457-b65f-4b32ee480923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1aedb564-4895-4457-b65f-4b32ee480923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_864e88e8-214e-4404-abe8-1d8c6ddd9670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_864e88e8-214e-4404-abe8-1d8c6ddd9670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7e8dc6cc-396d-4640-bc11-1dd325a5c831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7e8dc6cc-396d-4640-bc11-1dd325a5c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bb18ec89-3bdd-48bc-ac71-26555fb35623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f7fdaec9-88cd-473c-9d2b-e694a8f4ef6a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bb18ec89-3bdd-48bc-ac71-26555fb35623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5086da8e-e86c-4a80-8b27-5961a6b0e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5086da8e-e86c-4a80-8b27-5961a6b0e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c44c346-781e-40ed-8b91-0adad99637c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c44c346-781e-40ed-8b91-0adad99637c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a27cc320-8c56-4f41-91ca-bf70066da74b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a27cc320-8c56-4f41-91ca-bf70066da74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8ada4c91-4053-4170-bc65-eb705a1e63cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_InterestPaidNet_8ada4c91-4053-4170-bc65-eb705a1e63cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_38c6bcf4-ca13-4c4c-b9b8-2d689a74853a" xlink:href="lxrx-20230331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_38c6bcf4-ca13-4c4c-b9b8-2d689a74853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_98c080cc-5fe3-492f-b10e-4688963a934e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_98c080cc-5fe3-492f-b10e-4688963a934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb1941ca-1ea9-45ba-b710-a7996b0d58ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb1941ca-1ea9-45ba-b710-a7996b0d58ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCarryingBasis_4553d385-1f8f-4659-ad12-75646e5d66b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCarryingBasis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_TreasuryStockCarryingBasis_4553d385-1f8f-4659-ad12-75646e5d66b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69d5cee7-a7ce-4e19-aba6-6713b7d9ce63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69d5cee7-a7ce-4e19-aba6-6713b7d9ce63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_af5fd538-1628-4988-b166-0d46298dd077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_BusinessExitCosts1_af5fd538-1628-4988-b166-0d46298dd077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0862e8ad-b1e9-4429-b5a1-a9543371377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81858522-7d83-46bd-b9b9-dfb66c2e0493" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0862e8ad-b1e9-4429-b5a1-a9543371377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78d5ae14-1eff-4fb3-b1f0-eae92f229b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78d5ae14-1eff-4fb3-b1f0-eae92f229b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_da84cb29-2c6e-4dee-a429-de146a7a9376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_da84cb29-2c6e-4dee-a429-de146a7a9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_cd9fabdc-ee67-4f05-b94e-3b052e59ce5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_cd9fabdc-ee67-4f05-b94e-3b052e59ce5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fb96054f-a685-4c50-b6fc-19b9b99610e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fb96054f-a685-4c50-b6fc-19b9b99610e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4287e26e-0969-4151-b4ab-f862a926283c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ad22923c-22be-465d-b045-c8f667d354e3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4287e26e-0969-4151-b4ab-f862a926283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_827aeffa-c78c-4581-8eda-5dcb538c69a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_827aeffa-c78c-4581-8eda-5dcb538c69a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dbd6515a-370a-4cf2-9cf0-f5a3bdf4ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dbd6515a-370a-4cf2-9cf0-f5a3bdf4ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_78d4090b-ece8-425c-ad7d-92576434c2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_78d4090b-ece8-425c-ad7d-92576434c2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0bc5ec10-5085-445a-833c-28ea01fd27da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0bc5ec10-5085-445a-833c-28ea01fd27da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a677bfa-3d7b-47bd-aebd-310a64fae48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a677bfa-3d7b-47bd-aebd-310a64fae48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a72df8e-7d53-432d-ba32-56ec1800a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaff016b-d7a9-487b-a700-65951a34b416" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a72df8e-7d53-432d-ba32-56ec1800a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_45482b46-30da-418d-b5c6-64b5254f491e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_45482b46-30da-418d-b5c6-64b5254f491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bd6e14e-73ab-40df-9aa7-0c4f6fa56b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bd6e14e-73ab-40df-9aa7-0c4f6fa56b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00f26ed5-b824-4059-b4ac-68a89ed963ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00f26ed5-b824-4059-b4ac-68a89ed963ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_63d8ff5e-205a-4279-a5fa-4af17e517fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd39f85e-8df5-4f17-95fe-19a4bc0a6477" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_63d8ff5e-205a-4279-a5fa-4af17e517fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a81a6b76-3754-442a-87f7-6254f46321ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_63d8ff5e-205a-4279-a5fa-4af17e517fff" xlink:to="loc_us-gaap_InterestPaidNet_a81a6b76-3754-442a-87f7-6254f46321ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f47f4fe2-fc7b-4217-8aa2-6dad22dd2730" xlink:href="lxrx-20230331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_63d8ff5e-205a-4279-a5fa-4af17e517fff" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f47f4fe2-fc7b-4217-8aa2-6dad22dd2730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_97d61bee-7bf3-42d1-88ef-9a490cf625f0" xlink:href="lxrx-20230331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_63d8ff5e-205a-4279-a5fa-4af17e517fff" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_97d61bee-7bf3-42d1-88ef-9a490cf625f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20230331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_a2d7c8ed-24ee-4823-bf98-b9b8060c1f71" xlink:href="lxrx-20230331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_a2d7c8ed-24ee-4823-bf98-b9b8060c1f71" xlink:to="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b7b82dc7-b943-4d9e-bbb5-bf2192850e52" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8947457c-88d5-47c9-900c-556342f36297" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b7b82dc7-b943-4d9e-bbb5-bf2192850e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_88ed6c7d-e2b6-4da5-b9cf-410afb509a47" xlink:to="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_397733e6-ad9f-433a-8d02-4555a1b191d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_CommonStockMember_397733e6-ad9f-433a-8d02-4555a1b191d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7c8a10dc-b46a-4165-ac45-4858d762c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7c8a10dc-b46a-4165-ac45-4858d762c49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_259b5729-c10e-4476-b5d0-732d40df82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_RetainedEarningsMember_259b5729-c10e-4476-b5d0-732d40df82b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d45372a8-2644-45b8-8d0d-790fd95e127a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d45372a8-2644-45b8-8d0d-790fd95e127a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_52038c8b-66f0-4818-8688-a30f43d5b287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07239a21-2bbb-48f0-81d3-b1ab2f5055ea" xlink:to="loc_us-gaap_TreasuryStockMember_52038c8b-66f0-4818-8688-a30f43d5b287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88b705d3-67fe-49f4-ba8f-0bb96ee04ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_00af0793-3e80-42a2-8212-cdafe1200d18" xlink:to="loc_us-gaap_ClassOfStockDomain_88b705d3-67fe-49f4-ba8f-0bb96ee04ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfa87289-5bb3-4c14-86ab-1be6d5e91682" xlink:to="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d18e333f-ece4-4d97-a71c-b4c4df4ca05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_CommonStockSharesIssued_d18e333f-ece4-4d97-a71c-b4c4df4ca05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff0349df-aaba-4dca-b2b8-aa17dd9d91a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff0349df-aaba-4dca-b2b8-aa17dd9d91a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b52c311d-c3af-4901-95d1-c40a62bcb8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b52c311d-c3af-4901-95d1-c40a62bcb8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e4bc8cc-879d-4b9f-b41f-6a03068e8d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e4bc8cc-879d-4b9f-b41f-6a03068e8d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23329a74-bab3-4e6e-9717-5fd6e195a031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23329a74-bab3-4e6e-9717-5fd6e195a031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7fa2392c-2035-48f9-82d0-5cca87efb268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7fa2392c-2035-48f9-82d0-5cca87efb268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_90b7cd30-7886-43ff-a73e-e13ca0417a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_90b7cd30-7886-43ff-a73e-e13ca0417a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3e67cd9-e169-4ca8-9abe-3d7ba4394d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_NetIncomeLoss_d3e67cd9-e169-4ca8-9abe-3d7ba4394d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_60968fab-61cc-43ad-bce0-c8adfd8f2018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_60968fab-61cc-43ad-bce0-c8adfd8f2018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2e9d9d63-3c1b-4765-bb31-c937876ad548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2e9d9d63-3c1b-4765-bb31-c937876ad548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1228a0ea-b3e9-41f7-8916-497901bfbc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_CommonStockSharesIssued_1228a0ea-b3e9-41f7-8916-497901bfbc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b75ead-c792-42be-af94-ebb877a3ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b75ead-c792-42be-af94-ebb877a3ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e877bbe3-16b0-413c-ab9a-83375feea222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e877bbe3-16b0-413c-ab9a-83375feea222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a9922394-b4c1-4777-a90f-24745081cf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a9922394-b4c1-4777-a90f-24745081cf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d796cb08-82e2-4c9f-883c-5f12c1e3bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d796cb08-82e2-4c9f-883c-5f12c1e3bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_acc551c2-8543-4f49-b1b4-672af57667eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a7b93d-2dd7-43bc-b99b-db9951ccb4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_acc551c2-8543-4f49-b1b4-672af57667eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6ce20b87-a4d4-480a-9b19-a39f83f094da" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d6010d6a-da64-4e89-9568-f29a51787ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6ce20b87-a4d4-480a-9b19-a39f83f094da" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d6010d6a-da64-4e89-9568-f29a51787ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20230331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_739a7b50-0c5b-4bc8-8803-2d89f2f3bd6d" xlink:href="lxrx-20230331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a9f20393-93ec-4799-8961-1c73b322d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_739a7b50-0c5b-4bc8-8803-2d89f2f3bd6d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a9f20393-93ec-4799-8961-1c73b322d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_fb2253ba-5929-46e5-bf2d-e1f3ec392367" xlink:href="lxrx-20230331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_98b905e1-f1f9-4637-a4d4-e61ed8a29571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_fb2253ba-5929-46e5-bf2d-e1f3ec392367" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_98b905e1-f1f9-4637-a4d4-e61ed8a29571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_ff1280e6-4f90-4a3f-bc8a-e3a810fcc4d0" xlink:href="lxrx-20230331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_1c2246ca-a222-4d51-b49f-643bfb454364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_ff1280e6-4f90-4a3f-bc8a-e3a810fcc4d0" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_1c2246ca-a222-4d51-b49f-643bfb454364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20230331.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_3918b56b-9f28-440d-93c4-3d99de126d46" xlink:href="lxrx-20230331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_27194f0a-1821-49cb-aec0-cb60ab5e5410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_3918b56b-9f28-440d-93c4-3d99de126d46" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_27194f0a-1821-49cb-aec0-cb60ab5e5410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbae9510-08a6-4432-9ddb-0f8c147726a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_82e17b5d-9b9a-4319-ba42-b55e4f0f927e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbae9510-08a6-4432-9ddb-0f8c147726a5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_82e17b5d-9b9a-4319-ba42-b55e4f0f927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4dce949b-cb51-42be-9b66-efcda001b758" xlink:href="lxrx-20230331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_231c09c4-594d-40c2-8fab-d5affc7b2655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4dce949b-cb51-42be-9b66-efcda001b758" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_231c09c4-594d-40c2-8fab-d5affc7b2655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20230331.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6587cc53-c9c7-4b16-bffd-4a51cb17ba01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_56c5163f-3072-49f5-8482-31daff4383c2" xlink:href="lxrx-20230331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6587cc53-c9c7-4b16-bffd-4a51cb17ba01" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_56c5163f-3072-49f5-8482-31daff4383c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_156d8f87-8eed-4331-a5ba-ef74f1ca75ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6587cc53-c9c7-4b16-bffd-4a51cb17ba01" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_156d8f87-8eed-4331-a5ba-ef74f1ca75ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2e5bc0e0-4bc9-4304-9efc-eea83f692ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2e5bc0e0-4bc9-4304-9efc-eea83f692ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_227fd9bd-ce7f-4a1a-8ed4-1caab414a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_UseOfEstimates_227fd9bd-ce7f-4a1a-8ed4-1caab414a42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b6055467-81fa-4c28-9319-f2b05a0b3018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b6055467-81fa-4c28-9319-f2b05a0b3018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_435f2f55-a974-4a0d-a540-2873295155de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_435f2f55-a974-4a0d-a540-2873295155de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_94ee3ef4-c46b-4bca-94f0-d0349d8a0212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_94ee3ef4-c46b-4bca-94f0-d0349d8a0212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9d3753ec-b6e8-40e8-9dce-84bac24208b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9d3753ec-b6e8-40e8-9dce-84bac24208b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5a61f2d5-a330-47a2-a047-58d2ee07b944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5a61f2d5-a330-47a2-a047-58d2ee07b944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2bd32ac1-1f37-4f8f-8421-645a1429e3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2bd32ac1-1f37-4f8f-8421-645a1429e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_b2939e6f-7955-4020-9a62-d0c8f93ae0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_80e436f3-b266-4ec1-bbb8-d72507f7d5ec" xlink:to="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_b2939e6f-7955-4020-9a62-d0c8f93ae0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_cc89139d-7a57-4a24-8ae8-35ad338a834c" xlink:href="lxrx-20230331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ef5cf523-515f-4d19-b77a-eb89855048c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_cc89139d-7a57-4a24-8ae8-35ad338a834c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ef5cf523-515f-4d19-b77a-eb89855048c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cc656a59-8890-40ad-ac53-3129637d5a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_cc89139d-7a57-4a24-8ae8-35ad338a834c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cc656a59-8890-40ad-ac53-3129637d5a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_227cd17f-9ef6-42d3-aac2-64e1aa1491bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_cc89139d-7a57-4a24-8ae8-35ad338a834c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_227cd17f-9ef6-42d3-aac2-64e1aa1491bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_692b526d-a74f-432e-a291-813d67401a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_cc89139d-7a57-4a24-8ae8-35ad338a834c" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_692b526d-a74f-432e-a291-813d67401a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1c39d908-0dc3-4338-96b1-873c8dd0a033" xlink:href="lxrx-20230331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2cdd4501-ddda-435c-9911-0be42881a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1c39d908-0dc3-4338-96b1-873c8dd0a033" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2cdd4501-ddda-435c-9911-0be42881a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_dd54c8f8-45b9-49b6-a404-1217561d952c" xlink:href="lxrx-20230331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_78e25dd0-d908-4fd4-a430-0ed81252b909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_dd54c8f8-45b9-49b6-a404-1217561d952c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_78e25dd0-d908-4fd4-a430-0ed81252b909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20230331.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_f4e94d71-aad0-47cd-b713-592cf401b5c1" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_f4e94d71-aad0-47cd-b713-592cf401b5c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2f144f6-37da-4784-bc22-3c400c3feadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_98fd2ea6-c89e-4e2a-b988-9ee5ed593e72" xlink:to="loc_us-gaap_PlanNameDomain_d2f144f6-37da-4784-bc22-3c400c3feadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c23289a7-15b5-4111-84d3-cd40fc5bb101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_c4fbbc20-02d5-4c73-9316-397233089af5" xlink:to="loc_us-gaap_AwardDateDomain_c23289a7-15b5-4111-84d3-cd40fc5bb101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e9ebc63-8214-4cc2-9d57-25520fbf51ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_8daa9cb7-0a7a-4fa3-be64-77aa5a96551d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f2b42e0-fea0-462c-8d29-1c7b3b4620c1" xlink:to="loc_us-gaap_StockOptionMember_8daa9cb7-0a7a-4fa3-be64-77aa5a96551d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_39c8fb0b-aad8-44bd-8f86-aefbcb52cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6c7919b-c2f8-43f8-a6f1-767a5b86a430" xlink:to="loc_us-gaap_ClassOfStockDomain_39c8fb0b-aad8-44bd-8f86-aefbcb52cfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf13cfcd-28c5-437e-b35a-2a138b5a2d7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ffe57fd7-8d25-43c0-aa71-bf5441d07b6d" xlink:to="loc_srt_RangeMember_bf13cfcd-28c5-437e-b35a-2a138b5a2d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_504c1078-ac65-4e9e-bc63-db728c8bd964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_bda75552-0c90-473b-b70b-544f8eb9c70d" xlink:to="loc_us-gaap_VestingDomain_504c1078-ac65-4e9e-bc63-db728c8bd964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc102521-29ca-44a4-bfba-c0eb14ce30b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_652afc36-f340-4647-9400-b8fc651e337c" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_652afc36-f340-4647-9400-b8fc651e337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_9d387ecb-b456-465f-b5c0-b43a6156d9fc" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_9d387ecb-b456-465f-b5c0-b43a6156d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_aff90806-600a-497a-9ada-553e442f9b30" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_aff90806-600a-497a-9ada-553e442f9b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_6d7cd903-de0b-4822-841f-86a60d988874" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_6d7cd903-de0b-4822-841f-86a60d988874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0d412270-d583-4ebd-b99d-10e463ed74b6" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0d412270-d583-4ebd-b99d-10e463ed74b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_a6cca34e-f9f6-4cc7-9468-8f20f7e77e7b" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_a6cca34e-f9f6-4cc7-9468-8f20f7e77e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_1b67aa32-2d66-4ba4-9d4d-a9ea77278038" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_1b67aa32-2d66-4ba4-9d4d-a9ea77278038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c83339e1-df9d-40a4-b19e-f56b78640dac" xlink:href="lxrx-20230331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_c83339e1-df9d-40a4-b19e-f56b78640dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_e065fb71-9e9a-429b-904d-3bf2b3200f6f" xlink:href="lxrx-20230331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8744295e-7a6e-41fe-b84e-ecd1c892d179" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_e065fb71-9e9a-429b-904d-3bf2b3200f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_91523468-9a00-4a44-9c03-af83872fb108" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_91523468-9a00-4a44-9c03-af83872fb108" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c1420c4-9c29-43f8-ab50-73b00a7ce433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_03de0fe5-3369-4e59-9946-4767fb5968bd" xlink:to="loc_us-gaap_PlanNameDomain_6c1420c4-9c29-43f8-ab50-73b00a7ce433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f21932f3-3232-44ec-8233-866ef65b6572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_7444f608-6e68-4eb0-9fac-3cdda7209d04" xlink:to="loc_us-gaap_AwardDateDomain_f21932f3-3232-44ec-8233-866ef65b6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d859537a-e03f-4353-b0e6-38d03fad09ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25a77ced-05e5-481f-806b-3d1c2799c8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25a77ced-05e5-481f-806b-3d1c2799c8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e07e9dfa-07d6-4eb8-942e-3832a36e1e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9a5b536-92d0-4b5c-8359-22d22f3cd3e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e07e9dfa-07d6-4eb8-942e-3832a36e1e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4142e5e-04f2-4221-a873-c4a8b71db1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eae295b8-8848-4cda-972f-bfedbab55ae0" xlink:to="loc_us-gaap_ClassOfStockDomain_f4142e5e-04f2-4221-a873-c4a8b71db1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37341491-22a0-4d74-9473-d0f744b35747" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2257e77b-c1d6-43df-8a5e-4cfaa2b77bd0" xlink:to="loc_srt_RangeMember_37341491-22a0-4d74-9473-d0f744b35747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_51a90c1d-1b6f-49e3-a8bc-306cf563bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2015fb7b-2920-4845-a556-ce30f15a3ff4" xlink:to="loc_us-gaap_VestingDomain_51a90c1d-1b6f-49e3-a8bc-306cf563bcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48fd42ea-c5b3-4c5f-8f98-ced8069c7d50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3665c3b5-df2e-460e-85d6-24693c5ab9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3665c3b5-df2e-460e-85d6-24693c5ab9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4a17b5d-70c8-45ee-8a82-8c241eeafe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4a17b5d-70c8-45ee-8a82-8c241eeafe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7775ceb0-bc88-4797-aa56-77be133bae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7775ceb0-bc88-4797-aa56-77be133bae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49a149b2-8149-4953-8c03-29a308e912b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49a149b2-8149-4953-8c03-29a308e912b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_297f1141-7afd-4677-94c8-6d96d9360a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_297f1141-7afd-4677-94c8-6d96d9360a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d158baaf-10a0-40d5-a36f-dcdbd4d05d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d158baaf-10a0-40d5-a36f-dcdbd4d05d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3053f00d-2e47-4671-9429-8d429f088e31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3053f00d-2e47-4671-9429-8d429f088e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e1e14cee-ef11-464e-978c-772317a76240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e1e14cee-ef11-464e-978c-772317a76240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f01fc11-d0d1-411e-b171-118f1f5bdfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f01fc11-d0d1-411e-b171-118f1f5bdfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7941bdfc-0f29-40b1-a71f-dbf67308d709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7941bdfc-0f29-40b1-a71f-dbf67308d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5fdd391-72f6-4858-b84d-ba8be28eb325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5fdd391-72f6-4858-b84d-ba8be28eb325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_78f0ada1-1557-4cdb-8841-558e70461496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_78f0ada1-1557-4cdb-8841-558e70461496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c731c6eb-46ad-4848-91ac-60fec1c55ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c731c6eb-46ad-4848-91ac-60fec1c55ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f342570a-35b7-4895-990c-2efedfe1e776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f342570a-35b7-4895-990c-2efedfe1e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34e4bfd0-5933-44a7-af4e-ab7b6891628b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34e4bfd0-5933-44a7-af4e-ab7b6891628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84494122-01ae-4f1f-9f42-2f23786fa620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84494122-01ae-4f1f-9f42-2f23786fa620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb21bb1b-04c4-4728-8a61-9bc2744c9646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb21bb1b-04c4-4728-8a61-9bc2744c9646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6fab34bc-0d91-4738-a7f1-d665395255b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6fab34bc-0d91-4738-a7f1-d665395255b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_11263f9c-e397-49a2-975d-05246f9da0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_11263f9c-e397-49a2-975d-05246f9da0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_199a638a-2bf1-44ac-ac47-b7e190925240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c5fffae-4f38-44ad-9e65-8d610ea6e7d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_199a638a-2bf1-44ac-ac47-b7e190925240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_a27cee75-d288-4f20-be65-7c12aa61c198" xlink:href="lxrx-20230331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_a27cee75-d288-4f20-be65-7c12aa61c198" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_53099a32-c056-45db-917b-a4f88f5ec2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_41f72724-a9ac-4c62-890d-be3c1035ef55" xlink:to="loc_us-gaap_PlanNameDomain_53099a32-c056-45db-917b-a4f88f5ec2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fff5216c-6d25-4271-93b2-cfa371080c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_eae469a9-2d65-4391-89ce-de6731e5187c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fff5216c-6d25-4271-93b2-cfa371080c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58a7b193-bdc9-430a-b73b-a3fad20327d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a44ac0-840c-4a65-998b-d36b7a4aa8b1" xlink:to="loc_us-gaap_ClassOfStockDomain_58a7b193-bdc9-430a-b73b-a3fad20327d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_123149aa-8ae6-4569-820b-1ed23acdf886" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7bdb312c-e6f4-46a2-9b67-f52a7ee50ff6" xlink:to="loc_srt_RangeMember_123149aa-8ae6-4569-820b-1ed23acdf886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51845c1-13ec-4811-b519-d6d84e9c7d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575445fb-7ac9-4335-a829-1fc4a6ebc21d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51845c1-13ec-4811-b519-d6d84e9c7d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e1f2069-80b3-43a4-8b3b-ecb9c2853135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e1f2069-80b3-43a4-8b3b-ecb9c2853135" xlink:to="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_fa22f331-4da5-4882-a47c-7e891007118d" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_917cb3f5-ea59-4439-9f0a-b88c6296c498" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_fa22f331-4da5-4882-a47c-7e891007118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:href="lxrx-20230331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_f8d6b839-cf0a-475e-820a-80ea404677ea" xlink:to="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_61623f9c-6f3e-4d34-8e19-3897d98426fa" xlink:href="lxrx-20230331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_61623f9c-6f3e-4d34-8e19-3897d98426fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1aedc083-5b4b-4e03-8234-215acc3ffb55" xlink:href="lxrx-20230331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1aedc083-5b4b-4e03-8234-215acc3ffb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15ea49c8-a723-4fbd-a55b-5d8de7d9368a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15ea49c8-a723-4fbd-a55b-5d8de7d9368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d0f64a75-5d5f-4bac-883b-59f5e31f6470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d0f64a75-5d5f-4bac-883b-59f5e31f6470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_d276c842-7642-46c7-be32-987b94d55dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_d276c842-7642-46c7-be32-987b94d55dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_49eb4f96-8c17-41c0-a75d-8c63dbc5a368" xlink:href="lxrx-20230331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_97031245-6acb-4a7b-a860-a9dd27ed238f" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_49eb4f96-8c17-41c0-a75d-8c63dbc5a368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d26b0473-e010-4c27-a6e7-b1316bfa0077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2d681a2a-8cb9-409e-9176-fa44d9700e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d26b0473-e010-4c27-a6e7-b1316bfa0077" xlink:to="loc_us-gaap_AssetImpairmentCharges_2d681a2a-8cb9-409e-9176-fa44d9700e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_be62ca78-ee5f-458b-bbb7-0572602f6d3b" xlink:href="lxrx-20230331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_be62ca78-ee5f-458b-bbb7-0572602f6d3b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:to="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6357a823-9721-4c0a-ba46-d07ceba8cffc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_84e72fd7-6aba-45ce-95bc-aff6c6f166aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_CashMember_84e72fd7-6aba-45ce-95bc-aff6c6f166aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b32ce546-361e-4b22-b17c-cc57dcda38d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b32ce546-361e-4b22-b17c-cc57dcda38d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_001f2ac5-f59e-4379-a837-23f1f43afda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_001f2ac5-f59e-4379-a837-23f1f43afda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_0369c1dd-ad08-46db-8c34-0aa577a90bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_InvestmentsMember_0369c1dd-ad08-46db-8c34-0aa577a90bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9921fc26-17aa-454d-96ab-8a29dbca3fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_87a47db1-f425-4436-8f90-ba352f49e09b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9921fc26-17aa-454d-96ab-8a29dbca3fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_28bdc5dc-9df3-41f8-a9cf-f59cc7d1ab35" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00ebc91c-53ce-4d3b-a2b7-759c7e2663b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00ebc91c-53ce-4d3b-a2b7-759c7e2663b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3b7d65e0-20f9-443c-a807-6f79d030a347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3b7d65e0-20f9-443c-a807-6f79d030a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_bac785a6-55a5-4de2-8c4c-129071408a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_bac785a6-55a5-4de2-8c4c-129071408a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e94afebd-b505-4055-b7b6-cdc926747ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e94afebd-b505-4055-b7b6-cdc926747ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_489d2cc3-fd91-4c07-a734-9bdf3b2abe05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_489d2cc3-fd91-4c07-a734-9bdf3b2abe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_076f347a-6851-4032-ad62-f909bdfd6c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_076f347a-6851-4032-ad62-f909bdfd6c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_72999efb-47ab-4897-bd6f-deeae09030ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8dd25c0-fb35-4803-b6fb-8329588f6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_72999efb-47ab-4897-bd6f-deeae09030ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_d9abd15e-d3d0-4df1-8d2c-e96b61cc8f1f" xlink:href="lxrx-20230331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_d9abd15e-d3d0-4df1-8d2c-e96b61cc8f1f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_ba8a424d-e6b1-4ee4-82d9-3fb0a2e1e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_bd43c77f-9e1d-4264-8108-67dc9aa12f24" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_ba8a424d-e6b1-4ee4-82d9-3fb0a2e1e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8edf5568-39e0-459c-9183-e71f774935c0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_67e9b599-f1eb-40cb-9aa8-831b12912f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e02b0f6-6b46-40b1-a699-fd84b3153a47" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_67e9b599-f1eb-40cb-9aa8-831b12912f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_fbefc41c-da90-47be-a4a8-ceddbd1732eb" xlink:href="lxrx-20230331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_fbefc41c-da90-47be-a4a8-ceddbd1732eb" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b43de10-1865-4b88-87cb-1374e4380ee5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef6b1372-e805-410a-bdb4-eb15687e0bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef6b1372-e805-410a-bdb4-eb15687e0bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4599f1b4-59e1-4001-a1c6-f59227e5b542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4599f1b4-59e1-4001-a1c6-f59227e5b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1d7cd85e-b0b8-4d8d-b819-2a4c4fc73bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a67d655a-723a-48ea-8bd3-a05c89f43479" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1d7cd85e-b0b8-4d8d-b819-2a4c4fc73bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35d58b2a-1abd-4913-b59e-57e6995560e4" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d22057d6-d98c-472c-bbfb-55e511c96608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d22057d6-d98c-472c-bbfb-55e511c96608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d99981ea-3d8c-44ad-b4f2-36c390323f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d99981ea-3d8c-44ad-b4f2-36c390323f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_05423a36-38d0-4d06-a4ad-c063ef4ee6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_AvailableForSaleSecurities_05423a36-38d0-4d06-a4ad-c063ef4ee6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4ac52e40-af70-4c5a-880e-835c14b6378a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21d77662-8066-4935-9510-f226c7d2f255" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4ac52e40-af70-4c5a-880e-835c14b6378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_5efed82b-5076-4b1f-9081-fd1a03e4970f" xlink:href="lxrx-20230331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9a81e8b3-c038-46c3-8217-d6ab8eaf2c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_5efed82b-5076-4b1f-9081-fd1a03e4970f" xlink:to="loc_us-gaap_DebtInstrumentTable_9a81e8b3-c038-46c3-8217-d6ab8eaf2c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9a81e8b3-c038-46c3-8217-d6ab8eaf2c1d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_439b4cb2-7932-4971-8c0a-827d2baade78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_439b4cb2-7932-4971-8c0a-827d2baade78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0a7c5392-aa82-465d-b05b-bc05e65d4aed" xlink:href="lxrx-20230331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0a7c5392-aa82-465d-b05b-bc05e65d4aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_60182d26-00a0-48ba-946f-59589d4e4a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_60182d26-00a0-48ba-946f-59589d4e4a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8756c5f6-a2b4-4136-bc56-98ff4aef7e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8756c5f6-a2b4-4136-bc56-98ff4aef7e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_62d8aad3-3c24-4f41-bd35-27c818d91454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentFairValue_62d8aad3-3c24-4f41-bd35-27c818d91454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8fc59ee0-12e9-42fe-9146-afb651e5b351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_CommonStockSharesIssued_8fc59ee0-12e9-42fe-9146-afb651e5b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_8817e0e1-00c5-4908-822e-34dac50cb6d4" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchange_8817e0e1-00c5-4908-822e-34dac50cb6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_de6e533c-b15c-4aaf-b562-8439fcdac253" xlink:href="lxrx-20230331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_AccruedInterestOnConvertible_de6e533c-b15c-4aaf-b562-8439fcdac253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_36002dc2-5ce2-48b7-9d54-120c1a70985c" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_36002dc2-5ce2-48b7-9d54-120c1a70985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_8acb3fe5-2afd-472a-8ed3-eaff5fd1d380" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_8acb3fe5-2afd-472a-8ed3-eaff5fd1d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_42a28d95-0abc-47ae-9a9d-c1192fb11f6d" xlink:href="lxrx-20230331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_42a28d95-0abc-47ae-9a9d-c1192fb11f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_99c4f9bd-7df9-4357-86a8-17e76acc76a2" xlink:href="lxrx-20230331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_99c4f9bd-7df9-4357-86a8-17e76acc76a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_0f41108b-2611-4e81-aca2-0ab355ac273d" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_0f41108b-2611-4e81-aca2-0ab355ac273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_c43ba348-1abf-4d35-89b3-8c08740a2f7c" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_c43ba348-1abf-4d35-89b3-8c08740a2f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_eb04707f-7b27-4b3f-a860-3e5186309e11" xlink:href="lxrx-20230331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_eb04707f-7b27-4b3f-a860-3e5186309e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_db319cc8-e904-4aea-9e30-b31282be89ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_db319cc8-e904-4aea-9e30-b31282be89ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d07de78-772e-4688-9bfd-ef8d54284fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebt_4d07de78-772e-4688-9bfd-ef8d54284fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_b2020bd4-ade8-45a1-9fbf-914264bec7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtTerm_b2020bd4-ade8-45a1-9fbf-914264bec7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f3ca30bf-3529-4686-81ec-27efc6c750fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f3ca30bf-3529-4686-81ec-27efc6c750fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_cf86942d-3fcf-431a-9b0f-fa27ae7b7a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_cf86942d-3fcf-431a-9b0f-fa27ae7b7a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_fef3df6c-68dd-42d0-967c-0bbbedb36ae2" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanB"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanB_fef3df6c-68dd-42d0-967c-0bbbedb36ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_5fe01599-37e1-4e37-bbf7-0232d0ae7040" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanC"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanC_5fe01599-37e1-4e37-bbf7-0232d0ae7040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_07f841c3-776d-45ee-9a79-b2ff73f9cdd4" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanD"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanD_07f841c3-776d-45ee-9a79-b2ff73f9cdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_fb1ad4e6-082f-49de-929e-e00f04c468b9" xlink:href="lxrx-20230331.xsd#lxrx_OxfordLoanFacility"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordLoanFacility_fb1ad4e6-082f-49de-929e-e00f04c468b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_2db1ef96-9999-4d44-8eb3-91731b225b13" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanA"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanA_2db1ef96-9999-4d44-8eb3-91731b225b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_a3f82fcd-8dbd-4fdc-b020-2757c85e8023" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanABWarrant"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanABWarrant_a3f82fcd-8dbd-4fdc-b020-2757c85e8023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_568bbbec-63f6-48d7-9a11-ef7513bafe94" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanCWarrant"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanCWarrant_568bbbec-63f6-48d7-9a11-ef7513bafe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_b1621345-9b50-454c-9d01-bd613af43f4d" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanDWarrant"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanDWarrant_b1621345-9b50-454c-9d01-bd613af43f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_52002852-f24d-4fd7-93ce-fc613b8aae15" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_52002852-f24d-4fd7-93ce-fc613b8aae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_a2ca14aa-bce4-4a59-9ec1-02137614c256" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_a2ca14aa-bce4-4a59-9ec1-02137614c256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_78ca1575-d14f-4524-adf5-29c64b4efd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_78ca1575-d14f-4524-adf5-29c64b4efd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64edb283-5761-4249-b094-3a5191681981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64edb283-5761-4249-b094-3a5191681981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36184e8a-0034-4bbf-95cb-2839ba38d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36184e8a-0034-4bbf-95cb-2839ba38d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_d4366314-8d3a-4685-9b64-6e3811fbe884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_d4366314-8d3a-4685-9b64-6e3811fbe884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_d5ff093e-a4e3-4e66-a949-a88b6ec5bb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_d5ff093e-a4e3-4e66-a949-a88b6ec5bb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_28b5cd67-b0ed-4765-b41a-07097cbeba19" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_28b5cd67-b0ed-4765-b41a-07097cbeba19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_d1b513ee-8899-480e-ac4f-2e5ac15cec8c" xlink:href="lxrx-20230331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_FinalPaymentWithExtention_d1b513ee-8899-480e-ac4f-2e5ac15cec8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_8a4e7b2c-24e9-4282-93e3-7d32ddb3c3cb" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAFinalPayment_8a4e7b2c-24e9-4282-93e3-7d32ddb3c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_56260197-3cd4-4664-a2d6-e44fd08a1c94" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanANetCashReceipt_56260197-3cd4-4664-a2d6-e44fd08a1c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_11cecc97-cf9a-4e91-a995-6a98c87f3de7" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_11cecc97-cf9a-4e91-a995-6a98c87f3de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_a53f360a-d83a-4296-a98b-7dcd7c9bf599" xlink:href="lxrx-20230331.xsd#lxrx_OxfordFacilityFee"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordFacilityFee_a53f360a-d83a-4296-a98b-7dcd7c9bf599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_a7b7b3cf-42c7-4f4a-ad61-d7720b288b3e" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanADebtDiscount_a7b7b3cf-42c7-4f4a-ad61-d7720b288b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_4a04d684-a122-427d-ac95-0231ca8bedf2" xlink:href="lxrx-20230331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_TermLoanAInterestExpense_4a04d684-a122-427d-ac95-0231ca8bedf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_18aec9d5-fef2-4abe-8aa4-10e30f2032c3" xlink:href="lxrx-20230331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_18aec9d5-fef2-4abe-8aa4-10e30f2032c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_4d1e2ee3-0860-4a51-b3f9-b1e498fd5e86" xlink:href="lxrx-20230331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_4d1e2ee3-0860-4a51-b3f9-b1e498fd5e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_49c4dddd-41d5-49b0-9089-40e951a90e64" xlink:href="lxrx-20230331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_49c4dddd-41d5-49b0-9089-40e951a90e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordAmendmentFee_5d656d76-0cea-4db8-b8b5-fd36cdc7307f" xlink:href="lxrx-20230331.xsd#lxrx_OxfordAmendmentFee"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e8bfe7c0-9865-4e1c-955f-863dc2ae4d13" xlink:to="loc_lxrx_OxfordAmendmentFee_5d656d76-0cea-4db8-b8b5-fd36cdc7307f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_506803da-300b-44f1-a581-18f74bda431c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_7447eb16-e245-49d1-a25b-5b92bc3db351" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_506803da-300b-44f1-a581-18f74bda431c" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_7447eb16-e245-49d1-a25b-5b92bc3db351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_506803da-300b-44f1-a581-18f74bda431c" xlink:to="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71312960-9914-456c-976e-1d4b6526dddd" xlink:to="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dd275ff0-2c74-41db-bdf8-16672b24aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_bfd92f8e-4a83-44cb-92a7-9e9622c26169" xlink:to="loc_us-gaap_AccountsReceivableMember_dd275ff0-2c74-41db-bdf8-16672b24aac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f4694a6c-0939-4637-9fa1-9d76863b4d3d" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f465ad81-87c7-4fef-9301-286685ae2caa" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f465ad81-87c7-4fef-9301-286685ae2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c01f16ca-c51b-4e7b-8666-fc3e0c5f7033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c01f16ca-c51b-4e7b-8666-fc3e0c5f7033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4fdfe5d9-11d2-488b-8ca3-5c6a0576b6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4fdfe5d9-11d2-488b-8ca3-5c6a0576b6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b47bbe9a-b6ae-4da9-89d5-e001b02ecbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b47bbe9a-b6ae-4da9-89d5-e001b02ecbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8523fbb8-c57b-47da-b9ee-ceb6587850ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8523fbb8-c57b-47da-b9ee-ceb6587850ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d2ee35c-fa19-4448-bd30-346f91dcfeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d2ee35c-fa19-4448-bd30-346f91dcfeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18976f2f-4e98-4a08-a80c-42b17b131669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18976f2f-4e98-4a08-a80c-42b17b131669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b0a7493-3052-4a54-87d0-b7045c5a073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b0a7493-3052-4a54-87d0-b7045c5a073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86770d33-3307-4bd0-a93c-56e8807ba05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86770d33-3307-4bd0-a93c-56e8807ba05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7fc1293c-71cb-4129-a086-99b8b1d523ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7fc1293c-71cb-4129-a086-99b8b1d523ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a209cbf-0517-4184-a57d-ef094e15800b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseLiability_4a209cbf-0517-4184-a57d-ef094e15800b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_38a90037-d9fb-4a3b-9cb9-85547c0f9e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_38a90037-d9fb-4a3b-9cb9-85547c0f9e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_990d38b8-0736-4ea1-b37b-04b27dca28d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_990d38b8-0736-4ea1-b37b-04b27dca28d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_44ff38e7-87e9-4d24-9734-7708fec636a0" xlink:href="lxrx-20230331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_lxrx_SanofiDisputedCosts_44ff38e7-87e9-4d24-9734-7708fec636a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c4bff4cf-bdc9-412a-ae0f-97a8831a6ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_OperatingLeaseExpense_c4bff4cf-bdc9-412a-ae0f-97a8831a6ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_5113e0ac-1d2c-4046-b63e-c13ce8935537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_PaymentsForRent_5113e0ac-1d2c-4046-b63e-c13ce8935537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_38d481a4-a63b-45f4-922e-592e3ad088b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_38d481a4-a63b-45f4-922e-592e3ad088b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a7d20f65-b4c6-4288-8888-cb53db14f002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_31418d57-1b94-469b-baec-62b8864e2c7b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a7d20f65-b4c6-4288-8888-cb53db14f002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:href="lxrx-20230331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_4db892cd-2370-41ba-bc5c-06b4254a37db" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_4db892cd-2370-41ba-bc5c-06b4254a37db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_f9c8677b-a007-4f51-a5f8-bd6d4f4b2d96" xlink:href="lxrx-20230331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_SanofiRevenueRecognized_f9c8677b-a007-4f51-a5f8-bd6d4f4b2d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_91103c8c-fe09-4e34-9826-eb94a0c8f9a6" xlink:href="lxrx-20230331.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenTotalPayments_91103c8c-fe09-4e34-9826-eb94a0c8f9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_941b2d7f-205e-417f-b8a9-aac6ee61d0ca" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_941b2d7f-205e-417f-b8a9-aac6ee61d0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_2ad155a8-85d4-4c28-8115-662e22eec5bd" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenMilestonePayment_2ad155a8-85d4-4c28-8115-662e22eec5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_1f2ecaf7-2f46-4689-880b-ebbd0eaa977a" xlink:href="lxrx-20230331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_1f2ecaf7-2f46-4689-880b-ebbd0eaa977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_b86bd7ff-4709-435c-ac72-e1475eb3eea9" xlink:href="lxrx-20230331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_b86bd7ff-4709-435c-ac72-e1475eb3eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_4fef2288-72ef-4951-98d0-47fdf9d82c1d" xlink:href="lxrx-20230331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_IpsenRevenueRecognized_4fef2288-72ef-4951-98d0-47fdf9d82c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_a651145b-fb91-4fec-85ee-9aec18b7584f" xlink:href="lxrx-20230331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_a651145b-fb91-4fec-85ee-9aec18b7584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_07713327-9216-42f6-bb0f-48f9adbb8007" xlink:href="lxrx-20230331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_61be14a8-c6ec-4599-bd85-db86009e9a05" xlink:to="loc_lxrx_SettlementPaymentFromTermination_07713327-9216-42f6-bb0f-48f9adbb8007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20230331.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_f15c792e-825c-483b-a89e-83c278cad38c" xlink:href="lxrx-20230331.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_ATMOfferingTotal_f15c792e-825c-483b-a89e-83c278cad38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_a1746162-b1c4-4376-8521-22fc5b5f22a3" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_a1746162-b1c4-4376-8521-22fc5b5f22a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_56a8e3ab-7cdc-481f-9018-62672e348502" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_56a8e3ab-7cdc-481f-9018-62672e348502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_b32112c6-22ce-41f7-8e95-eff66bec9297" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_b32112c6-22ce-41f7-8e95-eff66bec9297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_28360da0-4af9-4a38-a6f2-83684943c215" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_28360da0-4af9-4a38-a6f2-83684943c215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_66c651c7-edbf-4d20-b1a7-6e625dfb7ea5" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_66c651c7-edbf-4d20-b1a7-6e625dfb7ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_c365ec82-f8c8-49c8-9937-836d3326fd81" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_c365ec82-f8c8-49c8-9937-836d3326fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_4a9824bf-02eb-4f91-9edf-ffc488b6cfa1" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_4a9824bf-02eb-4f91-9edf-ffc488b6cfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring_7d4d54a6-7fb4-4770-8e18-39f37f3e6df9" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOfferring_7d4d54a6-7fb4-4770-8e18-39f37f3e6df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_71c24ca6-ad11-4bb7-980f-83ece2f15a23" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_71c24ca6-ad11-4bb7-980f-83ece2f15a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJuly2022Offering_164c81e9-4766-4e60-aaf9-baf2fa524eb9" xlink:href="lxrx-20230331.xsd#lxrx_SharePriceInJuly2022Offering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_SharePriceInJuly2022Offering_164c81e9-4766-4e60-aaf9-baf2fa524eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJuly2022Offering_8458c9ef-a331-432e-8af4-95270e77b331" xlink:href="lxrx-20230331.xsd#lxrx_ProceedsFromJuly2022Offering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecd9ac99-c4f3-4756-8bdd-d013f0793cc4" xlink:to="loc_lxrx_ProceedsFromJuly2022Offering_8458c9ef-a331-432e-8af4-95270e77b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1" xlink:type="simple" xlink:href="lxrx-20230331.xsd#OtherCapitalAgreementsDetails_1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_95dface5-617d-4420-95cd-8a465c1ab985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJuly2022Offering_04636bef-5920-4bbf-92c4-489e3bb0c4b3" xlink:href="lxrx-20230331.xsd#lxrx_SharesSoldInJuly2022Offering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95dface5-617d-4420-95cd-8a465c1ab985" xlink:to="loc_lxrx_SharesSoldInJuly2022Offering_04636bef-5920-4bbf-92c4-489e3bb0c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689323015072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,561,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689320460080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 46,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">79,936<span></span>
</td>
<td class="nump">92,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">2,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">109,546<span></span>
</td>
<td class="nump">140,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $4,096 and $3,984, respectively</a></td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,420<span></span>
</td>
<td class="nump">6,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">162,716<span></span>
</td>
<td class="nump">194,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,311<span></span>
</td>
<td class="nump">10,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">10,060<span></span>
</td>
<td class="nump">12,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,371<span></span>
</td>
<td class="nump">23,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">5,454<span></span>
</td>
<td class="nump">5,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">74,670<span></span>
</td>
<td class="nump">77,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000 shares authorized; 190,430 and 189,214 shares issued, respectively</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,712,558<span></span>
</td>
<td class="nump">1,709,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,621,654)<span></span>
</td>
<td class="num">(1,589,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 868 and 488 shares, respectively</a></td>
<td class="num">(2,885)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">88,046<span></span>
</td>
<td class="nump">117,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">162,716<span></span>
</td>
<td class="nump">194,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">$ 48,845<span></span>
</td>
<td class="nump">$ 48,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325280144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 4,096<span></span>
</td>
<td class="nump">$ 3,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">190,430<span></span>
</td>
<td class="nump">189,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325211296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $1,203 and $1,032, respectively</a></td>
<td class="nump">12,026<span></span>
</td>
<td class="nump">14,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative, including stock-based compensation of $2,212 and $1,740, respectively</a></td>
<td class="nump">19,140<span></span>
</td>
<td class="nump">8,491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(31,166)<span></span>
</td>
<td class="nump">23,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,142)<span></span>
</td>
<td class="num">(23,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,821)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,934)<span></span>
</td>
<td class="num">$ (23,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">189,014<span></span>
</td>
<td class="nump">149,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (31,669)<span></span>
</td>
<td class="num">$ (23,503)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689322982096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="nump">$ 1,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="nump">$ 1,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689320395104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,934,000)<span></span>
</td>
<td class="num">$ (23,476,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,415,000<span></span>
</td>
<td class="nump">2,772,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="num">(234,000)<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(867,000)<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="num">(2,770,000)<span></span>
</td>
<td class="num">(3,308,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(31,613,000)<span></span>
</td>
<td class="num">(23,421,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">26,001,000<span></span>
</td>
<td class="nump">59,520,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,556,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCarryingBasis', window );">Treasury Stock, Carrying Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(248,000)<span></span>
</td>
<td class="num">(76,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(28,864,000)<span></span>
</td>
<td class="num">(17,816,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">41,205,000<span></span>
</td>
<td class="nump">13,484,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">12,093,000<span></span>
</td>
<td class="num">(4,408,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(824,000)<span></span>
</td>
<td class="num">(864,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,148,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(824,000)<span></span>
</td>
<td class="nump">23,284,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</a></td>
<td class="num">(20,344,000)<span></span>
</td>
<td class="num">(4,545,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">46,345,000<span></span>
</td>
<td class="nump">64,065,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">26,001,000<span></span>
</td>
<td class="nump">59,520,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 1,556,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCarryingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost basis for treasury stock acquired for purposes other than retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCarryingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325293600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 113,595,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 1,608,749,000<span></span>
</td>
<td class="num">$ (1,487,776,000)<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="num">$ (7,518,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,772,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,772,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,476,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,476,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2022</a></td>
<td class="nump">92,698,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">1,605,898,000<span></span>
</td>
<td class="num">(1,511,252,000)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(6,321,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,321,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Stock Issued During Period, Shares, Treasury Stock Reissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">189,214<span></span>
</td>
<td class="nump">189,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 117,124,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="nump">1,709,144,000<span></span>
</td>
<td class="num">(1,589,720,000)<span></span>
</td>
<td class="num">(428,000)<span></span>
</td>
<td class="num">(2,061,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,415,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,415,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(824,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(824,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,934,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,934,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">190,430<span></span>
</td>
<td class="nump">190,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 88,046,000<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="nump">1,712,558,000<span></span>
</td>
<td class="num">(1,621,654,000)<span></span>
</td>
<td class="num">(163,000)<span></span>
</td>
<td class="num">(2,885,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689320352384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2023 and December&#160;31, 2022, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements that include development milestones, the Company evaluates at contract inception whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with stock warrants, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325685696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting PronouncementsWe do not expect that any recently issued accounting pronouncements will have a material impact on our financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325579312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2023 and December&#160;31, 2022 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,100&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,937&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the three month periods ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325614128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2023 or December&#160;31, 2022. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325685696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $150&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with financial covenants relating to net sales of sotagliflozin following regulatory approval and minimum cash balance requirements following funding of the third tranche. The interest-only period will be followed by an amortization period extending through the maturity date.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche was funded on December 30, 2022. The loan and security agreement was amended on May 1, 2023, to increase the amount available for draw under the third tranche from $50 million to $75 million and decrease the amount available for draw under the fourth tranche from $50 million to $25 million.  The third tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. An unused fee will be due in the event Lexicon does not draw the full amount available under the third tranche. The fourth tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#8217;s common stock at an exercise price of $2.08 per share. Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase 224,128 shares of Lexicon&#8217;s common stock at an exercise price of $1.95 per share. The loan and security agreement provides that, upon funding of the third tranche, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 0.875% of such tranche, as determined by reference to a 10-day average closing price of the shares, and having an exercise price equal to such average closing price. All warrants are exercisable for five years from their respective grant dates and feature a net cashless exercise provision.  The warrants that have been issued in connection with the funding of the first and second tranches are classified as equity instruments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2023, the interest rate was 12.57%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded once for each tranche as a debt discount on the funding date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the balance of the debt discount was $4.2&#160;million which offsets long-term debt on the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023, the Company recognized interest expense of $1.8&#160;million.  As of  March&#160;31, 2023, the carrying value of the Oxford Term Loans was $48.8&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics.  The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenants, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689328989200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2023 and December&#160;31, 2022, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements that include development milestones, the Company evaluates at contract inception whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div>The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span>&#160;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with stock warrants, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325445488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325549856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,100&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,937&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325231984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689319386000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">112.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689318564512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">17,127<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">5,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">6,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">5,490<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 3.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325496960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="nump">$ 3,937,000<span></span>
</td>
<td class="nump">$ 3,252,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="nump">4,348,000<span></span>
</td>
<td class="nump">7,830,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="num">(1,291,000)<span></span>
</td>
<td class="num">(1,291,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">484,000<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 10,060,000<span></span>
</td>
<td class="nump">$ 12,777,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325300736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">$ 79,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">46,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">26,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">70,894<span></span>
</td>
<td class="nump">74,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">70,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">80,100<span></span>
</td>
<td class="nump">92,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">79,936<span></span>
</td>
<td class="nump">92,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">106,100<span></span>
</td>
<td class="nump">138,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">105,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">9,206<span></span>
</td>
<td class="nump">$ 18,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">$ 9,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689325453328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689323389680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 46,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">79,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">105,937<span></span>
</td>
<td class="nump">138,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">26,001<span></span>
</td>
<td class="nump">46,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">70,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">96,762<span></span>
</td>
<td class="nump">120,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">9,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">9,175<span></span>
</td>
<td class="nump">18,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689318493872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">190,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="num">$ (48,845,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,579,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="nump">$ 48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanB', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_OxfordLoanFacility', window );">Oxford Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanA', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAWarrantsNumber', window );">Term Loan A Warrants Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,673<span></span>
</td>
<td class="nump">224,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAWarrantExercisePrice', window );">Term Loan A Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Subordinated Borrowing, Interest Rate</a></td>
<td class="nump">12.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FinalPaymentWithNoExtention', window );">Final Payment % with no extention</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_FinalPaymentWithExtention', window );">Final Payment % with extention</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAFinalPayment', window );">Term Loan A Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanADebtDiscount', window );">Term Loan A Debt Discount</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxrx_TermLoanAInterestExpense', window );">Term Loan A Interest Expense</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with extention</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithNoExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with no extention</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithNoExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oxford Loan Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Final Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrants Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan B</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140689320360624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 5,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</a></td>
<td class="nump">673,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">1,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">1,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due Year Four</a></td>
<td class="nump">865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Lessee, Operating Lease, Liability, to be Paid, Year Five</a></td>
<td class="nump">881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Year Five</a></td>
<td class="nump">5,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="nump">10,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="nump">3,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">6,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">960.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>lxrx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20230331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20230331.xsd" xlink:type="simple"/>
    <context id="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i20996cadc68f450b9cdae24983d13cb4_I20221107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="icfbb05ea60fe4f339b459eb0a28c3454_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib79166a07a8341019133d1767451366c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b4486d192c3418a887c00fdae579410_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c0d60f9ebe14ff6adf4c90cbaf04f93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b52788551bf4ba09d90c25c260474ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3780c853ca62493095fa01c99c96a50b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fd9833fa7e645c68143dcfd76af2e58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i908be8c8318f430fa0dcb565f616e66e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib45dd874240c4c45a886170daf956a22_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1928596f4b5435191e331ad33500d98_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie5b75bdf9b3e45cfa77e885ac49788f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia219aede096c4cf0b514d5a736ae7245_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i40101591a3a747d39081c3865fa29914_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida35814b016d4540b1321674b0722978_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e92df6f278d4c19a869b984471be038_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d08dad083a947c387d54202008989a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i636d41fbcdb344b7be8e6238915276b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53b540e964324fb0b61132eb59b41f73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69cc6c5cf6684519a5d00d853fa37565_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1cfd6d4e8e2473aa197ec5caf0a0e38_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i017100090664431eae4b4d902a7a2069_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i561f3732275c4803bf200bd3d285c665_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ief76986da65f420f86dfa94119abd82f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i122cc45b24a040dca3939cb8ebe170a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i14d09fe0d1af4d7db5d3ab1d00f6cb8e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if294b62ddc5941a89003bac80ce657a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i30b21eb47f1d44a0801b1c165ff6a310_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f5c48a42a0b4346b4984be1e404c5e3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i122a411cbee64663b669721e52d22969_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4590c26f966346da952432b88fccff44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i52cb6e46f3004a31b017f45441c3a197_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1150bd512a24422facf2a358e5f34712_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69e6cd144aee4e95b362bf083223bd6d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a9aa0068e404b4d801ff1de1e630584_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86b7b245845b4744bdcafd4a64ae9457_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibbff2c0bc8914b5083a706874111931f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i48f0211b426c48a7928c9fe72bdf5fce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41c5cb7217034320b1cf86d2516d1891_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31ee63580e7f4cee956584a4be4fc152_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46ede3bf23094d30ab019f2c0cae03fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i375e3a3d13094b578b03f23910d47681_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i85ac8033ec684725b9503d12d0b48ada_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i901f7eff00b440ac8fd3b85aa8b94826_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iadb4426fae2448009d2f24b25517721b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied2630f42a2e4991858d1dab84290767_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cf58b0d98384a0e865d446c3a2387f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF81LTQtMS0xLTQxODg5_3be4854c-fd0b-4537-a089-7e427dc2f18a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF85LTQtMS0xLTQxODg5_3986df09-e54d-4964-b05c-19731f1ef33c">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xMC00LTEtMS00MTg4OQ_0952126b-2c94-4bf4-82d6-c4db30c9f183">2023</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xMS00LTEtMS00MTg4OQ_32dc04fd-d8db-4c0c-93b2-45cf24220d3d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80L2ZyYWc6Y2I0ZmE2OGU2MWFiNDcwYTljNjNlNmIwN2EwOGQyYTIvdGFibGU6ZjAzOTFkZDk3YWUwNDcwYmI3ZWE0M2ZhYmQ4MmFkZTAvdGFibGVyYW5nZTpmMDM5MWRkOTdhZTA0NzBiYjdlYTQzZmFiZDgyYWRlMF8xNC00LTEtMS00MTg4OQ_4d55197d-2e87-43e0-ac3f-a63f9e99f78b">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV84Mg_762fae39-f7b3-42e1-888a-21876220e218">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6NGJiNjhmMzU0NzVjNDg5N2EyYThjNTQxM2QxNDk3ZGEvdGFibGVyYW5nZTo0YmI2OGYzNTQ3NWM0ODk3YTJhOGM1NDEzZDE0OTdkYV8wLTAtMS0xLTQxODg5_4f1defff-b2b0-4271-b15b-8d462f1b8bd0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8xMjk_e8eb9b95-cd03-483d-8ffc-e4eed012c38b">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6OWRhNWExYjVjYWQ0NDllNzhkMjRhOTFhNTY4MWJlNDQvdGFibGVyYW5nZTo5ZGE1YTFiNWNhZDQ0OWU3OGQyNGE5MWE1NjgxYmU0NF8wLTAtMS0xLTQxODg5_1049616a-9311-47bd-b1cc-e08e9202ff19">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMjU_cddb464c-e90e-47fd-a484-a8e85b004ad7">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMjg_71201487-1aa0-4b6d-bb9b-ee44e077203c">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6ODFlZDY1YTFiNGY5NGMwMGE1OTlkMTIxM2U3MGEyNGYvdGFibGVyYW5nZTo4MWVkNjVhMWI0Zjk0YzAwYTU5OWQxMjEzZTcwYTI0Zl8wLTAtMS0xLTQxODg5_31a8fa80-8c12-4c2d-b041-0ad15a706b7c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6ODFlZDY1YTFiNGY5NGMwMGE1OTlkMTIxM2U3MGEyNGYvdGFibGVyYW5nZTo4MWVkNjVhMWI0Zjk0YzAwYTU5OWQxMjEzZTcwYTI0Zl8wLTEtMS0xLTQxODg5_bba6df93-d705-4079-ba3b-4ac0a47695d3">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yODc_98629628-a69b-4b4c-b49f-124d06c6013d">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTA_1d91a034-6e87-41b9-9b35-a9ef1b5b48c5">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTM_d8017cb1-445f-4d1f-a280-e430daa792a7">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yOTc_c3f06f04-ed63-4b7b-937f-3884756bb7c9">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zMDA_6da9bb86-e815-48ca-bf34-09d12ee71cc3">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zNTg_656d4378-4633-4896-b7b0-755733761422">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8zNjI_03f2b7bc-ac44-4f52-8efb-095589d5116b">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTAtMS0xLTQxODg5_863e03ba-3388-4a09-80cc-de4a31c8a8a8">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTEtMS0xLTQxODg5_1c7472df-b291-4041-96e4-6e69ee2e7aa2">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MzYyYzA3NmFlMjFkNGFiN2E1Y2Y2ZjhjNTBlNjQ2ZTkvdGFibGVyYW5nZTozNjJjMDc2YWUyMWQ0YWI3YTVjZjZmOGM1MGU2NDZlOV8xLTItMS0xLTQxODg5_28981613-6b7c-400a-8ccd-3c035c359670">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6NTc0MzUxMjc0ZTc0NGJhM2I0N2IzZGZkZWE4NzdiYTAvdGFibGVyYW5nZTo1NzQzNTEyNzRlNzQ0YmEzYjQ3YjNkZmRlYTg3N2JhMF8wLTAtMS0xLTQxODg5_f33a2389-9456-4da6-aa6b-ec617ffa79b4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6MjMyOTVlZTYzOGYxNGI3MWI5NDVkMzVjOGZhOTZlNTQvdGFibGVyYW5nZToyMzI5NWVlNjM4ZjE0YjcxYjk0NWQzNWM4ZmE5NmU1NF8wLTAtMS0xLTQxODg5_cd11204e-4bad-4ee0-97d3-4bb7f46de55a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMzAx_1f9954c6-4591-4268-911e-0982c5c6f035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV8yMzAy_11a6a3d9-609c-4632-b795-ba164be1afdd">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGFibGU6YWJlNTQyZjMzYzZhNDJlYzllZDcwMTViNTFlOTI3NTMvdGFibGVyYW5nZTphYmU1NDJmMzNjNmE0MmVjOWVkNzAxNWI1MWU5Mjc1M18wLTEtMS0xLTQxODg5_516d0bbc-39d5-424a-9484-4d46e980435c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i20996cadc68f450b9cdae24983d13cb4_I20221107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xL2ZyYWc6ZmJlY2U3M2ZiOTkxNGJkYTliNDdlYmU3Y2NiNjJmYTUvdGV4dHJlZ2lvbjpmYmVjZTczZmI5OTE0YmRhOWI0N2ViZTdjY2I2MmZhNV81NDk3NTU4MTYyMzA_3dd09e19-b831-43c4-aa37-63a68033f187"
      unitRef="shares">189561819</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNC0yLTEtMS00MTg4OQ_0b20ed5c-bdc7-46d9-969d-71f732150088"
      unitRef="usd">26001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNC00LTEtMS00MTg4OQ_04099760-4dd9-449f-aeec-903bd6beee26"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNS0yLTEtMS00MTg4OQ_a8018863-7d22-4bbc-82b3-0d93561ef426"
      unitRef="usd">79936000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNS00LTEtMS00MTg4OQ_acb7f4bd-ddaf-4a6a-8919-91ac653f4bde"
      unitRef="usd">92012000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNi0yLTEtMS00MTg4OQ_35ffce38-0262-41e7-98c3-8da04eedde5a"
      unitRef="usd">261000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNi00LTEtMS00MTg4OQ_bc75f933-ca0e-4134-a93c-74870666b68c"
      unitRef="usd">28000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNy0yLTEtMS00MTg4OQ_913b82ed-7a4c-4d58-8f2e-b6568800cd62"
      unitRef="usd">3348000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfNy00LTEtMS00MTg4OQ_af1a398d-cbb8-4a00-bb59-ff0e429acc2b"
      unitRef="usd">2481000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOC0yLTEtMS00MTg4OQ_2fe41355-faff-4d75-84a2-869417564390"
      unitRef="usd">109546000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOC00LTEtMS00MTg4OQ_c159b7e6-983e-4c72-90c0-8aaeb0b20fce"
      unitRef="usd">140866000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjE0ZmE1NzY1ZDlkODQ0YmQ5MmZlZmVmYjZhYzM4MmQ2Xzgw_2ef41df4-7783-42f1-83be-7b2bf9365525"
      unitRef="usd">4096000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjE0ZmE1NzY1ZDlkODQ0YmQ5MmZlZmVmYjZhYzM4MmQ2Xzg3_30ce6064-0bbf-49ee-80f5-1b15d9b74e16"
      unitRef="usd">3984000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS0yLTEtMS00MTg4OQ_b948e41a-f024-449b-94e4-43e935d80d21"
      unitRef="usd">2207000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfOS00LTEtMS00MTg4OQ_7e19d888-a332-45d6-8ede-70ce227335b5"
      unitRef="usd">2071000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTAtMi0xLTEtNDE4ODk_1c20677f-5ed7-46a1-bcd1-8efc139f26e5"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTAtNC0xLTEtNDE4ODk_f67213fa-6f29-4617-850e-d7070544c97a"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTEtMi0xLTEtNDE4ODk_66ad4899-b006-4bbb-a29e-1ff04602098c"
      unitRef="usd">6420000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTEtNC0xLTEtNDE4ODk_4faa9e39-d98a-4fe7-8b1c-6aacd969f681"
      unitRef="usd">6819000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTItMi0xLTEtNDE4ODk_4e2d657c-423f-4f0e-b6a5-5588a62c1c76"
      unitRef="usd">162716000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTItNC0xLTEtNDE4ODk_38edbf2e-f68d-4a8d-bb5c-519366db3aad"
      unitRef="usd">194299000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTUtMi0xLTEtNDE4ODk_9fb9cc78-a9c4-48b0-ac98-806b48eb6993"
      unitRef="usd">10311000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTUtNC0xLTEtNDE4ODk_68442efe-2eaa-434b-8508-83d5d61bd323"
      unitRef="usd">10395000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTYtMi0xLTEtNDE4ODk_9d30927b-098b-4553-84d2-0ed9c2dfda2a"
      unitRef="usd">10060000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTYtNC0xLTEtNDE4ODk_f8cf20b4-216d-498d-a74d-89cca6700cf3"
      unitRef="usd">12777000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTctMi0xLTEtNDE4ODk_6410c48b-8880-402a-a7c2-3337498f0483"
      unitRef="usd">20371000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTctNC0xLTEtNDE4ODk_e3794cbe-b2ff-43a0-a26a-3c8351df2a33"
      unitRef="usd">23172000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTgtMi0xLTEtNDE4ODk_215772f1-de28-4c4a-b410-86058883a9dc"
      unitRef="usd">48845000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTgtNC0xLTEtNDE4ODk_c378f3b4-2bd9-41d8-a412-62e87430a53d"
      unitRef="usd">48579000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTktMi0xLTEtNDE4ODk_c22c9a14-0928-416e-bf2e-45124e7ff099"
      unitRef="usd">5454000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMTktNC0xLTEtNDE4ODk_3ff9b801-6e49-468a-8b04-b379da5019ac"
      unitRef="usd">5424000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjAtMi0xLTEtNDE4ODk_98104564-2ded-4601-a122-edf414e2d0f6"
      unitRef="usd">74670000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjAtNC0xLTEtNDE4ODk_a983e219-4c75-4f3f-bc1c-3eaf3c9f9459"
      unitRef="usd">77175000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjEtMi0xLTEtNDE4ODk_ab469599-b910-46b5-a72b-19d2b2d69058"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjEtNC0xLTEtNDE4ODk_ea769f1c-4c8c-422d-9dae-d36518eb3ce2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8yMQ_5bbb3e57-b29c-4d57-b98a-0ddeb64e5bd9"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8yMQ_b5223806-e743-455b-af12-7baa4e52733d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8zNQ_3f7421f3-5055-46bd-93d4-6e333307f8b7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV8zNQ_bf6d22d9-6e16-4d49-83d9-9432d0d54acd"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_343d3796-bcd9-42e8-90cf-0084ef70e690"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_973f5d69-e06d-42c8-92bf-d60fa8bf9362"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_a6cd203d-71fd-473a-b72f-445ce1eff6bb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo1ZDhkNTg3ZGJkOTk0YmVmOTgzNDU0OTlmZWYwYmZmNV81Nw_b15f6b8f-dc66-4a66-bfbd-2ea913720d1a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtMi0xLTEtNDE4ODk_94912028-a014-4795-a1ab-d30f55c4f2ee"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjMtNC0xLTEtNDE4ODk_ee04d63d-2d3d-4a5c-9a9b-133b9d9ded60"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8xOA_584c53d4-c75c-427c-a02c-3aed48330611"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8xOA_5d0cca67-cb82-4004-b666-99fc0ffa2c6f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8zMg_7374f9b6-9342-4756-8b0e-508ef3d3b522"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV8zMg_9d051b41-4106-4ad3-bd71-eb01ad631680"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV81NA_250be8ff-65d7-4661-83a2-5fba9a4b63c0"
      unitRef="shares">190430000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjpiMGM0NWZiOWI4ZjQ0YjA0YTk5MWM0NGVhY2UyZDcyYV82MQ_6b60cff6-a856-4d75-b9a8-44947fc28d83"
      unitRef="shares">189214000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtMi0xLTEtNDE4ODk_8859b71a-26d4-4478-9850-489028bda7c2"
      unitRef="usd">190000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjQtNC0xLTEtNDE4ODk_3f600de3-0d1f-4ff9-b72c-4536b401416f"
      unitRef="usd">189000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjUtMi0xLTEtNDE4ODk_7cfc1f57-d845-4bc8-a8d8-42cfbce360cd"
      unitRef="usd">1712558000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjUtNC0xLTEtNDE4ODk_ef80c978-dc15-40a7-b25a-96c2b1bdea5c"
      unitRef="usd">1709144000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjYtMi0xLTEtNDE4ODk_542701a5-3790-422d-993c-f5b4b046fab4"
      unitRef="usd">-1621654000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjYtNC0xLTEtNDE4ODk_e8a31893-4652-472f-a24c-fa7e70b053d0"
      unitRef="usd">-1589720000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjctMi0xLTEtNDE4ODk_a8a9bf1f-cc5a-4ac5-b198-d91e184b80a3"
      unitRef="usd">-163000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjctNC0xLTEtNDE4ODk_6ff32939-b329-45d7-97f7-91dbb8b2e05e"
      unitRef="usd">-428000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo3ODBkN2JiY2E1Yzc0NjAzYWJmZGVjYjczNGExYjc2N18yOQ_1d642955-6827-4660-85be-3ae0ceade1e6"
      unitRef="shares">868000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMC0xLTEtNDE4ODkvdGV4dHJlZ2lvbjo3ODBkN2JiY2E1Yzc0NjAzYWJmZGVjYjczNGExYjc2N181NDk3NTU4MTM5NTc_effaab24-641b-4d66-bdbc-88882d59b5f1"
      unitRef="shares">488000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtMi0xLTEtNDE4ODk_599e5858-19a0-4fda-a648-424dd5bc6772"
      unitRef="usd">2885000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjgtNC0xLTEtNDE4ODk_12b8dbed-098d-4da1-9e28-41aa41ca877a"
      unitRef="usd">2061000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjktMi0xLTEtNDE4ODk_8d10bae4-fddb-4a62-a2e8-721a386aea71"
      unitRef="usd">88046000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMjktNC0xLTEtNDE4ODk_59505a19-62ff-4bd5-bccf-548d371d4bc3"
      unitRef="usd">117124000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMzAtMi0xLTEtNDE4ODk_b0d44f04-ce1a-46f6-83b9-4f50bc539b38"
      unitRef="usd">162716000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8xOS9mcmFnOmJhMGFiNWMzY2RlZTQ0MzVhOTBhZjMwNDU0ZDNmYzY3L3RhYmxlOjEwY2NlYzBkZGQ4NDQ5MjY5OTYyNGZiZTBhYjYxOGI1L3RhYmxlcmFuZ2U6MTBjY2VjMGRkZDg0NDkyNjk5NjI0ZmJlMGFiNjE4YjVfMzAtNC0xLTEtNDE4ODk_198b8660-dfff-4616-a322-8ad1b71d0294"
      unitRef="usd">194299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMy0xLTEtMS00MTg4OQ_5b68a0c5-09a8-4a93-bf6b-55dec47238d2"
      unitRef="usd">24000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMy0zLTEtMS00MTg4OQ_9ce50b0d-fd57-4d51-a9ff-7255861ab13d"
      unitRef="usd">37000</us-gaap:RoyaltyIncomeNonoperating>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOmM2MWVmNmU4ZDFhNTQ2NTRhM2E0ZWQ5YWNhNDQwOWMxXzY4_2b0f6dd1-2fe0-4a90-b484-e2d8c2c46565"
      unitRef="usd">1203000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOmM2MWVmNmU4ZDFhNTQ2NTRhM2E0ZWQ5YWNhNDQwOWMxXzcy_acb7ffb9-fef1-46b9-80b3-e156a95893e9"
      unitRef="usd">1032000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0xLTEtMS00MTg4OQ_eeb2f56a-0114-4d46-9cc4-c5388eee51c7"
      unitRef="usd">12026000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNi0zLTEtMS00MTg4OQ_2a76a703-469c-478b-85db-f3bf55576701"
      unitRef="usd">14926000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjAyOTM0YzZiYWY5NTQwMjJhMmI3MzM4ZmI1OWJjMzQ0Xzc5_edb5b250-3036-4ff1-b2fa-55768c739bf9"
      unitRef="usd">2212000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0wLTEtMS00MTg4OS90ZXh0cmVnaW9uOjAyOTM0YzZiYWY5NTQwMjJhMmI3MzM4ZmI1OWJjMzQ0Xzgz_e38fba18-e66f-4f1a-bdd4-d979ada0a3ea"
      unitRef="usd">1740000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0xLTEtMS00MTg4OQ_80e2a70d-0d66-456f-b632-3eff8f433aec"
      unitRef="usd">19140000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfNy0zLTEtMS00MTg4OQ_f5281726-8772-4fbf-acd6-65b283554c94"
      unitRef="usd">8491000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:OperatingExpenses
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOC0xLTEtMS00MTg4OQ_791a4bd4-d14a-407f-97ea-eb37e0f4ff2a"
      unitRef="usd">-31166000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOC0zLTEtMS00MTg4OQ_81230dab-bf90-4fe0-8ff0-e0e7d29031a1"
      unitRef="usd">23417000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOS0xLTEtMS00MTg4OQ_a0947ed7-4c0a-40d9-a92a-f3357b3eed20"
      unitRef="usd">-31142000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfOS0zLTEtMS00MTg4OQ_cd881e9a-6e1a-4a73-8655-478b11e07932"
      unitRef="usd">-23380000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTAtMS0xLTEtNDE4ODk_9ee55280-3637-421f-ac76-17b929b49d93"
      unitRef="usd">1821000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTAtMy0xLTEtNDE4ODk_2a452f43-5cf9-4dc7-a13a-620cb56282ad"
      unitRef="usd">110000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTEtMS0xLTEtNDE4ODk_1600b54d-0d39-4861-aca1-35e58af1e803"
      unitRef="usd">1029000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTEtMy0xLTEtNDE4ODk_9b177c8b-0ab8-4e90-bc74-8b162e0713b1"
      unitRef="usd">14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTItMS0xLTEtNDE4ODk_21cf9e3d-043b-4326-bc71-dcbe18627731"
      unitRef="usd">-31934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTItMy0xLTEtNDE4ODk_59c67a79-e53c-4731-b607-c81c715b8e24"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTMtMS0xLTEtNDE4ODk_8ed32585-0f4d-4bf6-872e-a1b2fe9b0730"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTMtMy0xLTEtNDE4ODk_f5bab7d2-c581-479e-82b4-798c28abab55"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTUtMS0xLTEtNDE4ODk_56d14aef-0c0b-4b14-9ba0-b5ff42a5fe54"
      unitRef="shares">189014000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTUtMy0xLTEtNDE4ODk_86e0520e-0dc9-43f8-ab0b-7b09c23d9b61"
      unitRef="shares">149150000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTgtMS0xLTEtNDE4ODk_34c3e812-57a6-49de-b570-2b20fd9a9b59"
      unitRef="usd">265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTgtMy0xLTEtNDE4ODk_ac28429b-e636-4148-8576-40457c850394"
      unitRef="usd">-27000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTktMS0xLTEtNDE4ODk_bb75c558-42ae-4d90-abf1-a60c0243e509"
      unitRef="usd">-31669000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yMi9mcmFnOjk5NGQ5Mzk4ZjYzMTRkYzE4YTYwYjNmODQ1MjRjM2YzL3RhYmxlOmVhZDM4YjI0YjI2MTRhM2JiMzk2ZmUxNDZhNTA3OGVkL3RhYmxlcmFuZ2U6ZWFkMzhiMjRiMjYxNGEzYmIzOTZmZTE0NmE1MDc4ZWRfMTktMy0xLTEtNDE4ODk_2924ede3-a6db-43b4-b2ad-ac12c8eb87c7"
      unitRef="usd">-23503000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9b4486d192c3418a887c00fdae579410_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0yLTEtMS00MTg4OQ_f19b3103-20fd-470b-a648-7a89be200eb7"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b4486d192c3418a887c00fdae579410_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi00LTEtMS00MTg4OQ_b6f9316b-4add-4ab3-88d1-5a89270aa06d"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c0d60f9ebe14ff6adf4c90cbaf04f93_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi02LTEtMS00MTg4OQ_df4cf9e5-1901-4deb-b3ff-dad5f7179a70"
      unitRef="usd">1608749000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b52788551bf4ba09d90c25c260474ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi04LTEtMS00MTg4OQ_af42f778-5216-4f3f-a2b4-dc9d7ca2224f"
      unitRef="usd">-1487776000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3780c853ca62493095fa01c99c96a50b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xMC0xLTEtNDE4ODk_0b84a04f-868c-4e4d-83ef-e5b22bfa411b"
      unitRef="usd">-10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fd9833fa7e645c68143dcfd76af2e58_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xMi0xLTEtNDE4ODk_c75a9952-3e34-476d-b8c9-6a66b5d038ae"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i908be8c8318f430fa0dcb565f616e66e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMi0xNC0xLTEtNDE4ODk_63199d35-2e2c-4c5e-af04-5d8b5de882d4"
      unitRef="usd">113595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy00LTEtMS00MTg4OQ_79799c4a-6de5-4de3-9b6a-ab7ab075ec9a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy02LTEtMS00MTg4OQ_f64cfabf-4b52-4ac8-820e-735e7c2316ce"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy04LTEtMS00MTg4OQ_ca309f95-5cbb-4e58-9328-4325c97c8f31"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xMC0xLTEtNDE4ODk_58ec37a9-224c-4cb2-920f-7a2d5213b5f4"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xMi0xLTEtNDE4ODk_505ed3b2-57aa-4782-b583-2fe7f9ff19eb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfMy0xNC0xLTEtNDE4ODk_d92ece76-ebc0-43f3-ad8a-d61ab9834304"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0yLTEtMS00MTg4OQ_024664fc-6f4a-4644-a39a-2288724af2b5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC00LTEtMS00MTg4OQ_a2d2ac9e-fd19-4c75-987d-1832495de9b0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC02LTEtMS00MTg4OQ_97f96034-4e3b-49d9-9c46-de5dfc7c09dd"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC04LTEtMS00MTg4OQ_b1d77113-8de8-4b65-8310-e9e0392c71dd"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xMC0xLTEtNDE4ODk_77a13f81-9408-41b3-b102-91a774f83e4d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xMi0xLTEtNDE4ODk_f5185b5b-b72d-4e3e-866d-7a05823dbbfe"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNC0xNC0xLTEtNDE4ODk_6c42204e-84d9-44c8-94eb-246c893f3fe8"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0yLTEtMS00MTg4OQ_f73c6251-5fbc-4085-a67d-033601e5f10f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS00LTEtMS00MTg4OQ_ff2ae27e-bf30-464a-aa07-2e635081d9c3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS02LTEtMS00MTg4OQ_267855f2-2ad7-4569-b3b7-4083ffeb42c0"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS04LTEtMS00MTg4OQ_fc00962a-e574-43a7-a28b-ef4c31293d7d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xMC0xLTEtNDE4ODk_8d4af8a6-f96f-43cf-8673-da129fa939a1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xMi0xLTEtNDE4ODk_0b168486-040f-48f0-82b3-14c82ec88b97"
      unitRef="usd">6321000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNS0xNC0xLTEtNDE4ODk_33d48efd-fb95-45a6-a75b-f98a137804fb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0yLTEtMS00MTg4OQ_bb9d3684-6c42-489e-94a6-210e21efd309"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi00LTEtMS00MTg4OQ_d8f2940c-f6c1-4245-8ea6-ec5ec36ea63c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi02LTEtMS00MTg4OQ_a95c03b9-bbea-411d-b718-c3b44e27356c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi04LTEtMS00MTg4OQ_6e992a04-e89d-4493-8975-3496df171cd6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xMC0xLTEtNDE4ODk_7cfb7898-17a3-47cf-b771-5160132d86f5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xMi0xLTEtNDE4ODk_79cc4de0-cc17-4e9b-a05f-cb19ec1160a3"
      unitRef="usd">-864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNi0xNC0xLTEtNDE4ODk_c8a736c2-98e8-4a63-bd60-21685dfa88ec"
      unitRef="usd">864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy00LTEtMS00MTg4OQ_033e0275-a074-4b1a-b372-a364d9946ad5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy02LTEtMS00MTg4OQ_4eb02e3c-f1d5-4b97-a0d9-b039d73e6a8a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy04LTEtMS00MTg4OQ_e598c5af-c61e-4d45-9243-4b63efd21030"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xMC0xLTEtNDE4ODk_d30dc5bd-882a-4bcb-b7d3-75ba0bf533ad"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xMi0xLTEtNDE4ODk_f8f011b1-cfc7-4d2e-ac72-eca09ac141cf"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfNy0xNC0xLTEtNDE4ODk_f8330fd9-3c00-44ee-9be5-bc66e63b81e1"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifee2aa1711f24f258629d07e7f927186_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC00LTEtMS00MTg4OQ_de8c36a4-85b9-4e2f-a8e3-8a34a41996ec"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5bbc3c17882841258987a1cc8feae2e8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC02LTEtMS00MTg4OQ_6c541894-7235-4e2b-a9e9-a2fe8444ab51"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie4a725eb0fbc4e87a0d479e533f83e94_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC04LTEtMS00MTg4OQ_ac9f3de3-af13-4279-b504-4174942aa246"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i074f651b14ee4a7e88b4260ea72fe17f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xMC0xLTEtNDE4ODk_53bc57f0-55c9-4e37-ba48-bc73a80bad91"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib45dd874240c4c45a886170daf956a22_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xMi0xLTEtNDE4ODk_9b165700-8c63-4955-8ee3-1adc354faca3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOC0xNC0xLTEtNDE4ODk_80a40ad6-7207-4500-995e-dc41b62df4a0"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="if1928596f4b5435191e331ad33500d98_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0yLTEtMS00MTg4OQ_984a6be7-b0b9-40b6-9a3b-5694aa0b494f"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1928596f4b5435191e331ad33500d98_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS00LTEtMS00MTg4OQ_db12dfba-5fdc-4885-b0fe-65ea0ad16e71"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5b75bdf9b3e45cfa77e885ac49788f5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS02LTEtMS00MTg4OQ_9f03c9ed-b94d-41f0-8487-ea96c2a03184"
      unitRef="usd">1605898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia219aede096c4cf0b514d5a736ae7245_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS04LTEtMS00MTg4OQ_a65b82e8-4604-455e-9a8e-ca776d9d4e88"
      unitRef="usd">-1511252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40101591a3a747d39081c3865fa29914_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xMC0xLTEtNDE4ODk_ffcec5ce-9f55-4325-ac08-0a3abbfc03c0"
      unitRef="usd">-37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida35814b016d4540b1321674b0722978_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xMi0xLTEtNDE4ODk_acd5a4cd-0194-4bb5-ae15-3ffe91dc709b"
      unitRef="usd">-2061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOmQ2ZmU2NTIwYWE4MTQ5YTk5Mzc0YWZjNjM2ZTM2NGU5L3RhYmxlcmFuZ2U6ZDZmZTY1MjBhYTgxNDlhOTkzNzRhZmM2MzZlMzY0ZTlfOS0xNC0xLTEtNDE4ODk_bd508427-212f-4470-9cfb-de26a84b0602"
      unitRef="usd">92698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9d08dad083a947c387d54202008989a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0yLTEtMS00MjM0Nw_60c415e2-2bee-4601-ae81-2a2b0c263306"
      unitRef="shares">189214000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d08dad083a947c387d54202008989a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi00LTEtMS00MjM0Nw_c985b5a8-5722-4fe9-979b-5359b261ce91"
      unitRef="usd">189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i636d41fbcdb344b7be8e6238915276b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi02LTEtMS00MjM0Nw_beb8433c-e1fa-4456-a3e7-bed552638b94"
      unitRef="usd">1709144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53b540e964324fb0b61132eb59b41f73_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi04LTEtMS00MjM0Nw_0b3b860f-4f8a-481c-878d-fbaca1463c3d"
      unitRef="usd">-1589720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69cc6c5cf6684519a5d00d853fa37565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xMC0xLTEtNDIzNDc_7d605407-6f63-4c3e-af5f-7118764a0caf"
      unitRef="usd">-428000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1cfd6d4e8e2473aa197ec5caf0a0e38_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xMi0xLTEtNDIzNDc_926ab7f5-32dd-42bf-99d1-da4fdeb33585"
      unitRef="usd">-2061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMi0xNC0xLTEtNDIzNDc_3c86f912-7ac4-4569-8575-68bcb2c26dcc"
      unitRef="usd">117124000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy00LTEtMS00MjM0Nw_373259e4-22d3-478c-997a-52714369d47c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy02LTEtMS00MjM0Nw_77396c31-3c4f-4094-990b-fe349ac39722"
      unitRef="usd">3415000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy04LTEtMS00MjM0Nw_43780746-4746-495c-a79b-55501954adaf"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xMC0xLTEtNDIzNDc_f1fae219-7ee8-4206-8342-87a8b0bf383c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xMi0xLTEtNDIzNDc_fe73f81a-4a46-42f6-8a63-5d6783bead11"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfMy0xNC0xLTEtNDIzNDc_bb55445c-bda9-4819-ae6e-4e61936db54e"
      unitRef="usd">3415000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0yLTEtMS00MjM0Nw_0e10ba5c-676f-4ee1-b3ab-6635ebe20741"
      unitRef="shares">1216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC00LTEtMS00MjM0Nw_33d25b5f-b024-4dc6-aa62-e2162f9a33e6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC02LTEtMS00MjM0Nw_014796e6-5f78-45f2-81b1-9af5176fb19c"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC04LTEtMS00MjM0Nw_4777e006-a0d3-4f77-aca3-cc02393df57b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xMC0xLTEtNDIzNDc_a2383946-e977-4ce9-a94c-557acd147d09"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xMi0xLTEtNDIzNDc_045ac294-0896-49e3-89e8-cd4436d74c52"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNC0xNC0xLTEtNDIzNDc_b5aed8af-a05e-4543-89d7-e451c1faeb1a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi00LTEtMS00MjM0Nw_c2021bb8-4b64-42c5-af96-b8004ef27178"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi02LTEtMS00MjM0Nw_7eda0b7c-68c6-4df4-83ee-899f98a39be8"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi04LTEtMS00MjM0Nw_b669b027-f0c4-4ea3-8989-01f94dc854fb"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xMC0xLTEtNDIzNDc_3a920e9e-4bba-467e-95aa-10c38eeca971"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xMi0xLTEtNDIzNDc_665aabaa-79f8-43a2-9b7a-5a6d1dca65a4"
      unitRef="usd">824000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNi0xNC0xLTEtNDIzNDc_dd42297f-8e77-453e-90df-a0de579f9612"
      unitRef="usd">824000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy00LTEtMS00MjM0Nw_212a52c3-9e65-4065-8f49-467ab24c6bc0"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy02LTEtMS00MjM0Nw_bdf014ff-c099-4ae2-b458-ebb0b9625104"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy04LTEtMS00MjM0Nw_307af532-015e-416f-bf0b-69c3f6ede097"
      unitRef="usd">-31934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xMC0xLTEtNDIzNDc_866f592b-749e-4b38-8747-3e6284ab51d9"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xMi0xLTEtNDIzNDc_89060c00-bb4a-4341-a1da-7d3200ae51d1"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfNy0xNC0xLTEtNDIzNDc_88077a16-f034-4114-83a6-a4cfd8128d99"
      unitRef="usd">-31934000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i017100090664431eae4b4d902a7a2069_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC00LTEtMS00MjM0Nw_7f90962d-6de4-4d21-95e7-59fd0897ba86"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i561f3732275c4803bf200bd3d285c665_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC02LTEtMS00MjM0Nw_c515020f-e3d4-45f5-b582-ed72ee910041"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ieea6df3e88b44d638c274ed09d7725c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC04LTEtMS00MjM0Nw_30ce0980-66be-453c-be5b-48738d2eb45b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ief76986da65f420f86dfa94119abd82f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xMC0xLTEtNDIzNDc_44691da7-daf3-420d-8743-d0954cb73f9d"
      unitRef="usd">265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2454d6f3d8624116aded925489ea61b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xMi0xLTEtNDIzNDc_ffcf24d9-3d4d-4b9a-adc2-fe52680688ce"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOC0xNC0xLTEtNDIzNDc_d66c3a45-e815-4351-8ef1-25198fb84f16"
      unitRef="usd">265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i122cc45b24a040dca3939cb8ebe170a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0yLTEtMS00MjM0Nw_b5d76e73-468c-4a97-8945-2e37131ff0b2"
      unitRef="shares">190430000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i122cc45b24a040dca3939cb8ebe170a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS00LTEtMS00MjM0Nw_da81694f-46ee-4946-ab6c-b622dea9a6a5"
      unitRef="usd">190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14d09fe0d1af4d7db5d3ab1d00f6cb8e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS02LTEtMS00MjM0Nw_88661f10-2a16-4f87-84e2-e5a01bb5b00a"
      unitRef="usd">1712558000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if294b62ddc5941a89003bac80ce657a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS04LTEtMS00MjM0Nw_d711cb7a-295b-460f-b2ea-f447ec3807c7"
      unitRef="usd">-1621654000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30b21eb47f1d44a0801b1c165ff6a310_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xMC0xLTEtNDIzNDc_97dd3344-1780-4293-9326-a67cda668aad"
      unitRef="usd">-163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f5c48a42a0b4346b4984be1e404c5e3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xMi0xLTEtNDIzNDc_62bdb59d-a4ab-464a-8363-24db4e488a3a"
      unitRef="usd">-2885000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yNS9mcmFnOmE1ZWU3NmUzMGVkNzRlODY5NzQ3MTFlOTM5ODFlYmUxL3RhYmxlOjVlNGE2NWQ1MWRkZTRiZDZhMWVkZjFkMDJlZTUxNzY5L3RhYmxlcmFuZ2U6NWU0YTY1ZDUxZGRlNGJkNmExZWRmMWQwMmVlNTE3NjlfOS0xNC0xLTEtNDIzNDc_0281ffb5-d700-471d-b4db-b7121c2c306a"
      unitRef="usd">88046000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMy0yLTEtMS00MTg4OQ_ba402028-95f8-4fdb-8bda-c0280630eea2"
      unitRef="usd">-31934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMy00LTEtMS00MTg4OQ_25246456-0da4-4f45-9184-7fd4a9af978b"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNS0yLTEtMS00MTg4OQ_015a0045-4ff4-4c21-912e-f1f3abe99500"
      unitRef="usd">112000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNS00LTEtMS00MTg4OQ_c9324415-1a11-4ff0-9ab5-7242026fb442"
      unitRef="usd">109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNi0yLTEtMS00MTg4OQ_1527aef2-d8f9-4303-b533-94dfbdce6b51"
      unitRef="usd">3415000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNi00LTEtMS00MTg4OQ_5a73dd79-075a-4352-997e-1bfed48c100a"
      unitRef="usd">2772000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNy0yLTEtMS00MTg4OQ_b8c24df5-d576-4657-9eb3-da5547693bad"
      unitRef="usd">265000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfNy00LTEtMS00MTg4OQ_03d08a4d-ed5a-49c7-8362-0e032c24a55f"
      unitRef="usd">25000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfOS0yLTEtMS00MTg4OQ_0b32bfc3-d531-430f-9b20-23340cebb4f6"
      unitRef="usd">234000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfOS00LTEtMS00MTg4OQ_243adf42-0546-4070-a389-5e8332a2fd50"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTAtMi0xLTEtNDE4ODk_928f96a5-e01d-4fb9-9b24-e6e60efd8b6d"
      unitRef="usd">867000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTAtNC0xLTEtNDE4ODk_edcdff53-6ed8-4e2f-97ca-b6a0d928373f"
      unitRef="usd">-273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTEtMi0xLTEtNDE4ODk_e745d945-11dc-4ba3-87d5-ceb6423a620c"
      unitRef="usd">-400000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTEtNC0xLTEtNDE4ODk_fc027070-2379-4562-8f47-4f7a82fac142"
      unitRef="usd">-207000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTItMi0xLTEtNDE4ODk_165ed8c0-064a-454a-af48-876c8ea9aba0"
      unitRef="usd">-2770000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTItNC0xLTEtNDE4ODk_12991a8e-ed3e-4287-9ea0-f3801cdc9e21"
      unitRef="usd">-3308000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTMtMi0xLTEtNDE4ODk_839c1bd2-77c8-4520-87d6-87710a1d2250"
      unitRef="usd">-31613000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTMtNC0xLTEtNDE4ODk_165f3a0c-210d-4fc4-9ce1-aa62484da36e"
      unitRef="usd">-23421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTUtMi0xLTEtNDE4ODk_00f6377e-87e1-4d2e-b700-06e2fdd252de"
      unitRef="usd">248000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTUtNC0xLTEtNDE4ODk_4455d7d3-a5e8-4eb7-91fc-95221b1f08c5"
      unitRef="usd">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTYtMi0xLTEtNDE4ODk_709855f6-f8a2-47b0-8ee6-84ea1c5b85c9"
      unitRef="usd">28864000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTYtNC0xLTEtNDE4ODk_23731229-d10c-4ccb-a872-b0c527cffc21"
      unitRef="usd">17816000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTctMi0xLTEtNDE4ODk_7ee2dceb-dd8d-4311-bd72-44c7f5a31209"
      unitRef="usd">41205000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTctNC0xLTEtNDE4ODk_fb8da4f3-9253-4170-aeb3-5562f859e109"
      unitRef="usd">13484000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTgtMi0xLTEtNDE4ODk_66b7b9ce-36f4-4d26-b2b2-e3ad480d2801"
      unitRef="usd">12093000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMTgtNC0xLTEtNDE4ODk_b525e0fd-f51e-439a-b1ab-8ec0bf55c29a"
      unitRef="usd">-4408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjEtMi0xLTEtNDE4ODk_c0c73e4b-d939-4dff-82b0-cf5fa0185202"
      unitRef="usd">824000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjEtNC0xLTEtNDE4ODk_15959900-7431-4da8-aae5-77bd341a52b2"
      unitRef="usd">864000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjItMi0xLTEtNDE4ODk_44eca5fd-89bd-4fce-acb3-4661ae6f9873"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjItNC0xLTEtNDE4ODk_a4879332-d9ee-48c1-9705-b374012dcc16"
      unitRef="usd">24148000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjMtMi0xLTEtNDE4ODk_d6979586-3c34-4154-813d-ececc340ba07"
      unitRef="usd">-824000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjMtNC0xLTEtNDE4ODk_ed0eb821-a356-4722-896b-da0a9b1a770f"
      unitRef="usd">23284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjQtMi0xLTEtNDE4ODk_eed96b7a-2814-4b7c-9828-9cc0c2052991"
      unitRef="usd">-20344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjQtNC0xLTEtNDE4ODk_ee6a1fcc-959b-4553-8109-eb2accd2ec51"
      unitRef="usd">-4545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjUtMi0xLTEtNDE4ODk_3620bedc-af55-453f-8bbf-eba67702fd22"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i908be8c8318f430fa0dcb565f616e66e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjUtNC0xLTEtNDE4ODk_c731970a-1061-4fd8-8b85-3f9bc1355686"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjYtMi0xLTEtNDE4ODk_4d1cb0b2-56f9-4629-b123-855f58a6cf6b"
      unitRef="usd">26001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjYtNC0xLTEtNDE4ODk_3e6d14be-91e5-44d8-b2f7-c7452311f4b8"
      unitRef="usd">59520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjktMi0xLTEtNDE4ODk_34900e40-c46f-4d34-9a22-a175d7ac615d"
      unitRef="usd">1556000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMjktNC0xLTEtNDE4ODk_a0f872c4-3133-400f-a2fe-55ce40ebea44"
      unitRef="usd">85000</us-gaap:InterestPaidNet>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzMtMi0xLTEtNDE4ODk_8e4a33c9-7753-424a-b273-12b6ec45ee56"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzMtNC0xLTEtNDE4ODk_690dfcf2-590a-424e-aaa7-6ebd75790c70"
      unitRef="usd">698</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzQtMi0xLTEtNDE4ODk_e4817ebe-c053-4ad2-b6e7-a8db92361e19"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockCarryingBasis
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzQtNC0xLTEtNDE4ODk_834106f1-5073-422d-aa3f-3c21238c6b50"
      unitRef="usd">6321</us-gaap:TreasuryStockCarryingBasis>
    <us-gaap:BusinessExitCosts1
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzUtMi0xLTEtNDE4ODk_77a4aff9-65b1-47b6-aefa-e51b3f02c3cd"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8yOC9mcmFnOmM4ZjVlYjZkNGYyZjQ1Y2NhMmZkMDI0NzcxZjE3NjA1L3RhYmxlOjJiOTM4OTMyZDI4NzQ0OWY5YmRlNTAzNTJhNzA2ZDg1L3RhYmxlcmFuZ2U6MmI5Mzg5MzJkMjg3NDQ5ZjliZGU1MDM1MmE3MDZkODVfMzUtNC0xLTEtNDE4ODk_28d8f282-e959-4b3b-8938-c903536286b8"
      unitRef="usd">1500</us-gaap:BusinessExitCosts1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzY_a81472f2-25f1-40a2-8054-c471ea193e58">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2023 and December&#160;31, 2022, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less. Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate ranging between 9% and 9.7% at the commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements that include development milestones, the Company evaluates at contract inception whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments. The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with stock warrants, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjQ_7d5bee75-8594-48e4-aa6e-94ca0d53f22c">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzNDA_95d5ca06-8a47-4373-9114-f66c0e95839b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjE_d442ec7a-64b4-4644-ad75-c1a0ae70b7d2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2023 and December&#160;31, 2022, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;The Company does not intend to sell any of its available-for-sale securities prior to their maturity dates. Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzA_38aa1a95-ffc6-4acc-bc05-a4cc9d429881">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfMy0yLTEtMS00MTg4OQ_55655b4d-daa4-4c09-be15-f2c1887edfd6"
      unitRef="usd">3937000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfMy00LTEtMS00MTg4OQ_4b46bce8-586e-409b-897c-81fdaac518ff"
      unitRef="usd">3252000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNC0yLTEtMS00MTg4OQ_3952b122-a1e9-4632-a4e1-f489c2ad1841"
      unitRef="usd">4348000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNC00LTEtMS00MTg4OQ_2c50feb3-da68-40ef-81d2-538c939c09a4"
      unitRef="usd">7830000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNS0yLTEtMS00MTg4OQ_89e4f1af-10cb-44c1-b43e-6f743ffe2020"
      unitRef="usd">1291000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNS00LTEtMS00MTg4OQ_78d1f1d6-2f8f-4a44-b74e-92028fd2fb1e"
      unitRef="usd">1291000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNi0yLTEtMS00MTg4OQ_8c53ff66-3aee-4623-94c2-34b0fd6d8ed4"
      unitRef="usd">484000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNi00LTEtMS00MTg4OQ_ff9e54da-fe24-4ec8-b2fd-b0dcdb2bbabc"
      unitRef="usd">404000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNy0yLTEtMS00MTg4OQ_3af02587-2ce7-4d44-9e0a-8f6e3700724a"
      unitRef="usd">10060000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjM0MTZiZjgxYWJmNzRmYzY5MmQxMTVjYjllYWUxNTRhL3RhYmxlcmFuZ2U6MzQxNmJmODFhYmY3NGZjNjkyZDExNWNiOWVhZTE1NGFfNy00LTEtMS00MTg4OQ_5d5b0aa9-c265-4e88-b8a8-6201424ed510"
      unitRef="usd">12777000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzNTM_ccb58324-3484-45f9-a9c1-144a9baa928f">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as its performance obligations under each of its contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements that include development milestones, the Company evaluates at contract inception whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMDU_c09b6f43-bff1-42dd-8c0d-398b2d2915d5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMjU_d90f34fd-b974-4fe9-9bbc-b8a70fb3eb77">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&#160;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTk_07c9be1d-2e52-41c2-9de5-121b05bf1d68">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi0yLTEtMS00MTg4OQ_7795da0a-4844-4922-a58a-dd79c42b4036"
      unitRef="number">1.12</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi00LTEtMS00MTg4OQ_fc41e433-ec43-4799-ac6c-facfbd3bd125"
      unitRef="number">0.041</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi02LTEtMS00MTg4OQ_b703a052-27c5-44ca-8b43-d030147ed090">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMi04LTEtMS00MTg4OQ_427a965c-c713-4203-a56e-1d654661bb41"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy0yLTEtMS00MTg4OQ_eccc5c3f-2348-4a2d-9daf-14d9ada66882"
      unitRef="number">0.98</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy00LTEtMS00MTg4OQ_11bc90df-c578-4d2c-9257-b065dd6d5dfa"
      unitRef="number">0.039</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy02LTEtMS00MTg4OQ_e36ccee2-2121-499e-b5d2-af8c6119765a">P6Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i1890926262c54e02b5417fe2efebfd89_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfMy04LTEtMS00MTg4OQ_daa4414a-a486-482b-8f40-e0f607b87c15"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS0yLTEtMS00MTg4OQ_63b138ae-c90c-421e-8115-69da967cd25c"
      unitRef="number">1.04</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS00LTEtMS00MTg4OQ_8c1c3f0e-b169-4f28-a2a0-fbf2f701124b"
      unitRef="number">0.018</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS02LTEtMS00MTg4OQ_c4d1c573-c788-4186-ae0f-cfc53459a39c">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNS04LTEtMS00MTg4OQ_5049b544-b104-4142-b5f1-ff8444d40432"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi0yLTEtMS00MTg4OQ_60f0b696-9f02-46bf-b22f-431f5de2f150"
      unitRef="number">0.91</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi00LTEtMS00MTg4OQ_fc88fad7-dc97-4599-928b-5f64727a7bf6"
      unitRef="number">0.019</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi02LTEtMS00MTg4OQ_ad848b54-ad39-4358-b525-0ba867022a5d">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="iff98c79f23a046b3a9c0e9d38f607f4e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM1NTI3MDZkYTA1NTQ1YWZiMmIyYWZiZTFlZGQ2Njc5L3RhYmxlcmFuZ2U6YzU1MjcwNmRhMDU1NDVhZmIyYjJhZmJlMWVkZDY2NzlfNi04LTEtMS00MTg4OQ_de323b6f-c7ef-4b47-b4cb-69f358386487"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTg_9b789b96-41f0-498d-8194-3f9a3e491fb5">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i122a411cbee64663b669721e52d22969_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMi0yLTEtMS00MTg4OQ_4332d37d-5970-4338-ace9-4e9849a50247"
      unitRef="shares">12349000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i122a411cbee64663b669721e52d22969_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMi00LTEtMS00MTg4OQ_d8049034-48d7-45d4-9f1f-d2de6aedeb05"
      unitRef="usdPerShare">5.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMy0yLTEtMS00MTg4OQ_9b7d604c-15f5-49f3-bd49-bceef1f48488"
      unitRef="shares">5077000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfMy00LTEtMS00MTg4OQ_4e605f82-5e5b-48c4-8f39-9bcc324e46e5"
      unitRef="usdPerShare">2.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNS0yLTEtMS00MTg4OQ_d729145a-6a75-40f0-aa7c-d880a818f8e3"
      unitRef="shares">129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNS00LTEtMS00MTg4OQ_a14f3a06-8835-4238-ae2e-a9c4747db9ce"
      unitRef="usdPerShare">14.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNi0yLTEtMS00MTg4OQ_a8ca2ebb-3821-464b-990d-fe9915097470"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i22fdde5e7ea9486d99fb1335daf6e66d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNi00LTEtMS00MTg4OQ_446929c1-9528-4f79-b1b8-c8368a953941"
      unitRef="usdPerShare">3.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNy0yLTEtMS00MTg4OQ_a1c3c279-f0b1-4eff-866f-b022a366ffad"
      unitRef="shares">17127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfNy00LTEtMS00MTg4OQ_93227fd2-f9a7-4d11-8ece-a2cd8b514f68"
      unitRef="usdPerShare">4.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfOC0yLTEtMS00MTg4OQ_dbb2597a-7e1c-4b07-834d-5bb235b8c524"
      unitRef="shares">6877000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic5f8c6317ce54f87acdd96796cc0c74c_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOmM3ZGM0YzdjYzhhMzQ0OGU4NzI0MmE4NTg0NzhmMTNjL3RhYmxlcmFuZ2U6YzdkYzRjN2NjOGEzNDQ4ZTg3MjQyYTg1ODQ3OGYxM2NfOC00LTEtMS00MTg4OQ_a65afe16-eb2e-4ea9-ac1f-0b752fee14e1"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMTQ_1b392d1e-1c37-4d3e-af5e-e518c297570a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4590c26f966346da952432b88fccff44_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMi0yLTEtMS00MTg4OQ_02e7d754-d299-4e57-a70a-5f01aada71cf"
      unitRef="shares">2748000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4590c26f966346da952432b88fccff44_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMi00LTEtMS00MTg4OQ_082e99f4-d88d-4fa6-9b44-573dec2e95cb"
      unitRef="usdPerShare">3.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMy0yLTEtMS00MTg4OQ_9ac02d4d-7276-44b5-a861-20b52ee85895"
      unitRef="shares">4070000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfMy00LTEtMS00MTg4OQ_27ee3bc4-333e-45ea-8156-c2cb6d384359"
      unitRef="usdPerShare">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNC0yLTEtMS00MTg4OQ_4da5630b-6aa3-4c22-9707-1acbf3f9964c"
      unitRef="shares">1216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNC00LTEtMS00MTg4OQ_e2e25980-076c-464d-8f0a-7a247a762c8b"
      unitRef="usdPerShare">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNS0yLTEtMS00MTg4OQ_999f10cc-9897-447a-a079-a85c4d0bb599"
      unitRef="shares">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ide4435f3bf364a1fb3476e8a8af6c57d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNS00LTEtMS00MTg4OQ_7e8c40f9-4cf5-497f-9582-89de45c643f1"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i52cb6e46f3004a31b017f45441c3a197_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNi0yLTEtMS00MTg4OQ_b7ae3695-894f-4079-a87d-e73e34d691de"
      unitRef="shares">5490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i52cb6e46f3004a31b017f45441c3a197_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RhYmxlOjlmNWQ3NmEzNzFiMjQ1NWZhYmQ5OTc0YzY1ZmIzMGU1L3RhYmxlcmFuZ2U6OWY1ZDc2YTM3MWIyNDU1ZmFiZDk5NzRjNjVmYjMwZTVfNi00LTEtMS00MTg4OQ_28ed3f37-114c-4488-83c1-6171158cf8b2"
      unitRef="usdPerShare">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNC9mcmFnOmMyNGMyZTVkZGZhNzRjMTNiNzIwNjM0NTRmMzIzY2E2L3RleHRyZWdpb246YzI0YzJlNWRkZmE3NGMxM2I3MjA2MzQ1NGYzMjNjYTZfMTAzMzQ_dc2cf51f-b530-4f69-9e74-850d38ff4c27">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with stock warrants, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV8zNy9mcmFnOjk1NDVjNDBiYmUxYzQ4ZTE4ODQ2ZDgwZGY4YjNmOTRkL3RleHRyZWdpb246OTU0NWM0MGJiZTFjNDhlMTg4NDZkODBkZjhiM2Y5NGRfNzc4_be18714b-c956-41d6-b15c-45dedc3cc0f5">Recent Accounting PronouncementsWe do not expect that any recently issued accounting pronouncements will have a material impact on our financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMzM1_66ca9705-4038-416b-a5ec-ff322d583419">Cash and Cash Equivalents and Investments&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at March&#160;31, 2023 and December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized losses during either of the three month periods ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMzI4_47d9be94-ab84-449c-a504-734c4a1d256f">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i1150bd512a24422facf2a358e5f34712_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy0yLTEtMS00MTg4OQ_c811dae8-5313-45f2-8089-76cf1809cb2e"
      unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1150bd512a24422facf2a358e5f34712_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy00LTEtMS00MTg4OQ_75f69d33-9f9b-4dc8-9c61-af66b1f159f3"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1150bd512a24422facf2a358e5f34712_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy02LTEtMS00MTg4OQ_760079f0-8072-4503-b4ab-e0378d4a1197"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1150bd512a24422facf2a358e5f34712_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMy04LTEtMS00MTg4OQ_fdf0e77b-5fd8-49ab-ae8b-3a0388d3d92b"
      unitRef="usd">26001000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS0yLTEtMS00MTg4OQ_baf208f3-4a73-4c00-9256-1191b3717fcf"
      unitRef="usd">70894000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS00LTEtMS00MTg4OQ_c710d613-7ddd-41d9-8d8f-854a54fb7b46"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS02LTEtMS00MTg4OQ_f97b9b8c-325f-42ff-9f22-8613a1795ad8"
      unitRef="usd">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i69e6cd144aee4e95b362bf083223bd6d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNS04LTEtMS00MTg4OQ_f926047f-e9ae-4f8d-a635-ddca5e3fff0b"
      unitRef="usd">70761000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi0yLTEtMS00MTg4OQ_e0042884-38aa-4f7e-8dff-0d679f3fac89"
      unitRef="usd">9206000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi00LTEtMS00MTg4OQ_a7884611-dcd3-4f09-aab2-950f08efa3ce"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi02LTEtMS00MTg4OQ_f2d7aa76-4094-417d-b825-8534d40cb111"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8a9aa0068e404b4d801ff1de1e630584_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNi04LTEtMS00MTg4OQ_bd965f60-e0b4-4712-9844-a87a564363c4"
      unitRef="usd">9175000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy0yLTEtMS00MTg4OQ_63243cc5-1529-44ef-92b2-a1d6c7d14a2d"
      unitRef="usd">80100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy00LTEtMS00MTg4OQ_3ab6cc5e-21f7-42fa-a96b-4dd3a6103fa3"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy02LTEtMS00MTg4OQ_c17ed57a-9322-4930-8e10-c4bd9599706e"
      unitRef="usd">173000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i86b7b245845b4744bdcafd4a64ae9457_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfNy04LTEtMS00MTg4OQ_80b2c72f-baf7-452b-ad7b-e3c6148fe5b2"
      unitRef="usd">79936000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC0yLTEtMS00MTg4OQ_8c879d61-cdba-464f-b594-953d84e12347"
      unitRef="usd">106100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC00LTEtMS00MTg4OQ_b455b878-fdeb-4ced-aaf9-618d1bf6a57b"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC02LTEtMS00MTg4OQ_4f47aa57-4d69-499d-91c5-ae5d4a3af3d4"
      unitRef="usd">173000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibbff2c0bc8914b5083a706874111931f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfOC04LTEtMS00MTg4OQ_f84478c2-8267-4a08-b3cc-88d6efc2081c"
      unitRef="usd">105937000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtMi0xLTEtNDE4ODk_d67f8786-8eff-4b12-91ab-02df92880280"
      unitRef="usd">46345000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtNC0xLTEtNDE4ODk_f3497334-3702-45bf-b618-0924b76c5a92"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtNi0xLTEtNDE4ODk_db835035-155b-4459-be2a-31406e2c64bd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i48f0211b426c48a7928c9fe72bdf5fce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTMtOC0xLTEtNDE4ODk_d0021d2c-7f50-4cb7-9986-613276d2da15"
      unitRef="usd">46345000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtMi0xLTEtNDE4ODk_b2a5dd20-840a-4a87-887e-bfe8409f7b0a"
      unitRef="usd">74022000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtNC0xLTEtNDE4ODk_ed8826f6-9db4-4eae-9d4c-3d5ef91511c7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtNi0xLTEtNDE4ODk_9b074d4c-ec34-4cb3-a640-33fefd4edabc"
      unitRef="usd">342000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i41c5cb7217034320b1cf86d2516d1891_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTUtOC0xLTEtNDE4ODk_76a72644-66dc-480d-812e-e8cc9032915d"
      unitRef="usd">73680000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtMi0xLTEtNDE4ODk_f6ed8930-167a-40ea-a8f3-691c83875f6b"
      unitRef="usd">18418000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtNC0xLTEtNDE4ODk_9b747f95-8105-4218-a07f-25173dfce298"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtNi0xLTEtNDE4ODk_58561502-019d-4916-9cef-44082ec96855"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i31ee63580e7f4cee956584a4be4fc152_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTYtOC0xLTEtNDE4ODk_0181d16f-a5be-4065-aa23-ba8876805600"
      unitRef="usd">18332000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctMi0xLTEtNDE4ODk_34b9ca79-57e1-4c62-a386-f28d1db4da66"
      unitRef="usd">92440000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctNC0xLTEtNDE4ODk_23c048f8-9e72-4727-8e88-bfe1bbf93b33"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctNi0xLTEtNDE4ODk_7c111834-d4c5-4ac5-abf7-5cb509cfcc5e"
      unitRef="usd">428000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i46ede3bf23094d30ab019f2c0cae03fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTctOC0xLTEtNDE4ODk_cabf26fd-1b1a-488c-b0a3-7af8a427fb81"
      unitRef="usd">92012000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i375e3a3d13094b578b03f23910d47681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtMi0xLTEtNDE4ODk_c476988e-8f2e-4082-91f9-acd9b4d319f5"
      unitRef="usd">138785000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i375e3a3d13094b578b03f23910d47681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtNC0xLTEtNDE4ODk_aa735043-39ff-4f65-b2bc-f0a54de201ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i375e3a3d13094b578b03f23910d47681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtNi0xLTEtNDE4ODk_51169c85-01cf-43bf-bbf6-6a1863299f8e"
      unitRef="usd">428000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i375e3a3d13094b578b03f23910d47681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RhYmxlOjAyM2NmZDMyOTA4YjQzOGRhNmRlNjU4YjAzYjgwZjljL3RhYmxlcmFuZ2U6MDIzY2ZkMzI5MDhiNDM4ZGE2ZGU2NThiMDNiODBmOWNfMTgtOC0xLTEtNDE4ODk_68b149eb-ae3c-4780-b935-3019a484cffa"
      unitRef="usd">138357000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMTcw_4ef6aafe-0391-4552-b6fc-aad887b7c9b1"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80MC9mcmFnOmJhYTI2ODBhYjgxMTQxYjJiMjc3MjEwY2E3ZWMwYjJkL3RleHRyZWdpb246YmFhMjY4MGFiODExNDFiMmIyNzcyMTBjYTdlYzBiMmRfMTcw_b950e8e4-549c-474c-90e6-e4b100fbfee9"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RleHRyZWdpb246MDExOWIzMmU2YTRlNDNkODk1MTNhMzllMDRhNzNhNDVfMTU3Mg_be616c5b-6224-411d-bd54-aeeef6cd4c44">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2023 or December&#160;31, 2022. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RleHRyZWdpb246MDExOWIzMmU2YTRlNDNkODk1MTNhMzllMDRhNzNhNDVfMTU3OQ_ff697cee-0f12-41be-a8c4-d2ebd31d67ac">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC0yLTEtMS00MTg4OQ_ad07a0ac-2597-4389-961c-5b916a121c06"
      unitRef="usd">26001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC00LTEtMS00MTg4OQ_b5cd6cee-8ec2-4e2e-b5cb-34bb778b186f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC02LTEtMS00MTg4OQ_ee0128bb-d994-41e1-b684-79963852e3fe"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNC04LTEtMS00MTg4OQ_6f14d4fb-d754-4e19-a06e-509a6289a770"
      unitRef="usd">26001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS0yLTEtMS00MTg4OQ_1a3f62a6-2b7f-493a-824e-3e7f05d407e4"
      unitRef="usd">70761000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS00LTEtMS00MTg4OQ_14410e9a-f79f-4bd7-9e08-9865e4054e75"
      unitRef="usd">9175000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS02LTEtMS00MTg4OQ_e5a7c05a-2427-4c79-a3fd-fca2dd56555f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNS04LTEtMS00MTg4OQ_4bf7ee4d-d4ad-49d1-9a01-c7e02f411d42"
      unitRef="usd">79936000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6a33dcb65a3a4454ad89e82d3f767da8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi0yLTEtMS00MTg4OQ_89caf90b-9e90-449c-abf9-f05e9cd5021a"
      unitRef="usd">96762000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i85ac8033ec684725b9503d12d0b48ada_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi00LTEtMS00MTg4OQ_ef201d34-fece-4698-8b22-acac821844a2"
      unitRef="usd">9175000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i901f7eff00b440ac8fd3b85aa8b94826_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi02LTEtMS00MTg4OQ_b1a59420-a50d-4238-b015-d9241c97c354"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOmI4MDZjODQ0MWM5NTQ0MzA4ZDMxZDE2OTJjODhlNzQ0L3RhYmxlcmFuZ2U6YjgwNmM4NDQxYzk1NDQzMDhkMzFkMTY5MmM4OGU3NDRfNi04LTEtMS00MTg4OQ_fc8574ae-4414-413d-ac08-ae531c63777b"
      unitRef="usd">105937000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iadb4426fae2448009d2f24b25517721b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC0yLTEtMS00MTg4OQ_90679471-69fe-419c-a67b-618ea35dbbc1"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ied2630f42a2e4991858d1dab84290767_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC00LTEtMS00MTg4OQ_69d6cab6-133c-4a2d-8d47-f8d8103ec8e1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC02LTEtMS00MTg4OQ_96d93e7b-9bbe-4e74-a082-932d93e59862"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNC04LTEtMS00MTg4OQ_c5e88551-5b58-427a-a2e0-d1a38ff9c9d5"
      unitRef="usd">46345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="iadb4426fae2448009d2f24b25517721b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS0yLTEtMS00MTg4OQ_90bce22a-5905-4d0a-bb30-d9a6d4768eda"
      unitRef="usd">73680000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ied2630f42a2e4991858d1dab84290767_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS00LTEtMS00MTg4OQ_1f071da4-e759-4125-a843-dc82290062c9"
      unitRef="usd">18332000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS02LTEtMS00MTg4OQ_e6e1b09d-2c2c-4e17-9175-4ba76df34234"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNS04LTEtMS00MTg4OQ_c6af218b-d426-45ef-8885-f697f5622199"
      unitRef="usd">92012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iadb4426fae2448009d2f24b25517721b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi0yLTEtMS00MTg4OQ_d08235ed-310f-4814-9d69-5ad854eec048"
      unitRef="usd">120025000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ied2630f42a2e4991858d1dab84290767_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi00LTEtMS00MTg4OQ_ee636bb3-9d8d-49a8-923e-a7c8e6204371"
      unitRef="usd">18332000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1cf58b0d98384a0e865d446c3a2387f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi02LTEtMS00MTg4OQ_619ef301-3baa-465b-8ad4-e580f45a0c02"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80My9mcmFnOjAxMTliMzJlNmE0ZTQzZDg5NTEzYTM5ZTA0YTczYTQ1L3RhYmxlOjYxN2M3MGExNmZhMzQ4ZjI5NmNlMWI3ZWNiMjljNzg5L3RhYmxlcmFuZ2U6NjE3YzcwYTE2ZmEzNDhmMjk2Y2UxYjdlY2IyOWM3ODlfNi04LTEtMS00MTg4OQ_37ee94e4-1e5a-4118-b677-4023d67cd3cd"
      unitRef="usd">138357000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNjE2Mw_77f92618-239a-4dde-be13-7580a1d07cdb">Debt Obligations&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oxford Term Loans.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In March 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#x201c;Oxford&#x201d;) that provides up to $150&#160;million in borrowing capacity (the &#x201c;Oxford Term Loans&#x201d;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#x2019;s option to 48 months if Lexicon maintains compliance with financial covenants relating to net sales of sotagliflozin following regulatory approval and minimum cash balance requirements following funding of the third tranche. The interest-only period will be followed by an amortization period extending through the maturity date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche was funded on December 30, 2022. The loan and security agreement was amended on May 1, 2023, to increase the amount available for draw under the third tranche from $50 million to $75 million and decrease the amount available for draw under the fourth tranche from $50 million to $25 million.  The third tranche is available for draw at Lexicon&#x2019;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. An unused fee will be due in the event Lexicon does not draw the full amount available under the third tranche. The fourth tranche is available for draw at Lexicon&#x2019;s option, subject to Oxford&#x2019;s consent, at any time prior to the expiration of the interest-only period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#x2019;s common stock at an exercise price of $2.08 per share. Concurrent with the funding of the second tranche, Lexicon granted Oxford a warrant to purchase 224,128 shares of Lexicon&#x2019;s common stock at an exercise price of $1.95 per share. The loan and security agreement provides that, upon funding of the third tranche, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 0.875% of such tranche, as determined by reference to a 10-day average closing price of the shares, and having an exercise price equal to such average closing price. All warrants are exercisable for five years from their respective grant dates and feature a net cashless exercise provision.  The warrants that have been issued in connection with the funding of the first and second tranches are classified as equity instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2023, the interest rate was 12.57%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded once for each tranche as a debt discount on the funding date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the balance of the debt discount was $4.2&#160;million which offsets long-term debt on the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023, the Company recognized interest expense of $1.8&#160;million.  As of  March&#160;31, 2023, the carrying value of the Oxford Term Loans was $48.8&#160;million.  The carrying value of the Oxford Term Loans approximates its fair value, as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics.  The fair value of the Oxford Term Loans is determined under Level 2 in the fair value hierarchy.       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon&#x2019;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenants, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <lxrx:OxfordLoanFacility
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTg4_4520ebdc-567d-478c-a5f5-2ed308a05b85"
      unitRef="usd">150000000</lxrx:OxfordLoanFacility>
    <lxrx:TermLoanA
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIyMTA5_d3b712bf-1e84-4b09-ae22-c999a8ba848e"
      unitRef="usd">25000000</lxrx:TermLoanA>
    <lxrx:TermLoanB
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIyMTU1_e5b58373-0b92-4182-895a-e7bb383ee89b"
      unitRef="usd">25000000</lxrx:TermLoanB>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTg5MA_e0fd7378-1481-4719-8394-3c5f1a3e3198"
      unitRef="shares">420673</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMTk1MA_98b21f0b-4c16-4716-9d88-f5f8d9f6efe9"
      unitRef="usdPerShare">2.08</lxrx:TermLoanAWarrantExercisePrice>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIzMTk0_169896a5-bf22-4221-bba5-86e316045026"
      unitRef="shares">224128</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODIzMjAw_78b2f383-0eaf-4a4d-a95b-d77b7fd41455"
      unitRef="usdPerShare">1.95</lxrx:TermLoanAWarrantExercisePrice>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjQ0OA_b48685c7-80fb-40be-99b1-5d7cb4d9f0af"
      unitRef="number">0.0790</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjQ3MA_9a780f29-161f-4c54-8aee-00c282fa9ed9"
      unitRef="number">0.0801</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMjU4Nw_64f5963a-734a-4a04-83fb-9cb304c61711"
      unitRef="number">0.1257</us-gaap:SubordinatedBorrowingInterestRate>
    <lxrx:FinalPaymentWithNoExtention
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzAwOA_9941466c-dc05-483f-ab7e-5e3ecf968f4b"
      unitRef="rate">0.06</lxrx:FinalPaymentWithNoExtention>
    <lxrx:FinalPaymentWithExtention
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzEzNg_d6e001b9-5c63-462f-95a7-1a7bd4f43d2c"
      unitRef="rate">0.07</lxrx:FinalPaymentWithExtention>
    <lxrx:TermLoanAFinalPayment
      contextRef="i5e92df6f278d4c19a869b984471be038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfMzI0Mw_225497c8-79ab-4104-aadd-b1aa31ebb7fc"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <lxrx:TermLoanADebtDiscount
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNTQ5NzU1ODI0NDg5_9936ac2e-7f8d-4d41-aa57-f6148bacfe15"
      unitRef="usd">4200000</lxrx:TermLoanADebtDiscount>
    <lxrx:TermLoanAInterestExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNDI3Mg_6db69083-1c3c-4d29-b676-9880e8e07e50"
      unitRef="usd">1800000</lxrx:TermLoanAInterestExpense>
    <us-gaap:LongTermDebt
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80Ni9mcmFnOjJkYjM5NDFjMGE3ODQ4YjI4OWFmMmI2ZThlNTFjNzNjL3RleHRyZWdpb246MmRiMzk0MWMwYTc4NDhiMjg5YWYyYjZlOGU1MWM3M2NfNDMzNg_14b5dcfd-9719-4dcd-bcae-d6ba7d27bc10"
      unitRef="usd">48800000</us-gaap:LongTermDebt>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTQ4_c9048f55-792b-4c7a-9d1e-ad81b159df7e"
      unitRef="usd">6400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE2ODU2_2ac6d2a7-e971-4573-aef2-b13d25916c86"
      unitRef="usd">6800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTY0_ecf2003a-e697-43b4-8181-00a58d500b3b"
      unitRef="usd">1300000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTU2_9f793bc6-211c-4523-a062-afed343133d9"
      unitRef="usd">5500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTcx_d72456c3-b4d2-49ed-93f0-e74f6463a5ef"
      unitRef="usd">1300000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE3OTgy_94d87a89-9974-4458-b824-1387dd500b77"
      unitRef="usd">5400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseExpense
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQy_f14312df-1398-4ddd-b46e-188181f911f1"
      unitRef="usd">0.4</us-gaap:OperatingLeaseExpense>
    <us-gaap:PaymentsForRent
      contextRef="i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQz_3f87d2e1-2620-4d62-a280-8adb98b748aa"
      unitRef="usd">0.1</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="ib79166a07a8341019133d1767451366c_D20220101-20220331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQ4_9c21080c-6970-4573-9144-6bbb4bdaa792"
      unitRef="usd">0.3</us-gaap:PaymentsForRent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODQ5_be219bff-b7b3-46f8-b107-88c4bb22c1c4">P9Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUw_1d289d73-93ad-4d9b-b6f9-eff24149113d">P9Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUx_14df1f81-7ce0-46af-a962-f4a54b23d3af"
      unitRef="rate">9.6</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i9c9c6b799b4f4f8da4f5eb4ef21bbc00_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RleHRyZWdpb246ZDAwNWQ3ZmVjYTg0NGM1ZGE1ZTJhYTBmMmZkZjJkMmFfNTQ5NzU1ODE4ODUy_1943b5b3-cfb0-412d-a9f5-8a34d08955d8"
      unitRef="rate">9.6</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMi0xLTEtMS00MTg4OQ_9dcd34c1-4f0d-49a0-b9fb-857dac07903e"
      unitRef="usd">673000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMy0xLTEtMS00MTg4OQ_8f99de18-ca74-4918-81a7-e58ca95981af"
      unitRef="usd">1378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNC0xLTEtMS00MTg4OQ_4027a258-862c-4c03-b784-db23822c95f7"
      unitRef="usd">1220000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNS0xLTEtMS00MTg4OQ_6a644e8e-69db-4789-91f5-96d2d528deca"
      unitRef="usd">865000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNi0xLTEtMS00MTg4OQ_c49f2192-0091-4a63-b153-e9ad202f9ae9"
      unitRef="usd">881000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfNy0xLTEtMS00MTg4OQ_4c1eca02-fec5-4c61-b498-d582dd07f40e"
      unitRef="usd">5644000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfOC0xLTEtMS00MTg4OQ_11fc30f8-f381-413f-8f99-14777f753126"
      unitRef="usd">10661000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfOS0xLTEtMS00MTg4OQ_7b700c5d-b7f8-4706-bd6a-feb9e67a0674"
      unitRef="usd">3916000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTAtMS0xLTEtNDE4ODk_0207894d-9755-48a7-b709-bd2df028bc10"
      unitRef="usd">6745000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTEtMS0xLTEtNDE4ODk_c18d4b04-f7da-4aac-898a-2eb378fbe0b6"
      unitRef="usd">1291000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="icfbb05ea60fe4f339b459eb0a28c3454_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhMTk5MzBlOWY3NjRjOGJhYTkxYmEwYjYyOTVjNmZlL3NlYzoxYTE5OTMwZTlmNzY0YzhiYWE5MWJhMGI2Mjk1YzZmZV80OS9mcmFnOmQwMDVkN2ZlY2E4NDRjNWRhNWUyYWEwZjJmZGYyZDJhL3RhYmxlOmMzMGFjZTE4ZTQ1YjQ5YWY5MTQ0NWE5OTc2NTEyYjQyL3RhYmxlcmFuZ2U6YzMwYWNlMThlNDViNDlhZjkxNDQ1YTk5NzY1MTJiNDJfMTItMS0xLTEtNDE4ODk_d9c4172c-c795-45d8-8342-23517b958a85"
      unitRef="usd">5454000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6D;YI2^X)U3V OR^DE+O;[(/5 ?=D_\ 4$L#!!0    ( %8YI%;+#=V?U 4
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M((T![J^%T$\3T[^T_6KT"U!+ P04    " !6.:16$Q,+]) $  !F$   &
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MIWL8'#%U&]N9'L#K%?]/7"R2.YUYN),)BQTTL7%?39_4&0^*8?3(8?3*LW^
MS 9&+@28,[Z'(C>'<"OD=Y7J.MIYB?4UO9,&XV$1_A^L)MVC7SB^S$)70_O!
MGB04#VOH^933NV>GMCT;AIUF8K$C_KAUUJM@NJV)K6#EQ@RR$NIVQU4UU#1O
MFV'YDQD1+][?Z2':3(*G,-4$#B/+)N,2Y6P-(;V;"2Q<60VUU8,26S,7/@D%
M4Z:Y31E-6*D-X/>U$.KXH#_0_&LA^A=02P,$%     @ 5CFD5B$^G.F[ @
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M9>7C0G#8RS@!^/]<*;M^<1_8W-=/_P=02P,$%     @ 5CFD5KZ--=L0!P
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M0K;)H-_^S(KB'4 >*B1F>U91Y:^06A.6/X<D(H<D(C6A=8+P8Y1$Z9)>O&5
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M<EM&;DJ]V:Q_41>CZXM+_C][.DLS21T P3YA6R!0+,E>YJ.+^96Z'%U=G N
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MBI%L-*"+P(P3KL/K@Z&-]:&4))+([M*:DABDH"I@*U5;<TS*?A214_:%]#C
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MB<R4X\C?(']D:A24.7C:,(50."AR>)"6IB^S?BOS-N&4GP?=.>IZ</-F_P[
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M!;V54!H%FE\+H?<#XZ!_?2W^ 5!+ P04    " !6.:16\'Q%04L%  !F#0
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M(7*\&T..Y0=N^>)$JPW3)(UHM'"N.FTD)TI*RHW5>"I0SRX^<J'9-RYK8)?
M3:T!(V[-R=@B.(F,TQ;HO &*G@&*V:4J;6[8;V4&V:[^&$GUS**.V7GT(N E
MUR,6ASZ+@BA^ 2_N/8T=7OQKGK*_SA)C-5;'W_N<;C G^S&I8XY,Q5,X]; E
M#.@U>(LWK\)9</P"XTG/>/(2^H"Q/Z3,/I=5;8W//@B32D7;^YC_+/9N-&YS
M8!>JJ'BY9;4!P]9<"U4;)IQ1_(<U;T%C*8IRQ2R*+PEJ[:#4D@DGM 9C&T!>
M9JQH+!@2-\"X,8 GU)/8UVFM-4%A;PDS8F?-(:E)P1,AA16HB7)*8V$Q;H<&
MD0Y12!4676GP&%=&29%QBQ\)E[Q,@;GV0$R-DGBP4EK\H..M4Y:P!DG45?(/
MS8JUL%OBJ%+A4#;"YDZP#4%-=JSJO*(CY/- :N2"N%02!QXYYO ;ZYE /ZS<
MHCO282,,(?-"U9A8Y&#JGR.!BKU%[N8;*N^$]U$$C]B;5P=1-#MF7YR_(7O/
M[FM%V)46*;C4-C,2YXN^(PB<^4Q@8*U(N1QFU6>;7*0Y;J6RSH!]'=V,F-4N
M(%MF**=-VG9M1FA3(4F\%,2J%$N$):\3:AR>R-ZYMPTN!6^7(A$RHA"2ZUTZ
M#6/,OM8J4=J%3+1M C8=O7O$V)!HY02QGA/[/.<8.0_9UN53OK</>4&"!=A<
M94JJU;:I%6)->2)_!G:H($IE60GHFL$VP[K@)0)E:&F04I9JR(1E6IB[)R71
M1(&072LHS/^#B<>5:!WI2JNUR)IN'/92,9P#:)I7E40FI-)-A+:T;(Y=2/1;
ME<==N:^SL;:H@QT-]=ATVR)XF^*80K1$K:F.B05> YBV[AYP5?T! U8D6$7M
M;K0S-;X,I@;2&@RZO8!=-W05VF7]5EFL^;=-5&N#R.9=9^:"F]S92FD!][5
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M'J6H;*OF<'*XV)KL&.1O="DUTGN=:VIFGF"A[,&,$%S-S3D:\FP^@AW2=03
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M^>E(N'@]'!^"7?.5[-(&)!S_Q $5%4,+\#VW-K0/I*"[H[_^+U!+ P04
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M1%84"8],6[A+M 8P51_#IN<%FYX?!8WW IQ?BT!?)^R]J1Q8%IEZK=YG:!Y
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M2D'Q^G)H='2>0=$[&'M:-!V-%Z)E86VMZ(K8),$[ <]KI#0>AFJW.(^E-@T
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MSF^[(T?H*)7NJ>$BN9#<G9QY,42:=G*U3VV2"TFQZFZ84RNDE%/<?@BJMNE
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M!DJS@.8W0NC#P"3H/EEF?P%02P,$%     @ 5CFD5N<OV.?Q @  4 <  !D
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M*N=@]V=2FK7B$C2/Z.@/4$L#!!0    ( %8YI%;IG3:IB ,  &(.   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;,V7;6_B.!" _XJ5DTYW4DO>*"]=
M0 +:ZE:ZWJ)RU_NPN@\F&<!J8F=M ^7?W]A)4V!=6'578K^ [<R,9QY/)I[>
M1L@GM030Y#G/N.I[2ZV+:]]7R1)RJAJB (Y/YD+F5.-4+GQ52*"I5<HS/PJ"
MEI]3QKU!SZY-Y* G5CIC'":2J%6>4[D=028V?2_T7A8>V&*IS8(_Z!5T 5/0
M_Q03B3._MI*R'+AB@A,)\[XW#*_'H56P$H\,-FIG3$PH,R&>S.1CVO<"XQ%D
MD&AC@N+?&L:09<82^O&E,NK5>QK%W?&+]3L;/ 8SHPK&(ON7I7K9]SH>26%.
M5YE^$)L_H KHRMA+1*;L+]E4LH%'DI72(J^4T8.<\?*?/E<@=A30CELAJA2B
M0X7F&PIQI1#;0$O/;%@W5--!3XH-D48:K9F!96.U,1K&S3%.M<2G#/7T8%H>
M'Q%S,F4+SN8LH5R389*(%=>,+\A$9"QAH,A4B^3ITC!+R5CDF$B*VJ-XI-FJ
M'/UV YJR3/U.+LGMEQ736_*IL$\^WT,^ _E?S]?HM=G;3RH/1Z6'T1L>QN1>
M<+U4Y):GD.[K^QAM'7+T$O(H.FKPGLH&B<,+$@51[/!G_.WJT1%WXOH$8FLO
M?NL$EE2""^M02LH7@.^,)K,MV96;T*U='FZH3,GG/]$D^:@A5TZ^Y?Y-]_ZF
M3ERK@B;0][ 0*)!K\ :__A*V@@\N.#_(V!ZJ9HVJ><SZ]Z.Z('>429NP0(8*
M:Y?-3G5!;I\++"R0/HH,36:8N0]4 Z[G12:V ,H%MO2V:[TU]7(]"!LAYL1Z
M%YA+*&C60GL@KFH05^<"\<#4$[F3@ G%-> 9:K)/P@6B]#8,=H(,,,CP (5;
M+.RX8;1J&*US9P7Y&V1^(AF..]DD6Z#2I3A^A^(>IW;-J7UV3C=LS5+@*?F&
MMZ?]U8L1'.3+,8D]!)T:0>?L"%XK2 7ATQP_JB 5H<CE+\$OH:*"M"3J"&=:
MC#I?!]_H=@X(.85"-Z1N#:G[TQ67=S+J.@M*W#V@Y!8+NVY.8?!Z=PK.GDYE
MY7DGGQ/^M]XN2B<TVR>K4KAS PW/3O&@+KT79WBR9!T5*0'Y.[?U'.3"-C&*
MV MW>8NM5^M&:6C;@X/UD6F@;!?P:J;LOO".NF!<D0SF:#)HM/'+*\N&IIQH
M4=B>8"8T=AAVN,0F$*01P.=S(?3+Q&Q0MY6#_P%02P,$%     @ 5CFD5G!]
MCY("!0  N!T  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULQ9E;;^(X
M%,>_BI5=K6:D#HE-N'4!J;>9K;3MH++M/(SVP20&K$EBQG:@_?;KF)"$),W2
M0#HOD(O/R3D_']M_R\,-XS_$DA )GGTO$"-C*>7JW#2%LR0^%BVV(H%Z,V?<
MQU+=\H4I5IQ@5QOYGHDLJVOZF ;&>*B?3?AXR$+IT8!,.!"A[V/^<DD\MAD9
MT-@]>*"+I8P>F./A"B_(E,C'U82K.S/QXE*?!(*R ' R'QD7\/P*V9&!;O%$
MR49DKD&4RHRQ']'-K3LRK"@BXA%'1BZP^EN3*^)YD2<5Q\_8J9%\,S+,7N^\
M?];)JV1F6) KYGVCKER.C+X!7#+'H2<?V.8O$B?4B?PYS!/Z%VSBMI8!G%!(
MYL?&*@*?!MM__!R#R!@H/^4&*#9 >0/[%8-V;-#6B6XCTVE=8XG'0\XV@$>M
ME;?H0K/1UBH;&D3=.)5<O:7*3HZGV^X#; ZF=!'0.75P(,&%X[ PD#18@ GS
MJ$.) %/)G!^?(F8NN&*^*B2!=5?L?'RX)A)33P#X$7P"OP,3B"7FRC+^HP'X
M9\E"@0-7#$VIHH]B,)TXTLMMI.B52-O@C@5R*<!-X!)WW]Y462>IHUWJEZC2
MX1WF+="&9P!9J%T2SU6U^35Q$G-4$4X[Z8FV]F>_UA,1I!CO!+^HH:*Z@7,<
M+$AT?0:^KC3M[W?$GQ'^;QG!RB]$,\*Y6&&'C PUY 7A:V*,__@-=JT_R](_
MD;,]&'8"P];>VP? V*NU#!$P>P&ET#:8N^#[W\HEN)7$%Z6H[%.B.I&S/52=
M!%7GX+JIA6I764)=A%)(-3S5N#\#]V%49V7LM@%U=$#1.K$>PQY$O:&YSD(I
M:87:]B!IM9=M-\FV^VNR_:8G?-7Z8DVX6L# S3/A#A4$3#AU2!F&;:2]3()V
M"W5R%(J-.BU8SJ"7,.B]&X,ORD+JJ7E".&7JU;W2#FHU4(ODG% 9JH(MR[U7
MZ-R.U<M70&4:-8=%/X'4/QJ2J$^I1KGT"Y6 6G8[AZPRJ9K(!@FRP;O5U<WS
MBG)MG<%61F50,DL,<E JPZX)!5JI0K+>KY)*N=0JISCJ;#U!N]7/%U1U<G7A
M9>0E?+>:RDQ)U345Q[2_0%EY,)6!UP6#4C#H_:JJE$R]JD*%JFJWNOE%K3JW
MNNQ2I0P/E\K'3U0:"9YYI$KRQ!%E2ZK;+RQXU7'7Y9**9E@I-)OC4J>0[$(A
M=5LHSZL)X0Q3Y0RKI?,#$5+%'R6F-[?@,:!JT'UXF#Z*CY4;K6K';]T^G,K;
M/H944L/N+]YLP4I1_V9<)_*VCRM5W[!Q^7WS,Z3R!=P&JO["[4S_52X)!W*)
M@W0,WK-@K4J4N)4S4XD4MP>%U:[8"O7L?OE&!*8B&QZOLD_.HC ;:7D.KK$D
MX#.F'#QA+RR?E,HT>'$6+[9JMWJOL4K5-6Q<7A_(*K]=*451%-ZV511)34AO
ME$IO=+ST;@;9,56&BLJ\9*=7G7I=M*DP1XT+\P/1/NEA6UV-J$2Q(]C-(VM"
MLJ-4LJ/C)7LSR(ZJQC)%/\@KL>K4ZZ)-%3UJ7-$?B#;>*OUO01;U/H0%:$W(
M?93*?=2XW'\;M&A_>50I%O<$J#6P\U1/NBDP,V=C/N$+?60H@#[>VAZ3)4^3
M8\D+?1AGILVW9YIWF"]H((!'YLK4:O54=?#M,>'V1K*5/FF;,2F9KR^7!+N$
M1PW4^SEC<G<3?2 YK!W_!U!+ P04    " !6.:16'10W_\L"   /"   &0
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M+/GNQ:K=@63KXMVD.R8E2XN/*TJ6E.<&ZO=[QN2O@_QUI^KUMNG_4$L#!!0
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M88$$FHX9W0.F6DLUM9/"3*-E^211]_U9,'F5R#@Q7>"5 %]6$5DC=1\X^+3
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M&XQ"S%0#>?V%4O%^H!(4_[V8_@]02P,$%     @ 5CFD5C-\ES3.!   ?!@
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M_=U:X[N-5\CA.L#V]%"%8#/%*Q&;*;[6@/C7#1A)XM]M+ \PL%W :@?R^_-
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 5CFD5IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !6.:16R&:<).0%  #T'@  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 5CFD5LL-W9_4!0  ;!<  !@
M             ("!* X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( %8YI%9O!\U_-@,  +L*   8              " @3(4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !6.:16$Q,+]) $  !F
M$   &               @(&>%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ 5CFD5B$^G.F[ @  ^@8  !@              ("!9!P
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %8YI%9CRB%"
M. <  +L?   8              " @54?  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !6.:16OHTUVQ '   2+   &
M@('#)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 5CFD
M5B2),MN5$@  J34  !@              ("!"2X  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( %8YI%;'NQJP6P(  &H%   8
M      " @=1   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8YI%8KZLW!C@0  -(+   9              "
M@>AB  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 5CFD
M5L$_WS=G P  O@@  !D              ("!K6<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !6.:16YR_8Y_$"  !0!P  &0
M        @(%+:P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( %8YI%;IG3:IB ,  &(.   9              " @7-N  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 5CFD5G!]CY("!0  N!T
M !D              ("!,G(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !6.:16'10W_\L"   /"   &0              @(%K=P
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %8YI%;L<[+M
MJ 4  .HF   9              " @6UZ  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ 5CFD5@H[2DE: @  N@4  !D
M ("!3(   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !6
M.:16N,%M(@X$  !#%@  &0              @('=@@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %8YI%9 WTV( 04  ,D8   9
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !6.:16K^R3I3@!   ?#P
M&@              @ &:F   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !6.:16_M]0Z&\!   6$   $P              @ $*F@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     (  @ )<(  "JFP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>61</ContextCount>
  <ElementCount>196</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2023 used in 15 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AvailableForSaleSecuritiesCurrent in us-gaap/2023 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AvailableForSaleSecurities in us-gaap/2023 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0540-EntityEmergingGrowthCompany-Missing] Submission type 10-Q should have a non-empty value for EntityEmergingGrowthCompany in the Required Context. lxrx-20230331.htm </Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:NetIncomeLoss with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:NetIncomeLoss fact are Context: i2454d6f3d8624116aded925489ea61b4_D20230101-20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:NetIncomeLoss with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:NetIncomeLoss fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation fact are Context: i2454d6f3d8624116aded925489ea61b4_D20230101-20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax fact are Context: i2454d6f3d8624116aded925489ea61b4_D20230101-20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest with a value of -2061000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest fact are Context: ida35814b016d4540b1321674b0722978_I20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest with a value of -7518000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest fact are Context: i9fd9833fa7e645c68143dcfd76af2e58_I20211231, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest with a value of -2061000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest fact are Context: ia1cfd6d4e8e2473aa197ec5caf0a0e38_I20221231, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued with a value of 6321000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest with a value of -2885000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest fact are Context: i4f5c48a42a0b4346b4984be1e404c5e3_I20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:StockIssuedDuringPeriodValueNewIssues with a value of -864000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:StockIssuedDuringPeriodValueNewIssues fact are Context: ib45dd874240c4c45a886170daf956a22_D20220101-20220331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:TreasuryStockValueAcquiredCostMethod with a value of 824000 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:TreasuryStockValueAcquiredCostMethod fact are Context: i2454d6f3d8624116aded925489ea61b4_D20230101-20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0001-Axis-With-Inappropriate-Members] The fact us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue with a value of 0 is dimensionally qualified with the us-gaap:StatementEquityComponentsAxis and the unallowable member us-gaap:TreasuryStockMember. Base taxonomy member is not allowed by rule.  The properties of this us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue fact are Context: i2454d6f3d8624116aded925489ea61b4_D20230101-20230331, Unit: usd, Rule Element Id: 75. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0005-Context-Dates-After-Period-End-Date] The date of 2022-11-07 used for EntityCommonStockSharesOutstanding with a value of 189561819.000000 is earlier than the reporting period end date 2023-03-31.  The properties of this EntityCommonStockSharesOutstanding fact are Context: i20996cadc68f450b9cdae24983d13cb4_I20221107, Unit: shares, Rule Element Id: 17. lxrx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0048-Required-Calculation-Parent-Element-In-The-Cash-Flow-Statement] The filing should include in the cash flow statement calculation linkbase(s) http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1 - 0000034 - Disclosure - Other Capital Agreements (Details) one of the following elements as the root(first element) of the calculation tree to represent the aggregate change in cash for the period: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect, NetCashProvidedByUsedInContinuingOperations (As long as the element NetCashProvidedByUsedInDiscontinuedOperations is also included the reconciliation between opening and closing cash). The calculation linkbase in the filing has the following root elements defined: CashAndCashEquivalentsPeriodIncreaseDecrease. Rule Element Id: 7482. lxrx-20230331.htm </Log>
    <Log type="Warning">[DQC.US.0057.9728] One of the following elements CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations should appear as the opening and closing balance in the cash flow statement using the group http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited. Instead the following balance items have been used in this statement CashAndCashEquivalentsAtCarryingValue, InitialRecognitionOfRightOfUseAsset, LiabilitiesAssumedByTerSera, TreasuryStockCarryingBasis. Due to the implementaion of ASU-2016-18 at least one of the opening and closing balance items listed must be used in the cash flow statement.  - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 1778, 8107, lxrx-20230331.xsd 234, 264 - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 1778, 8107, lxrx-20230331.xsd 234, 264</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20230331.htm">lxrx-20230331.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>lxrx-20230331.xsd</File>
    <File>lxrx-20230331_cal.xml</File>
    <File>lxrx-20230331_def.xml</File>
    <File>lxrx-20230331_lab.xml</File>
    <File>lxrx-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="372">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>41
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 372,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 61,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 362,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 5
   },
   "keyCustom": 23,
   "keyStandard": 173,
   "memberCustom": 0,
   "memberStandard": 16,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Cash and Cash Equivalents and Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Debt Obligations",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "13",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "menuCat": "Tables",
     "order": "14",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i1890926262c54e02b5417fe2efebfd89_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "menuCat": "Details",
     "order": "17",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i1890926262c54e02b5417fe2efebfd89_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "ic5f8c6317ce54f87acdd96796cc0c74c_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "ic5f8c6317ce54f87acdd96796cc0c74c_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets-Unaudited",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i48f0211b426c48a7928c9fe72bdf5fce_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements (Details 1)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Debt Obligations (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets Parentheticals",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "icfbb05ea60fe4f339b459eb0a28c3454_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i9b4486d192c3418a887c00fdae579410_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i9b4486d192c3418a887c00fdae579410_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230331.htm",
      "contextRef": "i876a9edf5aff4adbba8ecb50783c85c2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 16,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_A2025OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2025 Oxford Principal Payments",
        "label": "2025 Oxford Principal Payments",
        "terseLabel": "2026 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2025OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2026OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2026 Oxford Principal Payments",
        "label": "2026 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2026OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments",
        "label": "2027 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments2"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedInterestOnConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued interest on convertible",
        "label": "accrued interest on convertible",
        "terseLabel": "accrued interest on convertible"
       }
      }
     },
     "localname": "AccruedInterestOnConvertible",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities",
        "label": "accrued liabilities [Axis]",
        "terseLabel": "Accrued Liabilities [Axis]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAxis",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Domain]",
        "terseLabel": "Accrued Liabilities [Domain]"
       }
      }
     },
     "localname": "AccruedLiabilitiesDomain",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities [Table]",
        "label": "accrued liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeRemainingNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange Remaining Notes",
        "label": "Convertible debt exchange Remaining Notes",
        "terseLabel": "Convertible debt exchange Remaining Notes"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeRemainingNotes",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange- September cash portion",
        "label": "Convertible debt exchange- September cash portion",
        "terseLabel": "Convertible debt exchange- September cash portion"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberCashPortion",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - September share payment",
        "label": "Convertible debt exchange - September share payment",
        "terseLabel": "Convertible debt exchange - September share payment"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberSharePayment",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - Total Principal Amount",
        "label": "Convertible debt exchange - Total Principal Amount",
        "terseLabel": "Convertible debt exchange - Total Principal Amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FinalPaymentWithExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with extention",
        "label": "Final Payment % with extention",
        "terseLabel": "Final Payment % with extention"
       }
      }
     },
     "localname": "FinalPaymentWithExtention",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FinalPaymentWithNoExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with no extention",
        "label": "Final Payment % with no extention",
        "terseLabel": "Final Payment % with no extention"
       }
      }
     },
     "localname": "FinalPaymentWithNoExtention",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FutureConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "future convertible debt exchange",
        "label": "future convertible debt exchange",
        "terseLabel": "future convertible debt exchange"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FutureConvertibleDebtExchangeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Convertible debt exchange shares",
        "label": "Future Convertible debt exchange shares",
        "terseLabel": "Future Convertible debt exchange shares"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchangeShares",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_InitialRecognitionOfRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of right of use asset",
        "label": "Initial recognition of right of use asset",
        "terseLabel": "Initial recognition of right of use asset"
       }
      }
     },
     "localname": "InitialRecognitionOfRightOfUseAsset",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LexiconIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon incremental borrowing rate",
        "label": "Lexicon incremental borrowing rate",
        "terseLabel": "Lexicon incremental borrowing rate"
       }
      }
     },
     "localname": "LexiconIncrementalBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LiabilitiesAssumedByTerSera": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities assumed by TerSera",
        "label": "Liabilities assumed by TerSera",
        "terseLabel": "Liabilities assumed by TerSera"
       }
      }
     },
     "localname": "LiabilitiesAssumedByTerSera",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_OxfordAmendmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Amendment Fee",
        "label": "Oxford Amendment Fee",
        "terseLabel": "Oxford Amendment Fee"
       }
      }
     },
     "localname": "OxfordAmendmentFee",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordFacilityFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Facility Fee",
        "label": "Oxford Facility Fee",
        "terseLabel": "Oxford Facility Fee"
       }
      }
     },
     "localname": "OxfordFacilityFee",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordLoanFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Loan Facility",
        "label": "Oxford Loan Facility",
        "terseLabel": "Oxford Loan Facility"
       }
      }
     },
     "localname": "OxfordLoanFacility",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "principal amount of convertible notes",
        "label": "principal amount of convertible notes",
        "terseLabel": "principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from July 2022 Offering",
        "label": "Proceeds from July 2022 Offering",
        "terseLabel": "Proceeds from July 2022 Offering"
       }
      }
     },
     "localname": "ProceedsFromJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from September 2021 ATM Offering",
        "label": "Proceeds from September 2021 ATM Offering",
        "terseLabel": "Proceeds from September 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_SanofiDisputedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Disputed Costs",
        "label": "Sanofi Disputed Costs",
        "terseLabel": "Sanofi Disputed Costs"
       }
      }
     },
     "localname": "SanofiDisputedCosts",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $2,212 and $1,740, respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInJuly2022Offering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in July 2022 Offering",
        "label": "Share Price in July 2022 Offering",
        "terseLabel": "Share Price in July 2022 Offering"
       }
      }
     },
     "localname": "SharePriceInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in September 2021 ATM Offerring",
        "label": "Share Price in September 2021 ATM Offerring",
        "terseLabel": "Share Price in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharePriceInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInJuly2022Offering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in July 2022 Offering",
        "label": "Shares sold in July 2022 Offering",
        "terseLabel": "Shares sold in July 2022 Offering"
       }
      }
     },
     "localname": "SharesSoldInJuly2022Offering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails_1"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in September 2021 ATM Offerring",
        "label": "Shares sold in September 2021 ATM Offerring",
        "terseLabel": "Shares sold in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharesSoldInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "lxrx_TermLoanA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A",
        "label": "Term Loan A",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanA",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanABWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A&amp;B Warrant %",
        "label": "Term Loan A&amp;B Warrant %",
        "terseLabel": "Term Loan A&amp;B Warrant %"
       }
      }
     },
     "localname": "TermLoanABWarrant",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanADebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Discount",
        "label": "Term Loan A Debt Discount",
        "terseLabel": "Term Loan A Debt Discount"
       }
      }
     },
     "localname": "TermLoanADebtDiscount",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanADebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Issuance Costs",
        "label": "Term Loan A Debt Issuance Costs",
        "terseLabel": "Term Loan A Debt Issuance Costs"
       }
      }
     },
     "localname": "TermLoanADebtIssuanceCosts",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Final Payment",
        "label": "Term Loan A Final Payment",
        "terseLabel": "Term Loan A Final Payment"
       }
      }
     },
     "localname": "TermLoanAFinalPayment",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Interest Expense",
        "label": "Term Loan A Interest Expense",
        "terseLabel": "Term Loan A Interest Expense"
       }
      }
     },
     "localname": "TermLoanAInterestExpense",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanANetCashReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Net Cash Receipt",
        "label": "Term Loan A Net Cash Receipt",
        "terseLabel": "Term Loan A Net Cash Receipt"
       }
      }
     },
     "localname": "TermLoanANetCashReceipt",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrant Exercise Price",
        "label": "Term Loan A Warrant Exercise Price",
        "terseLabel": "Term Loan A Warrant Exercise Price"
       }
      }
     },
     "localname": "TermLoanAWarrantExercisePrice",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_TermLoanAWarrantsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrants Number",
        "label": "Term Loan A Warrants Number",
        "terseLabel": "Term Loan A Warrants Number"
       }
      }
     },
     "localname": "TermLoanAWarrantsNumber",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TermLoanB": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B",
        "label": "Term Loan B",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanB",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanC": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C",
        "label": "Term Loan C",
        "terseLabel": "Term Loan C"
       }
      }
     },
     "localname": "TermLoanC",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanCWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C Warrant %",
        "label": "Term Loan C Warrant %",
        "terseLabel": "Term Loan C Warrant %"
       }
      }
     },
     "localname": "TermLoanCWarrant",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanD": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D",
        "label": "Term Loan D",
        "terseLabel": "Term Loan D"
       }
      }
     },
     "localname": "TermLoanD",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanDWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D Warrant %",
        "label": "Term Loan D Warrant %",
        "terseLabel": "Term Loan D Warrant %"
       }
      }
     },
     "localname": "TermLoanDWarrant",
     "nsuri": "http://www.lexpharma.com/20230331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r257",
      "r264",
      "r295",
      "r296",
      "r297",
      "r349",
      "r350",
      "r372",
      "r403",
      "r404",
      "r458",
      "r477",
      "r482",
      "r483",
      "r514",
      "r536",
      "r537",
      "r547",
      "r554",
      "r558",
      "r561",
      "r564",
      "r600",
      "r604",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r257",
      "r264",
      "r295",
      "r296",
      "r297",
      "r349",
      "r350",
      "r372",
      "r403",
      "r404",
      "r458",
      "r477",
      "r482",
      "r483",
      "r514",
      "r536",
      "r537",
      "r547",
      "r554",
      "r558",
      "r561",
      "r564",
      "r600",
      "r604",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r166",
      "r265",
      "r580",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r166",
      "r265",
      "r580",
      "r581",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r119",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r76",
      "r128",
      "r363",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r7",
      "r26",
      "r316",
      "r319",
      "r343",
      "r373",
      "r374",
      "r584",
      "r585",
      "r586",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r71",
      "r560",
      "r647"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r386",
      "r591",
      "r592",
      "r593",
      "r631",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r51",
      "r52",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r8",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r8",
      "r41",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r243",
      "r335",
      "r552",
      "r553",
      "r587"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r5",
      "r39"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r98",
      "r122",
      "r151",
      "r179",
      "r186",
      "r190",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r311",
      "r313",
      "r327",
      "r357",
      "r425",
      "r560",
      "r572",
      "r602",
      "r603",
      "r635"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r116",
      "r130",
      "r151",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r311",
      "r313",
      "r327",
      "r560",
      "r602",
      "r603",
      "r635"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-Sale Securities (Deprecated 2023)",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax (Deprecated 2023)",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax (Deprecated 2023)",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-Sale Securities, Current (Deprecated 2023)",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r197",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Debt Securities, Available-for-Sale, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r32",
      "r118",
      "r540"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r112",
      "r125",
      "r126",
      "r127",
      "r151",
      "r169",
      "r170",
      "r172",
      "r174",
      "r177",
      "r178",
      "r201",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r327",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r413",
      "r434",
      "r452",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r579",
      "r588",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r107",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r66",
      "r359",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r206",
      "r207",
      "r535",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r591",
      "r592",
      "r631",
      "r646",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r70",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r70",
      "r362",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 300,000 shares authorized; 190,430 and 189,214 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r135",
      "r137",
      "r143",
      "r353",
      "r369"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r555",
      "r557",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r78",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r150",
      "r221",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r237",
      "r244",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r91",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r18",
      "r44",
      "r93",
      "r94",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r235",
      "r326",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r17",
      "r62",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument, Interest Rate During Period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r152",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r336",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r44",
      "r45",
      "r61",
      "r62",
      "r64",
      "r67",
      "r92",
      "r94",
      "r152",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r336",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r204",
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r5",
      "r183"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r144",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r167",
      "r169",
      "r172",
      "r173",
      "r174",
      "r175",
      "r322",
      "r323",
      "r354",
      "r370",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per common share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r144",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r172",
      "r173",
      "r174",
      "r175",
      "r322",
      "r323",
      "r354",
      "r370",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r113",
      "r138",
      "r139",
      "r140",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r176",
      "r202",
      "r203",
      "r254",
      "r299",
      "r300",
      "r301",
      "r308",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r343",
      "r373",
      "r374",
      "r375",
      "r386",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r235",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r325",
      "r346",
      "r347",
      "r348",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r235",
      "r258",
      "r263",
      "r325",
      "r346",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r235",
      "r258",
      "r263",
      "r325",
      "r347",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r235",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r325",
      "r348",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r235",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r346",
      "r347",
      "r348",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r340",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r339",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r5",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r120",
      "r205",
      "r352",
      "r548",
      "r560",
      "r598",
      "r599"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r104",
      "r141",
      "r182",
      "r334",
      "r437",
      "r570",
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r145",
      "r147",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r455",
      "r464",
      "r478",
      "r486",
      "r499",
      "r503",
      "r504",
      "r520",
      "r524",
      "r525",
      "r526",
      "r527",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r455",
      "r464",
      "r478",
      "r486",
      "r499",
      "r503",
      "r504",
      "r520",
      "r524",
      "r525",
      "r526",
      "r527",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of Stock and Warrants for Services or Claims"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r151",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r312",
      "r313",
      "r314",
      "r327",
      "r411",
      "r545",
      "r572",
      "r602",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r75",
      "r100",
      "r365",
      "r560",
      "r590",
      "r597",
      "r633"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r117",
      "r151",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r312",
      "r313",
      "r314",
      "r327",
      "r560",
      "r602",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r99",
      "r234",
      "r248",
      "r550",
      "r551",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r11",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "negatedTerseLabel": "Long-term debt, net of deferred issuance costs",
        "terseLabel": "Long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Long-Term Debt, Term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r77",
      "r86",
      "r103",
      "r115",
      "r134",
      "r136",
      "r140",
      "r151",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r171",
      "r179",
      "r185",
      "r189",
      "r191",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r323",
      "r327",
      "r368",
      "r433",
      "r450",
      "r451",
      "r546",
      "r570",
      "r602"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r185",
      "r189",
      "r191",
      "r546"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r129",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r131",
      "r133",
      "r200"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Payments for Rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r69",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r69",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r69",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r69",
      "r413",
      "r431",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r69",
      "r361",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r29",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r356",
      "r367",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $4,096 and $3,984, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.",
        "label": "Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]",
        "terseLabel": "Recognition of Asset and Liability for Lease of Acquiree"
       }
      }
     },
     "localname": "RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r31",
      "r383"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r68",
      "r307",
      "r642"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $1,203 and $1,032, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r72",
      "r95",
      "r364",
      "r376",
      "r378",
      "r384",
      "r414",
      "r560"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r113",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r202",
      "r203",
      "r299",
      "r300",
      "r301",
      "r308",
      "r309",
      "r315",
      "r317",
      "r318",
      "r320",
      "r321",
      "r373",
      "r375",
      "r386",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r255",
      "r256",
      "r351"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r435",
      "r538",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r142",
      "r151",
      "r180",
      "r181",
      "r184",
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r327",
      "r355",
      "r602"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments owned by investment company.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r10",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Secured Long-Term Debt, Noncurrent"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r266",
      "r273",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r101",
      "r102",
      "r583"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "terseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r112",
      "r125",
      "r126",
      "r127",
      "r151",
      "r169",
      "r170",
      "r172",
      "r174",
      "r177",
      "r178",
      "r201",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r327",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r413",
      "r434",
      "r452",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r579",
      "r588",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r23",
      "r113",
      "r138",
      "r139",
      "r140",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r176",
      "r202",
      "r203",
      "r254",
      "r299",
      "r300",
      "r301",
      "r308",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r343",
      "r373",
      "r374",
      "r375",
      "r386",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r176",
      "r351",
      "r379",
      "r397",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r176",
      "r351",
      "r379",
      "r397",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95",
      "r380",
      "r452",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r8",
      "r70",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r69",
      "r70",
      "r95",
      "r386",
      "r452",
      "r529",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "negatedTerseLabel": "Issuance of common stock under Equity Incentive Plans, value",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r50",
      "r69",
      "r70",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r8",
      "r46",
      "r69",
      "r70",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "negatedTerseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r88",
      "r415",
      "r431",
      "r453",
      "r454",
      "r560",
      "r572",
      "r590",
      "r597",
      "r633",
      "r649"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r54",
      "r56",
      "r113",
      "r114",
      "r139",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r202",
      "r203",
      "r254",
      "r299",
      "r300",
      "r301",
      "r308",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r328",
      "r329",
      "r333",
      "r343",
      "r374",
      "r375",
      "r385",
      "r415",
      "r431",
      "r453",
      "r454",
      "r533",
      "r571",
      "r590",
      "r597",
      "r633",
      "r649"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Subordinated Borrowing, Interest Rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCarryingBasis": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost basis for treasury stock acquired for purposes other than retirement.",
        "label": "Treasury Stock, Carrying Basis",
        "terseLabel": "Treasury Stock, Carrying Basis"
       }
      }
     },
     "localname": "TreasuryStockCarryingBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member] (Deprecated 2023)",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares (Deprecated 2023)",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r22",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 868 and 488 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r8",
      "r46",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r543",
      "r555",
      "r557",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r106",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r168",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r167",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480013/805-20-25-28B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4F",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r574": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org//705/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org//820/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>42
<FILENAME>0001062822-23-000024-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-23-000024-xbrl.zip
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MZ^U)N,U8JO3,+H!J8"*MPTK1,4X/@]UH97,-;W9AS):U 7)/ W.#@\/<>"-
M+VR-I[J\(([0:2KQ-D3WFG$#'A\8;QDKH#@R0%#&2MJ,Y$DL1X(DDJ1[(6VB
MM*VP'U&GT2JH*HU.0.!CRUXB+@0@T$+PK^Z2C!<38#\B*]U4"B6B/F]%PY?P
MRG>-AB+<A5M)A601 $KZ&5'7&FX#CLB6O0=*-P9*<2":YWTTHP2E^8_77Y_
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MJY/I$BW-FHVI48$Y88LS6HFP3W75R"FAN%7D@(HI/^2 @C15CM)P6)DNY.S
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M\R6<L5)(S*H"CH2<0> [;R$5TF9?B:H%!8984GA#9)+M[@0MOQ<%==O+JQ3
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MFHG#\AJ"V_.5*:.[T%2H/'[ZV9GYU?+V+KUR_6%>55/CD_)K=Z?1[BG[?VN
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M2]F&U7#_%FAMD>%UN7)LNI4?Z3APY;_P"L;WNVGS9\:OKL,7&#B$P%*!'Z#
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M(CMU^E;*,)V4/CT,9N[+'J8-&4.XWMJ"Z>4BV%-!E9LA@YNU6/-VH;2FW1Z
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M952?$4@L-T?,:B 1NEA<ZI4P-PF8&R^':ZWV#)@,2GLF@,?H@#0'J*,$!TH
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MC0[T,H";^@'/*J=QUP7.^!R<8<><EC@!$=, 9YIXI)4.*,'FMX1+YEFHR\F
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M!ZN)-#P!FL:(>"[(;YWTR$E*0[3&2BMJ-"U(6I"T(.ERD90';%+$@=C$@PK
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M)9_CGT1M:G(;RK*B =!UH"Q[=C#LU7ZY97"6IVV$/2AEZ75!"$+_CU[WY"_
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MV]C^?_\?30G];85"0T6HURD(?!6A+A[*VTGV/)FQ7"O#& 4+)$:46S@BH[!
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ML[%?6Y_'< EPRW8%;Q!&1\$;^*DQM]NK@.\!@  XC%T.-6:!?=BJ[<-^]J8
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MQV?C7WX#F^6T;<^>59WZR?67?COOY\FY)W-96K7$-1^/TE*,V1*29,_EZ(C
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MJKS(W=,LT@YP)F!89:YBP 8#NBSFV!5EO\K*_AYLC;%W\]UY2V.VB'*JOL6
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M[9ZC >>8D=)<@+A)8C@J9.D 7G2.3H.2<W\39X7(,'_L>,A% G-F^?P1"RH
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MBWO*Q2"A]\S GE: '#D #UGMDI_HPL]]"7;DF&@8Z-KR%!JC4)*X8KLA@[G
M_P70]7"<)L0PQ$0Q<0^^/,S..?P;)B@4-;30,V7$)TH!=$BF:I%-V%F:Q&GV
MB[8D3<7&YOQL"H]D.?#H&/D,AD/.!:4D&4Z'(MHW8"F]-L>PW]+^K<>(IR-T
M;9?^A\D@@5.1&]Y'-\/B=M(6P2+2%#='# 2;$\QP1]DPRR?)+X'\\JMB_X3G
M(<^F9P-ZD3A$( KT?O05Y3K=>#?"X%KO4ISDQ>3^00W9!KGFH,.R5N7H]&_[
M^-=G_>3PW>SH],#^'IF!JQM!K.K<LU0KT'R5<<-00]^' P EU/) T5D99EK"
MFN0+Y8(5Q#@"%% 3!?(6W )2,P,6W(0B;GNE.4<1?W04<3U%?-:_<RQK8;JF
MJ@6^H5JZ9ZB>;S.5NT%@>B;GGA_<C"+@MW5/!:UR#<.7KE2M8  XS7*$(Y ]
MTN'<0WF0C$(P10LN_,;#; J/U((279U1SBX4G$&^#.1*G&=#Y5^VIE3S!DW,
MM:L?<5) (IN] F4SB+(KWV%4[Q!.ZX5Y)47;*U8+VC%(%'+[_C4%;5;N+NQ0
M,!7**8A'1P.1,B.Y^;G_J=\J)%MD:JX,.,LGZ#%.P:SL*P?(L^1ZCSFOY!TJ
M$%0I&_2"<SRW4M1'&0@6O%^@%=#V3.&1I7U<<4*"0!9V=,/=Z:%>_X.'$]R@
M6A6G;\"WT='?PZ?Q\F,"@K#>35K.Y3C)A>"6ND";X+_VGF /Y?3K; 3LEE<&
MC#B<.;5'B'&Y[[79= :_F  %2&65 9?F^"O<L_$4-$]DEY5(7PQ Y2RV(OZU
M=NG_14RG $L<T&8]Y->>&/*#76,?'7SG6ARYINNINN7I8-GHONJ9OJ6:H1WK
MS.2F[GO/7EF&UG-<<PGT%7&62"Z+O >:/2C^0--9^%-P%[ 2S\.D( 8+R>B^
M4AWXP/-/./Q6*,6XDE+>R)E]P(D]89+XJ0-)^%Y@Z+$6J+"[#I*$@U'SGAK;
MH(3YL<-C[H,*T->\97H -!0TT5?6@!>I%-X'OMQ,F>SP91N:Y2]8E_9==WS/
M=YBM!C%8&!9LMAH$\*/G ,@XFF5KA@-D95@]W6BAK!T@S<UHID.:#8GCQ\'%
M=Q<P)P;[0M4XBU6+69'*?#M0(]<-W#BR=,M&!UO?7S8\FIASG351.5W1!=M3
MIF,@A*L\/34DD:)+N'0U*M5DB@[E.=(<L'-RL,G "_X/!KG LUK?<^U_D_(]
M#0?UJ\'RB3A6LP/-C1Q).09W<(J 08^TKJF@T8,JS'-VQDMSNR9Y0EB:3H_V
MHWS_$GM4,Z'WMXX'>C^L7RY8^ SE()42'B?G7)F!L5 (DP=>G^0PYV(,JC=^
M)G8/_5HBOS[FZ.L"FXJ\>NB42WE1-"<'AU74)E+U=O*?4[Q2@#$]25%,R4^/
MW#OB@KVOUF@E>32$CUA3F+*B2.($'1@%%028H-^TF.13<A"N5O/W1*?'?5IR
M(<,VL;PR6P@B%3#PA%,UQRBKB@)PBTQ!5V0E'F*CV5QY_^Z/DX_*.)T6J\7N
M2 K#+2AK[X[?MMUNOJL.XIU<RT>8_*<)_($0CC?N0+@5J*K&$T/5HQ]_:R<'
MWP/+<SP[=%5/BT&)TP*N@@C353MRP\ "#4YC\;-7;M]?OJWXMW 9H+U.O B<
M-MK5B;_/1F=(PWCR]>G^ :0,9/L64[F:5/"D3]U$K9VY<-Z&K^J.#A(TM"W5
M8YRKFA8:GA%C= %H[5Y?T]M.O>$AP9A^_#4 0@4924QB@SP[%",8LVD*_PQ!
MPLIB*45YFTXN7^5@59QH;\Z'(N 'G7R;4=F-XB6N)+=/4TQU2$8()G^4=W0=
MA0D*^VP=7WQW0/WU'9.IKFDQT-$TH# 3$,8/ U.S0D=W=<RA-OHMV2G_[BOO
M-J.A7BG'\+H13BY%^<PJUR&0UW2"\< DW&OOX57:'Q!W *0W'/(H@0--9^2V
MQ"^/V0SUF'[CAG*&0<#P>QIU6:2"MG$QR$#U 6F*FIYTQ#;<B.@J+0<9RD6O
M&*MH\E_CB9CS@G0K$2,P&<!*I(I%L5>+"@Y= Y=>4OFZE((O@"'I;C4M[WU!
MS4KH!;7L7\F!.5'_'/^%<1!H-F>.%G,K-DTPD6R?!QHSO-"T;(M0_BJV(^,(
M8R72#V)"7T!A.\[>X*4HOOT)<]NO@PN0XKX/1H_CA&H48F5>X#25!2Y7;6[R
M,/8=+[:"9Z^<94XK#UZZV.7M2\TAK?2'C$#64)->\^HVNKSZGR>ATOG/HA_3
M OTU>T%$'0D!";WY=7SV/7*XINF!K]JA8ZJ68\2J;S-7U9D;1%9LF9$1@B*X
M-@DA?5#40K'Z-D22AKP5$8;;"N"YSBMSIP$"3:KIKH;;B>B==G3QW3!LRW=#
M3W5]!M:$#E*?@8JH!CICILZ#P(U#],Q<=R.,.AZF^N3B)C<43H,YB857O2+_
M)$J*D$@O&\W). J*V=0&?Q@Y6=<HS&6XDN2Z^5W"O=V$E6X&O*M8J0P\QJET
MK'2-NU,[/CRS0;B;#@L-KKHQEB.*+!V8RG;5V-$M+V!AS'5L(M)?58NH8BJ2
MRED<4ZI>"A:S:'\ADK@$[Z"7"R";1W39C?G;:.)4!%4,.)_TE<,Z"4ZHF3)J
M3T1>K"3+,HNPD<17F7;\<HSOW13G;VG:K;BR*2VY-V)2'9VVTNGA._/H[+L3
M!8ZO>::JA]@I,#)\+$3@J+[G:=SCFLMM#2%_^99FCCHK+\!J\@E9GL^0[H1+
M?*6%=-\ U^:#ZDBFG62.4-74K<".PCA2?8P@L*(0%(20<35R N9&AAN$.I",
MY:U!,Z<;T 5%+EW" >"= IKA=6(KW9]4!G";"YQ<3W27,#<,6$ 87(1O'[+\
M)Q<^*F&'-ZX"Q U#D<#$8>1PP' ](/J+21(6I>);I]E>9?PW;GF$F59F)LN(
MJL8P@X3GR$PS> /]MZ36/"2=9RE>JTZFN=)@15<0^7=D@+6\U4D3/JK]/K7S
M<D1^H]*FD6GM\9S\(O?30@;(]=>)B#DBC)WG^ \E!#L8MB5'@2ASR.5R< 1Y
M@970A5P,<QY2 B)]-N)GXH<Z[AU_3>ZRHNDO UI-DY!NW<#<;B:R+,__W:CR
MYI:7.RT!]KVFR[=^?3(*TVF$')(5&"8/E)^$=&6$U1-D2B3FD\-)880F%=0>
ML-$97J]F-)M@6L"9%_"E(<_/, \?>(B%_TR3ZFDDP@#T$?$U/@JGPP#- =PC
M> ^\,YA67ZU*$_5$:K] $,F*N*-I4MTN%@U_+NE#XCC+ T>)0C>&\_D'.&M2
MGAK'L$HQWR0S?JNFR:JGULSJ])\MP<5])U(ZMTJD;/X)YSE,)L.J:/MK.H$S
M("3@@*LW5N3IHNLJB6?;1D!O+0!<*-JT.YC>-+MOS'-Q??R>0J/GLB!WE^;W
MHDD9R\' Y9Q3G',-<& ^810$3#BD(&:$B2]9%H%]% '2G/)+)FCKCSR)SO@%
M($K>HRG_!9#&A? @7RC%"M,8!],SH"N$"9L^_HL!*H!8,#33ZC6"(E(0Y$_,
MGT'[T5XI1A@%5#1,S6)U6E3B&I6OR6#AK.0Y#A@&XS0<)+NP%"J.((;XB$LX
MB3\7_ #G_S!,AY-/TG08_GUQ=/@_/X^-;^E7XPVH_Q]_''_Y.#C^\GD&SUY\
M^_'7\-N?7V??#O\:+)H.WPX/+HZ__&U^&_[/CZ^G9]KQGT?ZMS_?Z-].<9Y_
M@.GQ[2<\__-H^+;A%0'SY/1OZWOH:Y87V[;J^@9&G[I,]2.=JRSR]$"W_2AV
M.<H.ZQJO"+OG1*..!K9! \;)X6?CN\%")S*8JW*P)%7+=DV5P4&H@6Y&ANWK
M3N@Y2 /7V)'S&%M>7R45Z%.XV()$F ,>50)/LHD3[;6,=T8"K)UQ:Y7/ZLVE
MN9+=*M"-:EG= Z+92P$1V$V7_&<XD5K/.A@^'$?O;B'MJ_:=A[&A:293N>.[
MJF4&ENKIGJYJ&K.]R-:TP S0E;:<6K$,:5V%FV:%&V-UA9O=%*O9S3[L AF:
M7E%J2#]&PX%@HF$(= AQ/4* P ,[W3>#T%$-70]!X!D@\#3' 'KED6F9NFEB
MW)Y]W?UJN\!C9(W4$H^%88ZQTG,B:4Y8+<K$YC<WD(6+-HZRMFQ<91EL2SS>
M4-GKQ./6B3^\_!ZYAF4[H:D&5F2HEL\CU3=C3>6N%3N68S*;Q^N*QUT008>$
MVR*&L]EWWXH\EWF^ZONNI5J6[:F!9UBJ;GIN1+J2ZR(27F/^[3L2RIMVBGRI
M<H[6N7&G^=5NDM*3G8@TRTA.<S>W[DN<,6\+KW?K_E3)WSHY_'OV/=9!VAM1
M#/3N>UBR+@)4=+BJ>V@QQ+ZNQ_JS5UH+^5>E)!ZG)W'CT)05C#)D$1>UGZK:
M5^A67.;N';..C$HLWF;YQ^NC$Y\RT_SZ;L8@&PP..^L8&C -*LZ&IV$WHL#W
M M?R&$.F64YZ46ZJ.X#:H#L.TT!4F18<JH\JNNXZKF7KIN.$=-Q&>=Q+ :G=
M<=_XN*WO?FCHFJ>%JN.[FO .^KIEJ4X0!%80,>;Z!AYW2Z6*5NV@OSI/Z=IK
M"H%9H+&6";,YQ[IVM<* 6H0T4*XJ_;J)53Y/.;+4)$G8+W(V!V(R'\NYT(>H
MHNISA 58'+Z(ICDFDSQMHK*_!]S0_2".U< -,$P^!KU3UUS5\T(K" PCU$/K
MV2N_%KQE@=<R%0=]<U<<\";&1G? VS[@SQ??]<CP_ BQPF08;>L':N#$OLKC
MV+!T"S0K,\(#MML/>,F@P$"1)>ZO@K%%M!B RMVGPFQ",&6$-J8RRG3:3M2L
M))K+[[H5Q7KLZ:H;<A U#HM5YH-Z 2J>;06&&9F81>WWVS*P&HBPUNG?S!W1
MG?Y=G?[LN^Y;9F"#. #&A-,'NPQ./[9!KS2M2/-\VXZ\%:>_H&$\3IM,5.4K
MB^52TR3* 1B%2<I%W"VF[ BB0_\(FETQ?+V*O%SE7IF5#MXJ66CQ<S9IT]=>
M;'FC&[TG[/D&FN+>JZV*G]B'ZG*-.N>%6$%C7/ 7Y3]>ELVGDA'M*SWT<KY,
M(+YQH6L>O4Y\+&^G?*/OF0Y>4,G&8?+%\NZJ3W=7"XT Q6>>UG=,8^7'8"ZM
M_.RJ876WKSO>6L/>:;^S:P9?;H88AIPW&K;NM&FJOU9GT/9NCUM:K"3PG2QW
M*5Z4EOL;.5RS:8$A>;_/+7OCPU[HSOL0.N0BOFW:V?,)] %^G)U\;YT57UU.
M\:+@?-X1_[Z4HJ77Z7#*C^'5IQ<\/>?4*:#8FSZ^-]0"11_?X=&OHS_?_OAV
M^L;Z=OJW_O7'WYB_9!^=_JT=?\$YA,;QZ9L9_'ZVV,?WZZ^CBZ]?CM,CS)$Z
M_)_D^# =?/OQ\_+X$,:!]<*\]:/3O^#W?\5'B7:YT,?7C\+(M$)=M6(-S$V?
M:6K@QX'JV6[$0LWU-1/#&%O*J=ZLA^\]=.'=;Y&Y/HI:*R6FL=E:6Q&U@YU-
M8.<K9_GI1?8P6HH_""B:+4&1%_M^Q'5/#1E>J?OP+T_'X%K;"YEO^_ #QE?T
M3'=5/.W:8-0."/<#1@]3I;-O!$;KJG<=&&T,1GBYW,'1MN#H^/42'%F:X3+#
M!A!RC%"U0LU4 ]>SU"@P3,\P0M^.780CPUC52*O3C>X,CIQ.-]HK.'J;3?,.
M<#8!G$]+@.,PQ[*XQU7'CP+LV^>KOA[;JN]$1F0;'AP6>_;*<U8%5W?:SYW!
MC=MI/_L%-\DY[^!F$[A9]OR$EA\;NF^HFN;KJL4<T&]TVU2YSR(XLMAGV#G%
M\Y:CT3KMYBYY[W3 <TX)8)V.LS>@<X#G42-/9W9M"9:6O4!6J(.>HQEJS$-;
MQ4K=:F#YGAK9GA%%FAM;&G_VRNZ!KO3X]"#!J$;?L/<=I#*LH#07-;$R1N(V
MNI.,2\# !MP>2EM1RN5U&+=5C.M@;5NP=K+L3=+U.#2UV%-C$UL7ZF:LHK];
MU2W7=6/7-G5L**9K/<?9EL*U-N_L6!M[,*"'C/2BK#.>Q1+GJOR<JHJ>:&LO
M"OH],1WNM[T#N,\-&?7F,H2O;I+TW*'=&FBW[,IR U?30CM2 Q<@SW(U1PTB
MAX%.%_C<<9GFN-:S5V;/UY=C4G_O]+>[Y],/ JGJ>J_QE-K;S4-:I[GM5G-;
M 6D==&TM"N'T &&+X.N8PNE_?M<,S?5\"ZM#V]C+AKF 8IH/ &9$L69XHCJT
MTW.M6SOB.T7M+A6U HN>7%T>X6:V::>>;0/%9(V=#LRV!V9OEL LU+W("C1+
MC=T(V^"Q4/5\CZD&#TS7BP.N!0X%,?C+5F>GB-T'5%U;PF4)H]84)S([QX3-
MB+(IYOJ4J[F=:K9W6[AQ*/X6-VB_X7XGQO@6JTQUJ+\.ZK];0OW(#RW=-4(U
M='U08>W(4SW3,E3#M'4W\&V/>3;>H<"Y;E>%W0)+W4IP/*?\Q >8O[IA2?OW
M_(RERH<\ \&+.U?W>M]%?FVSD/VCRR#6C;KW"]9DCO-L2"US*?47_QZS7"0"
MARE+AK(R&QW0N#X@V;LG3PI>%F0;(0)B$Y-I+DJ@-;N0T"CT3#)1 IXF_!P+
M2&+A?FQX/F#GG/J1).=)-&5I.E.HXX_H&G-VEF.'%FPKA%U18<WP'A:=8P<
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M!\H$:($#A0GW'DY % B=*88K^SXV7U=,Q^,LGXA&I$*M..>5"2@LVXM,^3!
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M*K.D!PP'PX_.>G/R@47 VPF9.^CE$..!*9"%"4U4V/LU*5$H/3X(*IM*7<5
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M-<]>*==,L8PU%$74AN+>@=?W#O,9"97J$"F6\6]DZ'_9?;N\!][DYAG]J0U
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M:#Y@4X"^!BKKD*6+4^XKG\>96+0<BS0J5+]Y/F'PQ3?3'%".C=K*KA8D&BZ
M/4'W@2\ /T@;?\A^\FJ(/)NQ%!BE5,]!Q<:<1F2(?UE-9*1Y(;SC:C!0:S05
M4X9OI\.25_^EU\]LP;R\;WK\7(%(E$_/@ **$*T"V%58$>FN1"!_@#$^R5+U
M:,;S0OD$6QL$5V\W6[:$:+OJFL!3/.LH*R04D9L@R3$^%'"1BZMZIGP@>#47
M2]O" ^__US=T?3_W?$.0JB^/=^M_?C=G9R$\P1&GPN/,%,/NP?N5 KTT7(VS
M#$\T!CM3@<F&I(* ?:5\R;((1$\$G'7*+UG1I]^2VB6/&>Q683UB(6?XHM"N
MA,DEA+A>6> 'T[,IT(04[G:OC#T49A05-"N +(3>@[5@0.J3<2S".TH;')@V
M%^K'!"TEAU:"0S6"1*AHM>W21Z7?*L'H1BHQ(^=.$]]/HKM6\$S3F=2AR7*>
M!D4"D)^#D?F>7R8 TLAM^1#.<DH)!87R&[[]+^!Y/ON]A[I%O]>@!^-:>@#<
MB,[X!0B#O*?48RV31 L]-"G1K.BAEIZFM0U:\ QM%2WXGO,X:>&D=HZ&TLDG
M\5LZK"2H(X5,0-DL:XG3[R,.*CT8)B,L C[#F'F0PD5/QA66EU"@6(:\J!P^
M8P"$D3 .%EP[B]?RN-MSY=!AY+C2B5ZV#9Z-SC)\[UHM)'@,="(-0E(T A'R
MCQ74 U(01AP'1QIK4S+*LR=Q&<(HZ):#HQ%.&/1)2X3[@1IWJ6++M[Z4C">F
MCY7L"\SW2(H!S1].M\4K6(4YT)T@Y42$/!G3X)6,Q>!/4FP6.F*4-"^,!5'L
MO>&R$_LIRF2)+4F&4AXWLR]Z\ZD7HZ@EOH),O2A!JI+#YJ7C&*4(#)!-9"E_
M&JH*YQ#9'O16I!3A$FPN0I(8&"1(N*LI%DXG0[)E<<S)F@G0D3V;FQE.A?03
M=!5@Z*NPT$C)67:9"D4XA!<)%Q>=OD"*RGP4(PW'*3V"9%-Y8:L(XBE@"IPX
ME\X&G)#0V5$Q3D9EBP/:H2;3U6LM=[)J5, K3\'UH2Z++)25)!A/T? 7LT>U
M'+9W(R9:M"X7WBHTM(INQ6DN,,Y+X67.RH_+1*(PR\?(!KQADHO=F[L\(D^Z
MC.6<CAJ6+!GN\T<%LB!%E5;ZN<LOY# 8' &11GTRP"YH1),DJOWR-5&V,*IL
MTU#2? 6B*!-)H85AT2';G#1L?XF-S7L)V Y8',J7B70/74X4W2@]3=4%/FZA
M[+F#?2&0D6"3#D4P  Z"CDOQJ7 H$2G0TL5&2S9I>K8*,LN:DQ;.C!G-.ZWN
MB)H,6-L"(RY=0G0/$$7$-W">7+@G,GF#(!WGY(W)2^1M?!T$,?Q[#JO0,1_C
M>Y#XIR-RB=>H71F=]87%Q8"/:#X\Z@F^GXGK(#K>E-%LX#W34()V"-M T <V
M"WPTS')>(N&\^5'TQ*,K<M. T<YR-H09']0KJN>%\T![&:&J<NZCW0OZ$%!2
MB-=1Y>JFM#] "V"/":VIO/!HW5O $\H&Q:<7]QE?*Q,7YO<Z CD[D2XMDD_H
M!$)'%>AJ&P<(W;<N\Y98 48D[U:"D3*XAB!C.7E/(R!1$A^T?C:=#+(<AL>-
MG??@T?5^I5,T_7F"\$@!0HI:,7PQ($=(Q/$889H47%"]#N60D+ZAN,0#XKZ@
M!X+FV8]*MY[L'Q-B?('@RPKN6MY=O;1,\2!Z#C"0*"DCBN"!::U#S)VQHAS,
M3Z^07AW0]4@P%,G9* % 8"C]94W-<J,02VKY!.,_%ZQQQW1V977@^[XX/TR*
M,,T*5*A!)DPG:,OB\7U,BI]W/45O&_5D]]94^2+@'N1R)L/>4M!046I)#B%1
M+H1%#KN-O%219?,"2.CG!/_S-P%S5SA NBFJYDR(7<(53%*6(-%'_6,(XD:(
MG/8;)06E<)RE229?*J]]Z&V?^Y\ QM'*G(*F"+9'6MZZE^K.(FP3W].4R^LF
MV(0656!QKCWY]D:X#>YD:9E<NY.TUEI+B3*260,>424("2HT8SH<G!YVL@)V
M)K C_4DD@$O))YVG^;12F_&@VO;M 9K47\2E)"G9EPD<%T9!77$E6JN@Z]U2
MHKN__0*V12E&<KC(\I\RD(!,B%K3$%I%NWHZY'S2A/6&B;5*)VU>RA'-+%#9
M/*T48&$EI,_/2E8%O$2#AUP',F[B%%?_/F,C6C>\;$:6DF ZL"YD(!@."#Q2
M)869FAJ!D'__[H^3C_0I7;SREE&K2:%BS&9E> 6MFI:2BA@HP7=$K%5$B(MQ
M%X02Z&%*.$J[,4OHO@:4-WA3[3>'626Y$.ZKB?I)AF!X^QJ"L4^ <LZE9387
M,M#:1E"X4BK704HW.#+J"NT=Y!4:D.*"AF NX3@DCD2Q=+16B'J!M=*9#+,X
M%R&6!&TCO R$0T @KR ?35HPDX">I*P(9X(ORSA1U"9W'G;I:FN%7<[G:KG&
M8JX;_F9'H9GO)GRHF+(%K?CS[RD>]43(6#Q^^$5:_EQKI(5R<*U*NF>T_PF4
M'$KETUY>I5G35_27TF*2#]!&&7WXWH@)QP%EV;DO"]J3J6CF20T@P":9@6)V
M/S=N[<=ZARV%U]QK4"K>5OK9Z]+<I WZ* .MX2LGE7^HW'14!_Y9I,!_&A08
M-2A0')W4,TFYW+#2P)IL;CX*-K?FV/RUB)T0"/\AST(>X9ZN":G>_JC()^3=
MESUK08* B4.$(NX,95.0ZO/::"@_)VD49F7YBLH?4A-:&6=2=?^5>Z7\QM!'
M D.*J)I\BE)1-YFJV[_QW^G;NAW)GP2<H(3]5%MA;RY%DQ*0D>1*T7W3^EV8
MIG3;D BW(FBWPDZ36G@RHM2#B8B7JT,D@HH_A/]U6D44"B<N.:/C).5KS 94
MV#.&KF=T<S($M5]X/8L^R>H5I(Q6+E(T%5.ZD>BAQCK-63@K;W7(X2,^$O%\
M! 8*!Q-E6M\N3(59V[K9K+HCHWO"N!G.2,$E8LES+FN,R^8BV7V45?U@*A-1
MMGLNPXAPD :!B$'0(E@C"VXA&XA.JO0*D&Z#FI.\0"(O+YXQVNL9>IQGC027
MI0=ZF\UVV[F73]*,\%>;$1O(#>?9;FV/;6^>L9:P^8"W[._>*:I:9<16:+5.
M_ZF6\[^E_/;;Y/>>2VM]3EJ_YV? XR2F.<YZM9QN;.&/:3%)XMF.>&CO6XWI
M=NT(CA>O>RB G? X3%DB[U!2.H5Q?0H"YS&EL+H=&2&I(TI/\Z*ZYBMOZF5X
M"#S3<)^*^\U,R(L>)1R>)]%4!,_GY;CL["R'UT\PV[$VF%ETCI%/4ELH75]Y
MK6'7-["]AK"H[G_(,UU>O=Y)UGX;*=Z.G3WC4:CC^L$<AZ/EB=5^\.+MX?FI
MT1U:9]NA*5;>.LKX:!% A)>(0]13\,9/QM\(?A 7@R&C$'3T\*0U%><*AE*(
MC+LH 4K/FTJ2O*G(B 4I5U<H@B!S+E@>J6F6D<>Z0(=6>>-/\V7E+2=F.P;X
M%(<%5 G R'79")EP)*(X8HP^%)5HJ\O'54O% 61K0!CAYRB[&-7W[B4"-*Y!
M.%!$,JSY&F..\&89MHLE^3R(U#R]@0=L;X*2/]*.?:RS?-" ^Z,)D.]&$<!%
M/MO/VE$K2U6[=:6H)F,W__S"RSC' 6?GE*<E$'LY7+ E2+#=0XL>DZM#'?LR
MP 5_;+Q!)NDLO:8W3VTDGO Z1]K2U14[6M6A%%_2?(DX!K1<$;NZ_LGM<_FP
M=4A@1\XWF$)[:;!W=:A>'56U3(SSD7_-D-CU:$S>YY8Y.RU#D<]@(:+O'@GN
M 9.7;ER/,*^K@+(Z&Z]*PVG$%>/Y38=,!.8Q/$]TE9 L0I$V*Z-VN4I5I"EZ
MEQ3?H@H=F%6 $O%A-A+1C$K!8EZ6.D</&PMGO2I@ 65\'<-#D888,-<3,0.L
MU$C'%#M9>H5:(*H[[_+/DY:S7;@I9V"WC,XF@]F\FM+<UZ6311Z>/ZBKP]?G
MCUA:)94'2XBX,D*UBG %Y4M>HC3E7S/NF%=QVX]=I*RO1#6I8D="!J;0+F1.
M5TH/O.:M8O!+_3=;+%E2QE/*J-<Y(34M<S@CCH'TE*8@(XQ$:"M&1S  (@"J
MP:Q(8 8C*F5-67_P+Y!7*8B>D+IV,\HX++,UACPBT,2Y8Y;RWE3ZI,-N,<SW
MGZ ?(OFVQ8%7J31T75%=RH@("-"]0]YK=#!(1G'.,!@MI, Z>5LR ?-2A*AB
M_96RA$(CN%U&;<M7+F91-.#P1FSTV+'SL9!:'0%:WJC1O1;VR!())<DP0*\B
M135*MT>21ZIP54I(HWBZFU!)3[H.9=:*O'VC'!PQ*G;F ,R2DKJAI7?P=#\T
M\X7/Y7A45#.:HBN+:M)M+&%%EEDIL&7DA0 G$>9+"EW#"[524R-WPFIUK2.)
M.R*)5KUZT0:@#.BBC*?)D[,LS] 7*5-<I4I?E=^1J<I;DC;=T=_5T<\?<FG8
M"467]-R475#_ENIXR2X?D=Z"8D1D#DL?CN3I<3HKHXS1J8Y#2+N. AIN=OO4
M+/K7O(#JJ.5^J.6U3&9=H VI6)3D(8])Y/"G_"PI1(R'2$NLS/Z<XX5^4<;'
M-\8L9@7>;9&8PMM*:A[1] *LJU]T'IZFAX>*GX%@7I3>\^ LI335XF+IE-_8
M[NXVO_P3'1K9=$+Q.E5-/5#**9$\&['S))^*K-W7)__S[E#5_1Y5R121[15
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M-=?N -W=@Q&EK H5_TB!EU3(4$;1B!QE'F';D"FE5A6@H!98!ZP1>39AEQ3
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M>"FQ="U-^(I;]!L7>=ZSF_F]N82WVJZUY9]!%LW@K\%DF+[Z?U!+ P04
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MG0G+GV#ZBSUIKNL=+=Z$2&>"TZUB;D9*N!0?N;VAV$4BJ!9W/U/H^]PF3&#
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MG@_]\6\XGC[%N+@&XH+0Z+4%=#Z#LN@A),:!H90V,VN$;>[O;L-8AP/RR^3
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M]M+EQ$PO*_3!L[J% GOPM]X,0QR>D.;PCM.1%,M&HZ'(+\H:]UN(F"QP[6U
M8[P/I3&UJ]$</-V-%-V#3W89_/T6OM?([])3U%D8KQEYBC&7NJ:0SQF<@4)>
M@C7%QVA;>V/+D>R>^E9<K8BR.RBZ!T^,4$W.,-^5>6"YB,S9#%E)#\J1U,$K
M 1B"9#DEE57K"6 EF&,R@@;J[L&)>S,>?:K;@*\P7FW]^"*D%3F#99D$M2%
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MHCA?%W!&YB0"JLQ;#[\54#IWFI^,$V*>_DI#[.5X]!4GLV$\K]DQ4-)'E:(
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MH+O];(GU:"QJ%USU4%Y_7=S_!\/DXQ_C053D!Z /$$U <N.#!U<W59 Q'IG
M%&/K;G,;0GQJ%K4-,SV4W-\(+ED&#IP6LD2* Y.FB5793- ](B2,1COK- O-
M*\5L"O))&M/&[/10PG\3P+^.SR8#F>ONGTY0 O>@*&JI+0<82&6*YSD5BCP?
MT9HJQJ=H3!MST[ ?P%9XAU]QP)VWIM1[XN@=J, <!,<2*!&YC5QR8UKWY-T4
MXY.TI4VY:=B,8%.\+PI%H%>@963!*B]!,EW/GK2B #0SB)8IG71@=^K?[LR@
M;@%]:E:U/4L-.R%L"GK@C+4L2\(I6:WG21"#EPFT0>>8C10W-*^MMB:VIV9
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MK-NV^;D=2M:EN>%.YWT/Z^VMZ8M1/K=TFA7GMYZ_5N%^_G[]^4=Z]HMOP^G
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M0/37XSC[]M"T*:KM=3+(MD[U L<H]E@:*5=6AA!Q'$,J&89I%++8QU*F^EC
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M3NCOZ=M]QNX! 95&!SSJ;/D@JX!80Z##_N1RQ>J5OE?&5Z4._"/=[5ZP_:0
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MKJ<]PD).8RY@DD08HC2BD(3<AT2$C'HX25)N=2?FJ)2YN1N-DH T6@[(.7$
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MO)09H-(LQ(AF&'!I_J^4(A.,*H%3KR*Z/IU/C2:LT&WN=_O#CO@WW5E LM;
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M@$C! &%I 7"JBSR7%);2,Q3LH(>I$5@7]=1)F31B)D9.WVBP0R O7\Y?#<_
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M0#67H&0EA05F3"/E0X['74R-_#XM55/!QQ;PF===/&A;,J/S!TA8([\?O9W
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MJ%@A@+06@$@DC<DK$4480JCUFHK=6/ARIP$T.S##;@6UQJUH1$UJ*ZL?R3H
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MP@ZP]*<4[FM@Q-S"#GKL)QEV>2'PIGIM>KWY:4^G5#W3$J<000*$+E-;:+@
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M10G=TIE>[&EJK,A:68V-T'VUB[D]=5B+ZW,KWH>O SG&0FU@@AP),!^7@DC
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M3P]/]S8#Y\?5=[6T^?B6ZKN:U]4/U5YW_-9XPLVPR!C,M0)0V? 7S@O E9
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M3__SOZU_8_[/NL#_S__V_P-02P,$%     @ 5CFD5@%U$P)K70  *28$ !4
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MS$N7)++_^^1?,]/6QZS!1&-!B2@A.LOI=TM1FOY?1O]C_=#)>/KW?ZU_Q+#
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MW@@4LG]0["//3B!QCNB?I_D5N7<CRY)-'AEX34Z9*J6 <]Q"X)B-"DD6QYL
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MXXKRQ30_P(\E(:2@Z[UEKHU9;3F_MZ1(DJ>2>2FL=:N'IV@::$#HX2^)]]=
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M"9*&N3$?"%2[JJ(#9-UX\%Y[G'.G= C*0TA.@:*=0U^Q7+^*R5JE,K;.0=F
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M1OH63RPFC8DST,RMRJ #.%D=9(>!\9*%S<VO7YZDJLMX][@GZ<Y*ZN HW5R
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M5/CBZW@Q<EY9I6TB:UO;]MODP3.60&LCE2C2"+]172VM< ,V]-TU9-8NWLD
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MZ=QUO@@*!;+)&]FMS=;;_T7Y]W5+K/;#M_,_K_=$("Z8]!*\Q$31CO?@O.'
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M.INO;DHN.(E2)-2T<:3A""H*48=()4A)VYQRD"ZW[J:_GIIARRX/#)]&2N@
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M_O[A$PES\7JQ.,,\<B5IC\B "_2@1*FCBA1MB!*-YJBCU+PQ=-:0,FQWB4-
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M(-U<=3,D/8M;W<-*O(-[WC>SZ4D=65<9^W4V39=YV%%RGY(#]$R!"AC HV1
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MLCK?A )GAE[SX!F:;J'F4[MT@\9X\I*]2;0U-*YY."/"\[IW,3G).AMMLC7
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M].2/>Y<I9K,E%Y^=2'R/P^EE04[OJ;<6:'FA3%O#8AW++]?!VMO9=#4-%W6
MP,U!&XSF7.D()7I>GU$G.G(1P0=,W$6KG>K6#/');=H4GIXT6]*+A%MCY0NN
M5A=KL6RH_XV$^?4N S1AUG(IA04O>,TR%P,Q,OH$:BR78W04\W=+F3RS4Z,"
MT9,E3_H4]&#3^=<7(]?/ZGO)X3^]8#^)^SV([JFOYIO_7DU7?]^""E/V(1&4
MDBJ2CA1MP,6<(3,N"[->IM[;%CVDX+!>S%_??RR$P>GLVSH9-"E<)^L%@A/D
M/2DG(P3GZ5]E$G5F<98=!X!MK]RVZ<D!2GO8:?D0>34_+^C;P>67^45^._LP
M_T$Z8_?XF01NE>%&0.2)HGAI22A:<!"B4 "OR84*W1KV/[U/V]XD?0&A1UD.
M A:?%G1LKEE9MP9[R(TVP:$,$6S*%>2\@&?<@1&&7&JIG-XN*7@*&4]MU;95
M2*_@Z$VBK?'Q:3%/B'E9G9Y'H!ZEX%PD0]A.-2%<+#CT&K 48R(F+WPW)_/I
M?=JV[>@+&3W*LC4L[EO ?X7955C\3>SP^^P()PW+H0ZD*+Z^37 03!%T.!JG
MO*(CDG>K6'A^K[;--(YQJO0@TT% 9&,'=[!C3**(.UG '$LM-F=T9 8+!HW0
MN42+80^(/+E7VS87QSA;>I!I:XC<-X@[V$G2:$Q.0'')@?+TPWMI*^(S!=VF
M9->M-__S>[7M0'&,0Z8'F;:&R'VC^ 4O5QMWZHZA-4<J>"=4?5HI,((JGH/'
M7*"45)NLF51"-Y1TVJYM8XAC'#?]2'806-E8Q]T<V:RR5L& +9&B,VL9N5GD
M?4M?I"T232[=;NHZ;=>VC\,QSIU^)-L:*_?-Y*,<K1GB2:A$#(7,.:@8+7C'
M"AE*3"@*UT%T2XITV:UQGX5CG#^]"+8U4A[X7%<7]305MXQPHY+C]:6D-?7!
MK&$0JFL>0Q$E:*$P[F],MG=IW"7A*,[K(8)LC8@'+M8V(TYIESP6"*1?4+)F
MAT-]9*2%96AMI#_>WV%]$2(&GT?M39#CO%:;;-'?P\7:A)_B:FV;\.-<KGD*
M5T-"#8;;#$I1).MURH0"973B(7JWE1T8TN7:@VS.-K:9,M)$PK;VQ!6=?P6\
MJ'<%SJ.,D26U_5*T2V[L14;B1#9B'V7NSHH=(L?CVXC-?Z@_8ECB/__Q?U!+
M 0(4 Q0    ( %8YI%9Y@.,AU@<  #<E   >              "  0    !E
M>&@S,3%C97)T:69I8V%T:6]N;V9P<FEN8RYH=&U02P$"% ,4    " !6.:16
M,),RL[4'  !_)   '@              @ $2"   97AH,S$R8V5R=&EF:6-A
M=&EO;F]F<')I;F,N:'1M4$L! A0#%     @ 5CFD5O/.YR84!0  C!<  !X
M             ( ! Q   &5X:#,R,6-E<G1I9FEC871I;VYO9G!R:6YC+FAT
M;5!+ 0(4 Q0    ( %8YI%:A [D^] $! $&F"P 1              "  5,5
M  !L>')X+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    ( %8YI%8L24*8[@T  +B<
M   1              "  787 0!L>')X+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0
M   ( %8YI%;:LY1!G \  .:#   5              "  9,E 0!L>')X+3(P
M,C,P,S,Q7V-A;"YX;6Q02P$"% ,4    " !6.:16L*- &2P\  "[GP( %0
M            @ %B-0$ ;'AR>"TR,#(S,#,S,5]D968N>&UL4$L! A0#%
M  @ 5CFD5@%(7O<\J0  9Q4' !4              ( !P7$! &QX<G@M,C R
M,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( %8YI%8!=1,":UT  "DF!  5
M          "  3 ; @!L>')X+3(P,C,P,S,Q7W!R92YX;6Q02P4&      D
,"0!N @  SG@"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
